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Helicobacter pylori (H. pylori) is a micro-aerophilic, spiral-shaped Gram-
negative bacterium which colonises the human stomach of approximately 50% of 
the population worldwide (1). The infection is asymptomatic in the vast majority of 
cases, however, about 10-15% result in peptic ulcer disease and 1-2% result in 
gastric adenocarcinoma. H. pylori prevalence in developed countries is decreasing 
as the incidence of asthma and allergy is increasing. H. pylori infections are usually 
established in early childhood when the immune system is developing and at a 
common age for asthma onset. The infection induces cellular immune responses of 
types known to inhibit those that drive allergy. Previously, we showed that H. pylori 
secreted component stimulated  CD4+CD25hi regulatory T cells (Tregs) expressing 
the anti-inflammatory cytokine interleukin-10 (IL-10) more strongly than whole cell 
lysate. SDS-PAGE was used to resolve the H. pylori and a whole-cell lysate to 
determine which proteins from the supernatant were enriched and Mass 
spectrometry (MALDI-TOF) was used to identify the major proteins by peptide mass 
fingerprinting (PMF). From the result of the MALDI-TOF, vacuolating cytotoxin A 
(VacA) catalase (KatA), γ- Glutamyl transpeptidase (GGT) and Peptidyl prolyl cis-
trans isomerases (PPT) were selected based on the few pieces of evidence of their 
immunoregulatory abilities, their solubility and potential to be cloned and purified 





The main aim of this study is to investigate candidate H. pylori protein 
factors that are involved in the induction of the immunoregulatory response and 
how these effects could be utilised in the treatment of allergy and autoimmune 
response. Four H. pylori candidate proteins (VacA, KatA, GGT and PPT), previously 
selected on the basis of their immunoregulatory potential, were used in in vitro, in 
vivo or ex vivo investigations.  
  
Three of these candidate proteins factors, KatA, GGT and PPT were first 
investigated in vivo. To do this the genes for each H. pylori candidate protein were 
cloned and expressed in ClearColi® BL21(DE3) E. coli to minimise effects from LPS. 
The proteins were purified and characterised. LPS content in the recombinant 
proteins was assayed, using an E-TOXATE assay, and shown to be <0.1 EU/ml.  Jurkat 
T-cells, THP-1 monocytic cells and AGS epithelial were incubated for 1 hour with 10, 
25 and 50 µg/ml of the recombinant proteins, prior to activation with 
PMA/Ionomycin, LPS or TNF-. After 24 hours of treatment IL-2 (Jurkat cells), IL-6 
(THP-1) and IL-8 concentrations were quantified by ELISA. All three proteins induced 
a dose-dependent reduction in cytokine production, compared to controls treated 
only with PMA/Ionomycin, LPS or TNF-.  KatA most strongly suppressed IL-2 
secretion by Jurkat cells (79.5% reduction with 50 g/ml, p<0.05), whereas GGT was 
most effective in suppressing IL-6 from THP-1 cells (68.07% reduction with 50 µg/ml, 
p<0.05), there were no changes in the IL-8 production in AGS. There was no 




Likewise, VacA was investigated in vivo and ex vivo to compare the Treg 
response induced in vivo, by H. pylori mutants expressing different forms of VacA. 
Groups of 18 female C57BL/6 mice were infected orally with isogenic H. pylori SS1 
mutants expressing the s1/i1 or s2/i2 form of VacA. A control group received plain 
Brucella broth as a placebo. Mice were killed at 3-, 6- and 9-weeks post-infection 
and their infection status confirmed. Spleen cells were isolated, stimulated with 
mitogens for 6 hours and stained with fluorochrome-conjugated antibodies. Treg 
populations were quantified by flow cytometry. Treg cells were purified and assayed 
for suppressive functional activity in vitro. Mitogen stimulation resulted in 
significantly increased frequencies of IL-10+ Tregs at all time-points and all groups 
(p<0.001). No statistically significant differences were found in frequencies of IL-10+ 
Tregs between the groups. There were also no differences in the functional 
suppressive activity of purified Tregs.   Despite previously finding markedly 
increased Treg populations in peripheral blood from infected patients, we were 
unable to find increased Treg numbers in the spleen of infected mice. It is 
recommended that further investigation frequencies of Tregs in the gastric mucosa 
of the mice should be studied. 
H. pylori infection exerts immunomodulation, through the Treg induction 
notwithstanding some of the protein factors such as GGT and KatA also have a direct 
immune regulatory effect on the immune and could be harnessed for the 
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1.1 General background 
Helicobacter pylori (H. pylori) is a Gram-negative, spiral-shaped, 
flagellated, microaerophilic bacillus that inhabits the human gastric mucosa 
(Frydman et al., 2015, 2016a, Crowe, 2016, Wroblewski et al., 2010). Infection 
usually occurs during childhood but persists into adulthood when it frequently 
causes diseases (Blaser and Atherton, 2004).  H. pylori have been implicated as 
the main causative agent in several gastro-duodenal diseases, including 
atrophic gastritis, peptic ulceration, and gastric cancer development (Cover, 
2016b, Algood and Cover, 2006, Fox and Wang, 2007). This bacterium is also 
implicated for contributing to other disorders such as iron and vitamin B12 
deficiency as well as growth retardation and idiopathic thrombocytopenic 
purpura (ITP)(Banatvala et al., 1993). The most remarkable feature of H. pylori 
infection is its ability to evade or skew the host immune response using several 
strategies, allowing the bacteria to successfully establish persistent 
colonization leading to chronic inflammation. Several virulence factors such as 
cytotoxin-associated gene A (CagA), Vacuolating cytotoxin A (VacA), HP0986, 
JHP0940, peptidyl propyl cis-trans isomerase (PPT), outer inflammatory 
protein (OipA), gamma-glutamyl transpeptidase (GGT), and duodenal ulcer 
promoting (dupA) play key roles in pathogenesis and also in the persistence of 
the bacteria. These proteins assist in the colonization of the host on a long-




immunity and achieving a balance between the pro-and anti-inflammatory 
response (Devi et al., 2015).  
1.1.1 H. pylori and humans: An interesting relationship 
The genus Helicobacter contains a number of species known to inhabit 
the gastrointestinal tract of mammals and birds. They are mostly host-specific 
showing possible coevolution of hosts with each infecting species (Falush et al., 
2001). 
Isolation of H. pylori, originally named Campylobacter pyloridis, from 
human stomach tissue sample was reported more than 30 years ago by Barry 
Marshall and Robin Warren as a certain spiral-shaped bacterium(Oleastro and 
Menard, 2013). It was shown to be a spiral-shaped bacillus of 2 to 4 μm long 
with a diameter of 0.5 to 1 μm with 3 to 5 polar flagella that made it efficiently 
motile (Weeks et al., 2000).  Since the discovery of this curved, microaerophilic, 
urease, catalase, and oxidase-positive, Gram-negative bacterium; several 
studies have shown a worldwide spread of the infection, with more than 50% 
of the world population affected (Eusebi et al., 2014). Statistics report a higher 
prevalence rate of about 90% in developing countries and a lower rate of about 
40% in most developed countries except for Japan (Garza-González et al., 
2014). Despite this high incidence of the infection all over the world, only a 
minor fraction of infections results in the two most prominent diseases-peptic 
ulcer and gastric cancer. The reason for this phenomenon is yet to be answered 
fully (Atherton and Blaser, 2009). H. pylori are mostly acquired during 




family members, and can persist for life if left untreated (Salama et al., 2013, 
Chen and Blaser, 2008). H.pylori association with humans has been dated have 
been occurring for tens of thousands of years, providing some evidence of co-
evolution (Blaser and Atherton, 2004). Nonetheless, there has been a 
significant disappearance of the bacteria in recent years which has coincided 
with increase in other diseases notably, gastroesophageal reflux disease 
(GERD), allergic diseases such as asthma and type 2 diabetes (Atherton and 
Blaser, 2009). These evidence from epidemiological and experimental data 
suggests the relationship between H. pylori and immune-physiological 
imbalance and how it affects several disease outcomes. 
 In most cases, the immediate consequences of H. pylori infection 
include acute inflammation and gastritis which if the bacteria are not cleared 
can progress to chronic low-grade inflammation of the gastric mucosa(Buzás, 
2014). The inflammation may be restricted to the antrum, angulus, or 
extended to the corporeal mucosa(Algood and Cover, 2006). This type of 
inflammation lacks the characteristics of classical inflammation since 
consequences such as pus production, abscess, granuloma, or sepsis are not 
seen(Buzás, 2014).  At this stage, it is generally asymptomatic and persists for 
a lifetime in more than 85% of infected individuals despite the stimulation of a 
continuous immune response (Garza-González et al., 2014, Oleastro and 
Menard, 2013). Notwithstanding, about 10% of infected persons experience 
more severe consequences such as peptic ulcer disease, gastric 





1.1.2 Peptic Ulcer Disease 
Ulcers are deep lesions penetrating through the entire thickness of the 
gastrointestinal tract (g.i.t) mucosa and muscularis mucosa. A peptic ulcer is 
actually a broad term used in defining ulcers of the stomach or the 
duodenum(Kaur Amandeep, 2012). Peptic ulcer disease (PUD) is known to 
develop as a result of damage by gastric acid and pepsin of the protective cover 
offered by the mucus and bicarbonate secretion of the gastrointestinal 
mucosa. It is usually divided into a gastric ulcer, occurring in the stomach and 
a duodenal ulcer found mainly in the proximal duodenum (Sung et al., 2009) 
(Figure 1.1). Both are usually not easily differentiated by mere observation as 
they are generally characterized by epigastric pain, which is a feeling of 









Figure 1.1 An injury in the stomach is known as a gastric ulcer while the 
development of an injury in the intestine is known as a duodenal ulcer. 




H. pylori is present in more than 90% of duodenal ulcer patients and about 84% 
of those with gastric ulcers (Berstad and Berstad, 1993, Kuipers et al., 1995). 
Over the years, it has been shown that therapeutic eradication of H. pylori 
enhances healing of ulcers and also prevents their relapse, which supports a 
direct involvement of the bacterium in the disease condition (Laine et al., 1998, 
Rauws and Tytgat, 1990). It is still intriguing that among those with the 
infection only 10-15% develop PUD and the reasons for its occurrence in these 
individuals are not completely understood. Olbe et al (Olbe et al., 2000) and 
Dore and Graham(Dore and Graham, 2000) observed the important role of 
host factors, differences between strains, and bacterial load in the different 




and several other products released as a result of H. pylori contributes a great 
deal to the observed tissue damage (Nielsen and Andersen, 1992). Research 
has shown that bacterial characteristics such as cytotoxin-associated gene A 
(cagA)-positive and toxic type of vacuolating cytotoxin (vacA), i.e. strains signal 
sequences (s1), are associated with a higher tendency of leading to the 
development of PUD in an infected individual (Tham et al., 2001). 
However, apart from the impact of H. pylori several other factors such 
as the use of nonsteroidal anti-inflammatory drugs (NSAIDs) low-dose aspirin, 
smoking, excessive alcohol use, emotional stress, and psychosocial factors 
have been observed to be important factors leading to the development of 
PUD (Peura et al., 1997) (Cryer and Kimmey, 1998). 
1.1.3 Gastric Cancer 
Russel (Russell, 1890) in the 1890s was the first to propose the 
possibility of bacteria being a carcinogen. Since then, Thomas Glover and 
others have shown this association between bacteria and some cancers by 
consistent isolation of the bacteria from the cancer tissue (Nath et al., 2010). 
Among these bacteria associated with cancer, the best studied is Helicobacter 
pylori which have been linked with MALT lymphoma and gastric 
adenocarcinoma (Marshall and Windsor, 2005). It was recognized as a type I 
carcinogen in 1994 and is seen as the commonest cancer-related etiologic 
agent(Wroblewski et al., 2010). Only 1-3% of H. pylori infections lead to gastric 
adenocarcinoma and 0.1% leads to MALT lymphoma(Peek and Crabtree, 




cancer worldwide and are the second most common cause of cancer-related 
death(Bozzetti et al., 1999, Parkin et al., 2005). 
Eradication of H. pylori can completely cure  MALT lymphoma at an 
early stage (Stolte et al., 2002). Eradication of H. pylori in laboratory animals 
can also significantly slow gastric cancer progression (Romero-Gallo et al., 
2008, Wroblewski et al., 2010). Several independent case-control studies 
including Forman et al (Forman et al., 1991) and Parsonnet et al (Parsonnet et 
al., 1991) showed an increase in the risk of developing gastric cancer by 3 -5 
times when infected with H. pylori. All these studies and more, substantiate 
the significance of H. pylori infection in gastric cancer and MALT lymphoma 
development. 
1.1.4 Other diseases associated with H. pylori  
Apart from the peptic ulcer disease and gastric cancer, there are a 
number of other serious illnesses that are frequently associated with H. pylori 
infection. Kaptan et al reported in their prospective cohort study that 
eradication of H. pylori infection effectively improved anaemia and vitamin B12 
levels the infected patients (Kaptan et al., 2000). Similarly, studies were also 
able to link some cases of iron deficiency to H. pylori (Annibale et al., 2001). 
Interestingly, vitamin B12 and iron deficiencies are known to be common in 
gastric atrophy conditions which are a well-known condition linked-to H. pylori 
infection. Gastric atrophy usually results in the reduction of secretion of 
hydrochloric acid and a vitamin B12 binding protein termed intrinsic factor, 




1.1.5 H. pylori absence: The consequences.  
As discussed earlier, H. pylori has coevolved with humans and this is 
believed to be since the human population started leaving Africa about 60,000 
years ago (Atherton and Blaser, 2009). This “long-term relationship” may have 
resulted in human genetic modification to the presence of H. pylori which 
consequently created a permanent change in the physiology and immunology 
of the human host to enhance bacterial colonisation.  
In recent years, the infection rate of H. pylori is on the decline as a result 
of improved hygiene and quality of life worldwide especially in industrialised 
countries (Yamaoka, 2009). This is believed to also have a ripple effect resulting 
in the drop in the prevalence of sequelae linked to H. pylori infection. One 
report showed a steady decline in the prevalence of H. pylori infection in Japan, 
from 59.1% in 1950 to 15.6 % in 1990 among individuals born within this 
period. It also went further to suggest a prevalence of less than 10 among 
individuals born after 1998 (Wang et al., 2017). Northern American average 
prevalence of H. pylori is down to 37.1% while in Oceania countries have an 
average prevalence of 24.4% (Hooi et al., 2017). However, as the overall in H. 
pylori prevalence is decreasing there is a concomitant increase in other 
diseases(Atherton and Blaser, 2009). The question arises, do H. pylori infection 
confer protection against certain diseases? 
The most interesting association suggested that the absence of H. pylori 
is a significant contributor to the development of allergic diseases such as 




that exposure to childhood infection promotes the immune maturation 
necessary for protection against atopic, allergic, and autoimmune diseases 
(Gold and Wright, 2005). On the other hand, the hypothesis could also be 
explained in terms of disappearance of endogenous microbiota which have 
had a long term association with humans. In this case, H. pylori sufficiently fits 
the description of such an organism, having lived with humans for a long time, 
a childhood infection and currently, the prevalence is dropping (Blaser, 2008). 
Currently, a number of studies have reported a strong link between H. pylori 
and several atopic and allergic diseases (Matricardi et al., 2000, Chen and 
Blaser, 2007, Wang et al., 2013b, Correa and Piazuelo, 2012). To support this 
hypothesis, it has been shown that H. pylori strains with the cagA gene are 
more linked with asthma than strains without the cagA gene (Chen and Blaser, 
2007). 
Further support came in the light of the finding of differences in the 
gastric regulatory T- cell (Treg) levels in H. pylori-infected and H. pylori 
uninfected individuals. A higher level of Treg is associated with H. pylori 
colonisation which may be linked to allergic disease prevention as opposed to 
the uninfected individual (Robinson et al., 2008). Although these Tregs are 
induced in the gastric mucosa, there is evidence that the effect could be 
systemic, which explains the suppressive activities in the lungs (Arnold et al., 
2011a). The Treg activity also has been linked to the tendency to develop 
peptic ulcer disease (PUD), as H. pylori infection tends to produce PUD 
individuals with low Treg as compared to the ones with higher Treg (Robinson 




colonisation and therefore it is suggested to increase the level of Treg compare 
to the strains without cagA (Harris et al., 2008). Another potential explanation 
for this phenomenon is the difference in the type of T-cells associated with H. 
pylori infection and allergic diseases; which are largely the Th1 and Th2 
subtypes, respectively.  
Similarly, there is a strong link between H. pylori eradication and 
obesity and/or obesity-related illnesses, especially in more industrialised 
countries. The mechanism is explained by the effect of bacterial colonisation 
on the two opposing hormones leptin and ghrelin. Leptin is a hormone that 
decreases appetite and hunger, thereby controlling the fat storage, on the 
contrary, ghrelin induces appetite and hunger, which could have a long-term 
effect on fat storage (Friedman and Halaas, 1998). H. pylori infection induces 
chronic inflammation in the stomach which impedes both leptin and ghrelin 
production. But overall leptin level remains the same in the body, this is 
because most of the leptin is produced else in the body other than the 
stomach. Contrastingly, the ghrelin level is affected since two-thirds of the 
hormone is produced in the gastric corpus on the stomach. Hence, the 
influence of H. pylori colonisation of the gastric corpus is observed on the 
ghrelin production rather than leptin which has been also confirmed by 
observed increases in serum ghrelin level as a result of H. pylori eradication 
(Nwokolo et al., 2003). Also, infection by cagA-positive strains decreases 




 Another condition that could be negatively associated with H. pylori 
absence, is gastroesophageal reflux disease (GERD) including its complication 
at the lower oesophageal sphincter. Case studies have shown a difference in 
acid production in patients eradicated of H. pylori depends on the site of 
gastritis. Patients with corpus gastritis, when treated for the eradication of H. 
pylori experience a rise in acid production while the reverse is the case with 
patients with antral gastritis (Haruma et al., 1999, Atherton and Blaser, 2009). 
This finding supports the hypothesis that H. pylori presence in the stomach 
decreases the acid level at the corpus, thereby preventing acid reflux.   
Finally, Atherton and Blaser.,2009 schematically summarise our 
relationship with H. pylori in a graph (Figure 1.2) in which they described the 
association as biphasic. They explained that the resultant of our coevolution 
entails that a H. pylori-free stomach, could be seen as an abnormality as it 
would dispose of an individual to one of the “modern diseases”. Hence, early 
childhood infection offers protection against a number of disease conditions 






Figure 1.2 A graphical representation of the biphasic model relationship 
between H. pylori infection and human diseases. In which H. pylori is seen to 




1.1.6 Factors influencing the development of H. pylori diseases 
There are variations in the outcome of an H. pylori infection, several 
factors which include the bacterial virulence factors, host genetic diversity, and 
environmental influences have been reported to play important roles in 
determining the extent of tissue damage due to H. pylori infection and also 





1.1.6.1 Bacterial virulence factor 
A number of virulence factors are known to play a role in determining 
the outcome of H. pylori infection. These include the cag pathogenicity island 
(cag PAI), vacuolating cytotoxin (vacA), adhesins, and outer membrane 
proteins (Wroblewski et al., 2010). 
The cag PAI is a 40-kb DNA insertion element which is made up of 27 to 
31 genes edged by 31-bp direct repeats. It encodes Cytotoxin-associated gene 
A (CagA) protein and its associated type IV secretion system (T4SS), encoded 
by about 18 cag genes and it is responsible for the transportation of CagA 
protein across the plasma membrane into the host cells (Cover, 2016a, 
Kodaman et al., 2014). H. pylori induces gastritis but strains with the cag PAI 
tend to cause severe gastritis and distal gastric cancer more common in 
contrast to those infected with strains without the pathogenicity island(Jung 
et al., 2012). CagA, a 120-to 140-kDA effector protein, primarily was strongly 
linked with peptic ulceration and serves as a marker for the presence of the 
whole cag PAI. Strains can be regarded as either cagA-positive or cagA-
negative(Shimoda et al., 2016). Furthermore, polymorphisms in the CagA 
protein can also influence the risk of gastric pathology.  One polymorphism is 
found in glutamate-proline-isoleucine-tyrosine-alanine (EPIYA) amino acid 
sequence motif within the carboxy-terminal of CagA which is also a site for 
CagA tyrosine phosphorylation. Four of these tyrosine phosphorylation motifs 
(TPMs) have been identified so far including EPIYA-A,-B,-C and D (Beltran-




the whole world whilst the –C and –D motifs are present in strains from 
geographically distinct areas. EPIYA-D motifs as shown in Figure 1.2, are found 
in strains from Eastern Asian countries. It has been shown that the strains with 
the EPIYA-D motif have a tendency to induce higher amounts of interleukin-8 
(IL-8) expression by gastric epithelial cells as opposed to those with EPIYA-C 
(Shimoda et al., 2016, Beltran-Anaya et al., 2014).  
 
Figure 1.3 CagA phosphorylation motifs and cellular morphogenic 
alterations induced by intracellular CagA. A: tyrosine phosphorylation of EPIYA 
sites within the COOH terminus of CagA leads to alterations in host epithelial 
cells. Variation in the number and sequence of these sites determines the 




strain colonizing individuals in Western countries typically have Western-type 
CagA (C) 
 
CagA phosphorylation motifs and cellular morphogenic alterations 
induced by intracellular CagA. A: tyrosine phosphorylation of EPIYA sites within 
the COOH terminus of CagA leads to alterations in host epithelial cells. 
Variation in the number and sequence of these sites determines the degree of 
CagA phosphorylation and the intensity of cellular changes. H. pylori strain 
colonizing individuals in Western countries typically have Western-type CagA 
(C) motifs, whereas those from East Asia have Eastern-Asian CagA (D) motifs 
(Peek et al., 2010a). 
Apart from the CagA protein, the T4SS of the H. pylori also delivers 
soluble components of peptidoglycan into epithelial cells, this activates a 
pattern recognition receptor (PRR) Nod-1 that acts as a cytosolic ligand for 
peptidoglycan from Gram-negative bacteria. These interactions lead to 
activation of the transcription factor, NF-κB, leading to the expression of 
proinflammatory cytokines such as IL-8 and β-defensin-2(Suarez et al., 2015). 
It has been suggested that other intracellular sensors could also interact with 
H. pylori peptidoglycan, leading to the induction of type I interferon 
production(Nagy et al., 2011). 
VacA, an 87kDa protein was initially recognized for its ability to induce 
intracellular vacuolation in cultured cells(Sinnett et al., 2016). The protein is 




targeted via endocytosis and can possibly lead to cell death by apoptosis 
(Rassow and Meinecke, 2012). The vacA gene is present in almost all strains of 
H. pylori, and it is known to contribute to the long-term establishment of the 
infection by its ability to suppress the T-cell response(Utsch and Haas, 2016). 
There are considerable differences in the gene structure of vacA which affect 
the vacuolating activities of different strains. The gene structure includes the 
signal (s) region, the middle (m) region and between them is the intermediate 
(i) region. These three regions each have two subtypes, s1/s2, m1/m2 and i1/i2 
respectively(Sinnett et al., 2016). It has been shown that s1/i1/m1 forms of 
VacA induce more vacuolation than the s2/i2/m2 equivalent(Wroblewski et al., 
2010).  
 
Figure 1.4 The proposed model multimeric structure of VacA showing the p33 
and p55 subunits(Ivie et al., 2008). 
 
There is a strong link between duodenal and gastric ulcer diseases and gastric 








was established in East Asian where most strains are s1/m1 (Rhead et al., 2007, 
Doorn et al., 1999, Van Doorn et al., 1999). The presence of i-subtype may 
explain this as determines the outcome of the vacuolating activities of the 
chimera; s1/i1/m2s strains produce vacuolation while s1/i2/m2 strains would 
not. In other words, the i1 subtype is an important determinant of strain 
toxicity (Rhead et al., 2007). 
 
Figure 1.5 Schematic representation of the possible combinations of 
different varieties of VacA: s - signal region, i - intermediate region, and m - 
middle region. Classified into different genotypes; s1/i1/m1 type is strongly 
associated with disease and active toxin while s2/i2/m2 type is an inactive 
toxin. 
 
Apart from s, m, and i–regions in the vacA gene, there is another 
determinant of toxicity, which is a deletion of about 61-to -81 bp, named d1 
and d2 subtype for no deletion and deletion respectively. vacA d1 is associated 








There is a number of important outer membrane protein (OMP) that 
work together to facilitate adherence of bacteria to the gastric epithelial cells 
leading to colonization and subsequent translocation of virulence factors via 
T4SS(Oleastro and Menard, 2013). One of the most researched H. pylori OMP 
is the blood group antigen-binding adhesin (BabA) which is encoded by a gene 
known as a babA2 gene. This OMP bind to a fucosylated antigen (Leb) found in 
the epithelial cells surfaces(Keilberg and Ottemann, 2016). The babA2 gene has 
been strongly linked with gastric cancer, as well as duodenal ulceration and 
presence of cagA and vacA s1 alleles, increase the chances of severe disease 
development(Wroblewski et al., 2010). 
Another H. pylori adhesin is the sialic acid-binding adhesion (SabA) 
which binds to the gastric epithelium via its sialyl-Lewisx, a carbohydrate found 
on the surface of the host epithelial cells(Pinho and Reis, 2015). SabA is a phase 
variation regulated adhesin and is also strongly linked to an increased risk of 
gastric cancer but a reduced risk of duodenal ulcer (Yamaoka et al., 2006). 
The Outer inflammation protein (OipA) was initially identified in 
relation to inflammation as a result of its tendency to induce proinflammatory 
cytokines such as IL-8, IL-1, TNF-α, and IL-17 which enhances neutrophil 
infiltration (Peek et al., 2010b). It has been shown that OipA is either present 
or absent in a strain and when present has a strongly associated with an 





Duodenal ulcer promoting gene (dupA) is known for its tendency to 
increase the risk of duodenal ulceration in individuals infected with dupA-
positive strains(Yamaoka and Graham, 2014). The dupA gene is found in the 
plasticity zone (PZ) of the bacterial genome and has a characteristic low G+C 
content(Wroblewski et al., 2010).  It is believed to be associated with the virB4 
gene and therefore linked with activities of the type IV secretion system (Grove 
et al., 2013). DupA increases the production of IL-8 in human gastric biopsy and 
is known to stimulate IL-12 from monocytes in vitro (Hussein et al., 2010). Like 
several other H. pylori virulence factor genes, dupA has two subtypes dupA1 
and dupA2. The dupA1 allele has a sequence of about 1889-bp while dupA2 a 
shortened form with several mutation(Yamaoka and Graham, 2014).  
 
1.1.6.2 Host Factors 
Although the heterogeneity in the genetic makeup of H. pylori has been 
seen as a powerful tool of the bacterial infection and colonization(Honarmand-
Jahromy et al., 2015),   individuals colonized by a disease-causing strain type 
are still asymptomatic. This shows that bacterial factors acting alone are not 
sufficient to determine the outcome of H. pylori infection(Wroblewski et al., 
2010).  H. pylori infection affects the host in two main ways; by inducing gastric 
inflammation and causing changes in acid production in the stomach these, in 




Polymorphisms in the genes encoding a number of cytokines that are 
produced in response to H. pylori, such as IL-1β, IL-8, TNF-α, and IL-10, have 
been shown to strongly influence disease outcomes of the infection (El-Omar, 
2001). The polymorphisms that promote increased expression of 
proinflammatory cytokines particularly, IL-1β, IL-8, and TNF-α, are associated 
with acid suppression and an increase in the risk of atrophic gastritis and gastric 
cancer (Rasmussen et al., 2012, Ohyauchi et al., 2005). Polymorphisms 
controlling IL-10 gene expression which reduce expression of this anti-
inflammatory cytokine increase the risk of gastric cancer development 
presumably by removing a limiting factor of gastric inflammation (Wroblewski 
et al., 2010).  
1.1.6.3 Environmental Factors 
In addition to the bacterial factors and host genetics, certain 
environmental factors contribute immensely to the development of H. pylori-
associated diseases (Kao et al., 2016). One of the most important factors is a 
high intake of dietary salt (Gaddy et al., 2013, Monteiro C, 2016). A number of 
reports have shown a correlation between high intake of salt by H. pylori-
infected individuals and enhanced colonization, as well as the increased risk of 
developing gastric diseases as compared to individuals with a lower salt 
intake(Shikata et al., 2008). This could be as a result of up-regulation of 
proinflammatory cytokines expressions such as IL-1, IL-6, and TNF-α(Juan Sun, 
2016). High salt concentrations can also increase the expression of some 




by which salt influences the risk of H. pylori-associated diseases include direct 
damage to the gastric epithelium, but the overall mechanism is still poorly 
understood(Wroblewski et al., 2010, Huang and Chiou, 2014). 
A number of studies have shown an increase in the chances of H. pylori 
disease development due to cigarette smoking (Shikata et al., 2008). One study 
suggests that individuals infected with CagA+ strains who are also cigarette 
smokers have an increased risk of gastric cancer development (Brenner et al., 
2002).  A handful of other studies showed that there is not a significant 
difference in gastric cancer risk between smokers and non-smokers but 
observed a trend for increased risk amongst current smokers(Wroblewski et 
al., 2010). 
Some studies have shown that co-infection with H. pylori and helminths 
reduces the severity of H. pylori-associated gastritis, where T-helper (Th) 
response is directed towards Th2 with a decrease in Th1 cytokines (Fox et al., 
2000). Whary et al (Whary et al., 2014) observed increased frequencies of 
FOXP3+ cells in the corpus and reduced H. pylori-associated gastric 
atrophy, dysplasia.  Helminth co-infection also prevented H. pylori-induced 
changes in the gastric flora. 
 A couple of studies have shown that a diet high in antioxidants can 
offer some protection against the development of H. pylori-associated 
gastritis(Stanner et al., 2004). Researchers have suggested the importance of 
food supplements such as vitamin C and β-carotene in decreasing the chances 




shown that high vegetable consumption may provide protection against gastric 
cancer among individuals infected with H. pylori (Kim et al., 2013b, Mera et al., 
2005). 
1.1.6.4 Host Immune Response 
H. pylori are generally regarded as a non-invasive bacterium and 
seldom cross the gastric mucosa but both surface and secreted bacterial 
proteins have been found in the lamina propria (Tan et al., 2015). The bacteria 
have the ability to induce epithelial damage, which then allows whole bacteria 
as well other bacterial components, delivered via outer membrane vesicles to 
reach the lamina propria where there are encounters with immune cells (Ito et 
al., 2008). 
H. pylori infection elicits a wide range of immune responses including 
innate and adaptive immunity and involving cell populations such as 
neutrophils, macrophages, dendritic cells (DC), T-cell, and B-cells. The 
combined activities of these immune responses to bacterial factors determine 
the extent of gastritis(Wroblewski et al., 2010). 
Macrophages and monocytes are central to the immune response to H. 
pylori infection (Tan et al., 2015). Monocytes, circulating in the blood, are 
attracted to the gastric tissue where they differentiate into macrophages as a 
result of exposure to bacterial components and proinflammatory chemokines 
acting as chemoattractants  (Tan et al., 2015). Macrophages are capable of 




lamina propria(Whitney et al., 2000). Detection of the bacterial pathogen-
associated molecular patterns (PAMP) by its pattern recognition receptor 
(PRR), especially the Toll-like receptor families (TLR2, TLR4, and TLR5) and 
Nod1 (Fig 2) leads to the amplification of the inflammatory response and 
production of proinflammatory cytokines such as IL-1, TNF-α as well as IL-
6(Peek et al., 2010a). These innate immune cells also participate in the 
activation of the adaptive immune system by producing IL-12 which activates 









Figure 1.6 Toll-like receptors and pathogen recognition. Activation of Toll-like 
receptors (TLRs) and intracellular receptors (e.g., Nod1) by pathogen-
associated molecular patterns (PAMPs) triggers multiple intracellular signaling 
pathways that culminate in NF-κB activation and subsequent production of 





Macrophages also produce nitric oxide (NO) which acts as an 
antimicrobial agent capable of eliminating H. pylori (Soleimani et al., 2016). 
This is elicited as a result of the upregulation of the enzyme inducible nitric 
oxide synthase (iNOS) by the H. pylori infection (Son et al., 2001). 
H. pylori is also capable of evading nitric oxide-mediated destruction via 
the activities of its enzyme, arginase, this competes for the iNOS substrate L-
arginine thereby suppressing the production of NO (Xiong et al., 2016). The 
bacterial enzyme metabolizes L-arginine to produce urea, this is the substrate 
for urease which is necessary for bacterial colonization via the synthesis of 
ammonia for neutralization of gastric acid (Wroblewski et al., 2010).  
H. pylori also avoids other bactericidal functions of macrophage by 
evading phagocytosis (Lina et al., 2014). One of the ways it does this, is by 
ensuring that the phagosomes formed following phagocytosis fuse with each 
other to form a large phagosome known as a megasome. Cag PAI-positive and 
toxic vacA positive H. pylori can also prevent the fusion of lysosomes with the 
phagosome thereby ultimately preventing the killing of engulfed bacteria 
(Zheng and Jones, 2003). 
Neutrophil infiltration of the mucosa is a very important hallmark of 
defence against H. pylori infection, which is followed by phagocytosis and 
subsequent elimination by oxygen-dependent and/or oxygen-independent 
killing mechanisms(Peek et al., 2010a). Neutrophils are activated by the 
interaction of PRR such as TLR2. interaction with the bacterial PAMPs 




κB and subsequently upregulates expression of IL-12, IL-23, and TNF-α.  
Nevertheless, H. pylori have developed several mechanisms of evading the 
attack from neutrophils, which include avoidance of phagocytosis by 
preventing complement and antibody-mediated opsonization (Berstad et al., 
1997, Rokita et al., 1998). 
Dendritic cells (DCs) act as the bridge between innate and adaptive 
immunity, functionally capturing bacterial antigens, and presenting them to 
the T-cells (Novak et al., 2010). The DCs are thought to be capable of infiltrating 
the gastric epithelial apical-junction and interacting with the colonising 
bacterial cells and components (Wroblewski and Peek, 2011). The bacteria 
contain major ligands for PRRs on DCs leading to DCs activation and maturation 
(Fig 3).  This leads to the activation of  Th1, Th2, regulatory T cell (Treg), or Th17 
responses directed by the expression of interleukin (IL)-12, IL-4, IL-10, or IL-23, 





Figure 1.7 Schematic demonstrating how dendritic cells may bridge the innate 
and adaptive immune response directed against H. pylori within the gastric 
mucosa. Dendritic cells can penetrate the epithelial barrier in vivo and 
sample H. pylori antigens directly. Dendritic cells, in turn, activate T cells in 
different ways, being capable of inducing either a Th1, Th2/regulatory T cell 
(Treg), or a Th17 response by the generation of interleukin (IL)-12, IL-10, or IL-
23, respectively. Direct interactions between H. pylori and gastric epithelial 
cells or H. pylori constituents such as urease can also activate 
polymorphonuclear (PMN) cells and/or macrophages, which further amplifies 





T cells are broadly separated into helper T cells (Th) and cytotoxic T cells 
(Tc) also known as CD4 T cells and CD8 T cells respectively (2016b). The CD4 T 
cell specifically performs its function in the immune response by the 
production of cytokines and chemokines which activates targeted cells to 
perform specific actions and recruit other immune cells to the site of infection 
respectively(Charles A Janeway et al., 2001). The main function of CD8 T cells 
is to eliminate pathogen-infected and malignant cells, but are also capable of 
producing cytokines(Pennock et al., 2013).  
An uncommitted T cell, known as a naïve T cell, is activated by 
engagement of its T cell receptor (TCR) by an antigen presented to it on the 
MHC (class I for CD8 and class II for CD4) of an antigen-presenting cell 
(APC)(Pennock et al., 2013).  
The cytokines in the surrounding environment, produced as a result of 
interaction between innate immune cells and the pathogen, then strongly 
influence T cells differentiation into a particular type of T helper subsets such 
as Th1, Th2, Th9, T follicular helper (Tfh), Th17, and Treg (Baranovski et al., 
2015). These types are conventionally divided based on cytokine differences 
and chronology (Th1 and Th2), cytokine profile (Th9 and Th17), and biological 
significance (Tfh) and  (Treg)(Pennock et al., 2013). 
Th1 is characterized by its production of IFN-ϒ and TNF-α, which act on 
macrophages and DCs to enhance their phagocytic and antigen-presentation 
function. Differentiation into Th1 of naïve T cells usually occurs in the presence 




Szabo, 2000). Th2 cells are characterised by the expression of IL-4, IL-5, and IL-
13 and they are specialized in activating neighbouring eosinophils, mast cells, 
and basophils in addition to promoting the production of antibodies by B-cells. 
The differentiation is induced in the presence of IL-4 from innate immune cells 
(Fields et al., 2002). The Th9 subtype is similar to Th2, producing similar 
cytokines especially IL-4, IL-10, and IL-13 in addition to its signature cytokine 
IL-9. IL-9 supports CD4 T cell expansion and survival as well as having potent 
effects on mast cells. Th9 differentiation usually occurs in the presence of IL-4 
and TGF-β (Dardalhon et al., 2008).  
IL-17 together with IL-8 potently recruits neutrophil migration to the 
site of infection. IL-17 is mainly produced by the Th17. The differentiation into 
this subset usually occurs in an IL-6, IL-21, IL-23, and TGF-β rich environment 
(Mangan et al., 2006). Fazilleau et al (Fazilleau et al., 2009) described T-
follicular helper cell (Tfh) as the class of effector T helper cells that regulate the 
step-wise development of antigen-specific B cell immunity. Naïve T cells 
differentiate into Tfh cells in the presence of IL-21 and IL-27 which induces the 
upregulation of the Bcl-6 transcription factor(Liu et al., 2012). Tfh cells are 
deployed to the B cell zones of lymphoid tissues where they usually have stable 
cognate interactions with B cells (Fazilleau et al., 2009). 
The function of the Treg subset is to control the inflammatory response 
and as such maintain immune homeostasis (Pennock et al., 2013). They are 
quite unique in that some types called natural Tregs (nTreg) are produced 




in the presence of TGF-β and retinoic acid(Pennock et al., 2013). Most Treg 
subtypes are CD4+  and express high levels of CD25 (the IL-2 receptor) and have 
the expression of the FOXP3 transcription factor which mediates the 
immunosuppressive activities(Fontenot et al., 2003). Tregs can also be 
categorised on the basis of FOXP3 and CD45RA expression as resting 
(FOXP3dim CD45RA+) or activated (FOXP3high CD45RA−) Tregs. In contrast, 
activated non-suppressive T cells are FOXP3dim CD45RA− (Miyara et al., 2009). 
Tregs may control immune responses by the production of anti-inflammatory 
cytokines, chief among them are IL-10(Pennock et al., 2013),  TGF-β, and IL-35. 
Their function is to abrogate T-cell proliferation and cytokine production from 
other activated T cell subsets (Moore et al., 1990). Functionally, there are 
differences between human and mouse Tregs. In humans, only CD4+CD25hi T 
cells can function as Tregs while in mouse, almost all CD4+CD25+ T cells function 
as Tregs (Lastovicka, 2013). Below (Table 1) are common extracellular and 



















FoxP3+ is a transcription factor that is 
regarded to be a lineage molecule for 
Tregs. It is necessary for their thymic 
development, function, and 
phenotype and is responsible for 
controlling the expression of a number 
of genes including suppressive 
cytokines and Treg surface molecules.  
Helios Helios +/- Intracellul
ar 
An Ikaros family transcription factor 
originally used to differentiate 
induced Treg cells from natural Treg 
cells as nTregs 
(FoxP3+Helios+) and peripherally 
induced (FoxP3+Helios−) iTregs. 
Although presently CD304 is preferred 





Binding of RUNX to Core-binding 
factor β (CBF-β) aids expression of 
FOXP3 in nTregs. It works together 
with CBF-β in maintaining the 
development of Treg. It is so 
important in that RUNX deficient mice 
to produce autoimmune disorders 
resembling those occurring in Foxp3-
mutants, although the symptoms are 
less severe. 
CD25 IL-2R –α high Surface Deemed most important Treg marker, 




tendency of depriving other cells the 
needed IL-2 when present. 
CD26 DPP-IV 
ectoenzyme 
Low/- Surface CD26 is an extracellular serine 
protease with dipeptidyl peptidase IV 
(DPPIV) activity. Found always 
upregulated inactivated and memory 






 Surface 50% to 90% of CD4+CD39+ T 
lymphocytes are FoxP3+, but CD39 is 
also expressed on effector T cells upon 
activation. Also, a new subset of 
human CD4+CD39+FoxP3− T cells that 
produce IFN-gamma and IL-17 has 
been found 
CD45RA  +/- Surface Tregs expressing CD45RA are resting 
/naive Tregs, while CD45RA negative 
are called effector or activated Tregs 
CD45RO alpha chain of 
VLA-4 
integrin 
- Surface CD45RO+ Tregs are so-called memory 
Tregs and exert enhanced suppressive 




Low/- Surface Marker of effector T cells producing 
pro-inflammatory cytokines has been 
used for negative selection of Tregs, 
but in some degree expressed also on 
Tregs 
CD127 IL7R- α Low/- Surface They showed that the expression of 
CD127 inversely correlates with FoxP3 
expression and suppressive activity of 
Tregs and has been used in 






1.1.6.5 T cells and H. pylori 
Gastric inflammation is initiated by epithelial cells and innate immune 
cells following colonization by H. pylori. This is followed by the activation and 
attraction of lymphocytes, evident by the increase in CD8 and CD4 T cells ratio 
in the gastric mucosa (Portal-Celhay, 2006). A common observation is an 
increase in the IFN-ϒ producing T-lymphocytes in the lamina propria, which is 
characteristic of Th1 cells(Wroblewski et al., 2010). It has also been shown that 
in peptic ulcer patients, CD4+ T-cell clones specific for H. pylori are mostly of 
the Th1 type, based on the cytokine profile(Fassi Fehri et al., 2010). Bamford 
et al observed that there are higher concentrations of IFN-γ and IL-2 than IL-5 
and IL-4, which are the signature cytokines for Th1 and Th2 subsets 
respectively(Bamford et al., 1998). A number of studies have also shown that 
H. pylori infection preferentially induces production of IL-12 by DCs, which is 
necessary for Th1 differentiation (Haeberle et al., 1997, Fassi Fehri et al., 2010, 
Meyer et al., 2003). 
Another cytokine that is increased at a high level in the infected gastric 
mucosa is IL-17, which is connected to the increase in the neutrophil level 
during H. pylori infection in mice and humans (Luzza et al., 2000). DeLyria et al. 
demonstrated that immunization of mice with a  H. pylori lysate enhances IL-
17 expression in the gastric mucosa. Also, CD4+ T cells isolated from spleens 
and cocultured with H. pylori-pulsed DCs or macrophages showed increased 




observed that H. pylori infection induces a Th17 response in gastric mucosa 
which contributes significantly to the suppression of the infection (DeLyria et 
al., 2009).  
1.1.6.6 The Treg Response to H. pylori 
An inability to eliminate H. pylori by the immune response leads to 
chronic inflammation of the mucosa(Romero-Adriàn and Leal-Montiel, 2013). 
It has been shown that a number of the H. pylori components, such as CagA 
and TLR2 ligands were able to induce Tregs in vitro by skewing (Fig 4) the DC 
response towards the activation of IL-10 producing T cells phenotype. This was 
notably by a decrease in IL-12 production during the antigen presentation (Ya-
Hui Wang, 2016, Xia Sun 2016). Serrano et al. (Serrano et al., 2013) showed 
that although there were no significant differences in the levels of colonization 
with H. pylori of the same genotype between children and adults, there was a 
significant reduction in the severity of gastric inflammation and neutrophil 
infiltration in children compared to the adults. This reduction in the gastric 
inflammatory response among children correlates with a reduction in Th17 and 
corresponding IL-17 mRNA and an increase in IL-10 producing T cells, with 
increased IL-10 and FOXP3 mRNA. The presence of elevated Th1 and Th17 cells 
in adults as opposed to FOXP3 Tregs and the associated regulatory cytokines 
(IL-10 and TGF-β) explains why children tend to be more susceptible to H. pylori 
colonization than the adults (Nader Bagheria, 2016). Investigations with 
a C57BL/6 (H2b) mouse model proved this observation to be correct, as FOXP3 




recruitment, with reduced bacterial colonization compared to non-Treg 
depleted H. pylori-infected mice(Rad et al., 2006). These findings show the 
ability of H. pylori to survive an inflammatory immune response by induction 
of the Treg response, thereby creating a state of equilibrium between the 








Figure 1.8. Role of Treg and H. pylori infection. H. pylori-induced gastritis is 
characterized by a predominant Th1/Th17 response that is regulated by Treg 
cells. The various T-cell lineages secrete different cytokines that modulate 
further the immune response that is a critical factor for the development of 
severe diseases such as a peptic ulcer or gastric cancer(Nader Bagheria, 2016). 
 
It has also been shown that there is a reduction in IL-8 production in H. 
pylori primed-AGS cells when cocultured with Tregs as compared to those 
without(Nader Bagheria, 2016). Treg cells numbers have also been shown to 
correspond with an increase in the colonization of the gastric mucosa of H. 




signature cytokines (IL-10 and TGF-β) following eradication therapy (Kindlund 
et al., 2009). 
Furthermore, it was discovered that in peptic ulcer disease patients the 
CD4+CD25hiIL10+ Treg response is significantly reduced compared to an 
infected asymptomatic patient and increased Th1 and Th2 responses are also 
present. This change in Treg numbers directly affects the response since 
reduced production of IL-10, in turn, could increase the severity of 
inflammation, leading to ulceration (Robinson et al., 2008). Robinson et al. also 
investigated the level of IL-10 production by H. pylori stimulated peripheral 
blood mononuclear cells (PBMCs) and showed that there was reduced IL-10 
production by PBMCs from peptic ulcer patients compared to asymptomatic 
patients (Robinson et al., 2008). This result partly explains how an imbalance 
in the Treg/Th cells leads to ulcer disease. 
In contrast to PUD, there is a remarkable increase in the Treg response 
and its corresponding cytokine expression in gastric cancer tissue with a 
parallel decrease in Th1/Th2 signature cytokines (Shen et al., 2009, Nader 
Bagheria, 2016). Investigations showed that Treg differentiation is enhanced in 
response to a CagA+ strain of H. pylori, which permits chronic colonization and 
inflammation (Jang, 2010). Even higher populations of 







Chronic inflammation resulting from  H. pylori infection has a large 
impact on the gastric acid secretion by parietal cells of the stomach, which 
could lead to atrophic gastritis (Crowe, 2015). The overall clinical outcome is 
determined by a combination of several host and bacterial factors together 
with influence from the environment and others still to be discovered 
factors(Crowe, 2015). Bacterial factors such as Catalase, CagA, VacA,γ-
glutamyltranspeptidase (GGT), urease, and peptidoglycan have been shown to 
exact substantial influence on the magnitude and nature of the gastric mucosal 
inflammatory and immune response (Nader Bagheria, 2016). 
 
1.1.6.7 Catalase 
H. pylori catalase (KatA) is one of the highly expressed proteins in the 
bacteria accounting for approximately 1% of the total protein (Hazell et al., 
1991). The enzyme is responsible for the notable effervescence reaction 
observed when the bacteria is mixed with hydrogen peroxide and this is used 
in the biochemical identification of the bacteria (Ayala et al., 2014). KatA is an 
~59 kDa heam-containing tetrameric protein known to be a very soluble 
ubiquitous enzyme. KatA has been identified to be expressed in the cytoplasm, 
and periplasm, and is released in outer membrane vesicles and adsorbed onto 
the cell surface of the bacteria (Hazell et al., 1991).  
During H. pylori infection and corresponding immune response, 




by innate immune cells; polymorphonuclear leukocytes (PMNs), and 
monocytes  (Cadamuro et al., 2014). Nevertheless, H. pylori a survive these 
hostile environments owing to its ability to counteract the harmful effect of 
these bactericidal chemicals. The mechanism through which H. pylori does this 
include; conversion of the O2 into H2O2  by its superoxide dismutase (SOD) and 
subsequent removal of the still harmful  H2O2 by the catalase (Harris et al., 
2002) (Figure 1.9). KatA has been shown to be essential for the persistence of 
H. pylori in vitro and in vivo and resistance to a high concentration of hydrogen 
peroxide is eliminated in mutants lacking KatA(Richter et al., 2016).  
 
Figure 1.9 Catalase catalyses the breakdown of harmful H2O2 formed during 
inflammation to harmless H2O and O2. 
 
Apart from the potency of hydrogen peroxide to react with reduced 
metallic oxides to produce toxic hydroxyl radical which is capable of causing 
DNA damage, hydrogen peroxide is also known to influence NF-kB activation 
leading to the production of cytokines such as TNFα and IL-1β (Seo et al., 2002). 




system, it could also be said to have an indirect influence on the immune 
response in an infected patient. Furthermore, a recent report by Richter et al. 
(Richter et al., 2016) provided some evidence of the mechanism through which 
H. pylori utilizes the interaction between KatA and vitronectin (Vn), plasma 
component, in preventing complement activation, a very important innate 
immune response. 
Antibodies against H. pylori KatA are known to be detected in serum 
but the protective role of these antibodies is still questionable, even though it 
gave the idea of the involvement of KatA in adaptive immunity(Kotiw et al., 
2012). 
The H. pylori catalase amino acid sequence is unique when compared 
with other prokaryotic or eukaryotic catalase, in that it possesses a tetra-lysine 
motif on the C-terminus of the protein (Harris and Hazell, 2017). The 
importance of this unique sequence is yet to be discovered. 
 
1.1.6.8 Cag Pathogenicity Island 
Cag pathogenicity island (CagPAI) contains 27-31 genes that encode a 
type IV secretion system (T4SS). This is a channel system for the translocation 
of CagA protein, another protein encoded by the island into the cytoplasm of 
the host cells (Cook et al., 2014). When delivered, CagA is phosphorylated at 
the EPIYA sites by host tyrosine kinases such as SRC and ABL, depending on the 




the well-studied translocation into epithelial cells, CagA has been discovered 
to be injected into B lymphoid cells as well as dendritic cells (Nader Bagheria, 
2016). 
When delivered into the dendritic cells Tanaka et al. demonstrated that 
following CagA phosphorylation, the CagA protein negatively regulates the 
functions of DCs by causing a decrease in the IL-12p40 production and an 
increased in IL-10 secretion. Cag-PAI-Positive strains, therefore, induce 
regulatory immune responses enhancing chronic colonization by the bacteria 
(Tanaka et al., 2010). Again, there is a high expression of the receptor CCR6, 
the receptor for the chemokine CCL20, on the Treg (Kitamura et al., 2010).  
Studies have shown that there is an increase in both the concentration of 
CCL20 and migration of Treg into the gastric mucosa of a host infected with 
cag-PAI-positive strains(Cook et al., 2014). 
1.1.6.9 Vacuolating cytotoxin A (VacA) 
A pore-forming protein that is encoded by the vacA gene which is 
present in all strains of H. pylori (Sinnett et al., 2016). Because of the ability to 
damage the epithelial cells and disrupt the tight junctions, VacA has clear 
access to interact with the T-cells in the lamina propria (Müller et al., 2011b). 
Takeshima et al. showed that VacA prompts gastric inflammation by activating 
NF-κB in a classical rather than alternative manner. The process leads to the 
initiation of IL-8 production in epithelial with contrasting interference with T-
cell activation in a way of inhibiting IL-2 secretion, thereby having a 




also been shown to promote inflammation by disruption of autophagy which 
aids infection (Raju et al., 2012). Oertli et al. investigated the effect of two 
factors VacA and GGT and suggested that isogenic H. pylori mutants lacking 
either VacA or GGT are capable of inducing stronger Th1 and Th17 responses 
in mice. The presence of both factors induces a Treg response in a manner yet 
to be properly understood in humans (Oertli et al., 2013a). They also showed 
an increase in TGF-β1 in the gastric mucosa, which has been shown to induce 
suppression in T-cells, induction of IL-10 production in VacA exposed DC, as 
well as promotion of Treg differentiation. Mammalian microRNAs have been 
suggested to play a key role in regulation of the immune response and H. pylori 
infection was shown to elicit the expression of miR-155, a microRNA, both in 
vivo and in vitro, miR-155 inhibits protein kinase A inhibitor α (PKIα), a 
regulator of the feedback mechanism for cyclic adenosine monophosphate 
(cAMP) activities, thereby allowing continuous expression of cAMP which 
induces upregulation of FOXP3 transcription factor in T-cells (Fassi Fehri et al., 
2010).  
1.1.6.10 γ-glutamyltranspeptidase (GGT)  
All strains of H. pylori constitutively express γ-glutamyltranspeptidase 
(GGT) and it has been demonstrated to be very important in colonization of 
the mouse gastric mucosa by the bacteria(Chevalier et al., 1999). GGT is known 
to have direct immunosuppression effects on both T- cells and DCs. On T-cells 
it induces cycle arrest at the G1 phase by a mechanism described by Schmees 




The mechanism by which GGT induces polarisation of DCs and subsequent 
induction of a Treg response is still not yet well understood. But it has been 
shown that GGT exposed DCs produce IL-10 and induce the FOXP3 and contact-
dependent differentiation of T-cells into CD4+CD25+FOXP3+ regulatory T-cells 
while simultaneously preventing T helper 1 (Th1) and Th17 differentiation 
(Oertli et al., 2013a). 
1.1.6.11 Urease 
H. pylori urease is made up of two subunits, UreA and UreB. Among the 
two, UreB is the immunogenic subunit. The protein makes up to 5% of total H. 
pylori protein and is capable of eliciting Th17 responses both in vivo and in vitro 
(Jin-Yu Zhanga, 2011). H. pylori infection stimulates caspase-1 (CASP1) in 
macrophages and DCs which leads to activation of ASC- and NLRP3-containing 
inflammasome and subsequent IL-1β and IL-18 production (Hitzler et al., 2012). 
IL-1β promotes Th1 and Th17 activation which is proinflammatory leading to 
gastric immunopathology (Kim et al., 2013a), whilst IL-18 are protective against 
immunopathology by promoting Treg differentiation (Oertli et al., 2012, Kim et 
al., 2013a). Koch et al. showed that activation of NLRP3 and TLR2 by H. pylori 
is required for stimulation of the inflammasome in DCs. H. pylori LPS elicits 
expression of pro- IL-1β while the UreB subunit of the H. pylori urease is 
essential for NLRP3 inflammasome activities by activating TLR2. A ureB mutant 
was unable to activate caspase-1 and failed to induce IL-1β and IL-18, and as a 
result, was unable to promote Treg differentiation. This shows the importance 








Chapter 2  
 



























2.1 Introduction  
2.1.1 Immunomodulatory properties of H. pylori molecules  
A genetic predisposition to developing allergic diseases does not always 
culminate in the appearance of the disease, and this explains the interaction 
between genetics and the environment in the manifestation of allergy (Eder et 
al., 2006). The role of environmental factors is epitomised in the overall 
increase in the prevalence of asthma and other allergic diseases among 
children in recent times (Eder et al., 2006). The “hygiene hypothesis,” suggests 
that cleaner living conditions are associated with the development of allergies 
(Strachan, 1989). That is to say that sufficient exposure to factors in the 
environment is necessary for normal maturation of the immune system. This 
led to a slight modification of the hypothesis to focus on the ancestral 
microorganisms and parasites which have coexisted with humans for years and 
are capable of bringing about a balance in the immunity (Gold and Wright, 
2005).  Therefore, it was concluded that reduced contact with these ancestral 
microbiotas due to hygiene and the use of antibiotics during childhood is one 
of the main reasons for the increase in allergy, especially in western countries 
(Blaser and Falkow, 2009, Blaser and Atherton, 2004).  
Helicobacter pylori is a component of this ancestral microbiota, as the 
bacteria coexisted with humans for over 60,000 years, but the prevalence of 
the infection has continually decreased over recent decades  (Correa and 




the world’s human population, and it has evolved a strategy to persist life-long 
within its host. Therefore it is considered to be the most effective gastric 
colonizer, causing conditions such as gastritis, peptic ulceration, and gastric 
cancer (Parsonnet et al., 1991, Cover and Blaser, 2009). There is evidence to 
show that disease outcome is not only a result of the H. pylori virulence factors 
but also due to the activities of the immune response (Robinson et al., 2008). 
Nevertheless, there has been overwhelming evidence of inverse associations 
between childhood H. pylori infections and allergic diseases (Bodner et al., 
2000, Matricardi et al., 2000, Tsang et al., 2000, Wang et al., 2013b, Chen and 
Blaser, 2008, Konturek et al., 2008).  
There are a number of regulatory mechanisms that block the 
debilitating effect of immune response and one of the crucial mechanisms is 
through the CD4+CD25+ Treg, which could be natural Tregs (thymus developed) 
or induced Tregs (in the periphery as a result of a response to antigens). Studies 
have shown that the tolerogenic ability of H. pylori infection is facilitated by 
dendritic cells (DCs) which are skewed towards a tolerogenic phenotype, and 
IL-10 producing CD+CD25+ Treg cells (Arnold et al., 2011a, Ray et al., 2010, 
Wang et al., 2013b).  
Two H. pylori virulence factors, vacuolating cytotoxin A (VacA) and - 
Glutamyl transpeptidase (GGT) have been shown to aid H. pylori colonisation 
since mutant strains lacking these factors failed to colonise mice (Chevalier et 
al., 1999, Salama et al., 2001a). Both factors were also shown to inhibit T-cell 




showed that VacA and GGT are independently capable of reprogramming DC 
leading to persistent colonisation and induced immune tolerance in mice since 
DCs exert a strong influence on the adaptive immune response. They further 
showed that vacA and ggt null H. pylori mutants induced more effector T cell 
responses, had a reduced ability to inhibit DC maturation, failed to induce 
CD4+CD25+ Foxp3+ Tregs, and infections were cleared relatively easily 
compared to the wild type.  
The Helicobacter research group has previously shown reported an 
increase in IL-10 producing Tregs in gastric biopsy samples of H. pylori-infected 
patients, compared to uninfected patients.  They also found that peripheral 
blood Tregs from infected patients (but not uninfected patients) responded to 
stimulation with H. pylori antigens by secreting IL-10. Components in the 
secreted fraction of an H. pylori culture were markedly more effective in 






Figure 2.1 IL10+ producing CD4+CD25hi cell frequencies in the PBMCs 
stimulated with the secreted component, whole-cell lysate, and culture 
medium. 25 μg/ml of total protein SS1 H. pylori whole cell lysate, 25 μg/ml total 
protein from culture supernatant (secreted components) or Hams F12 medium 
(control) alone were cultured with peripheral blood mononuclear cells 
(PBMCs) from 9 Hp infected patients for 16 hours and Treg stimulation 
(proportion of CD4+CD25hi cells expressing IL-10) was analyzed by flow 
cytometry (Dr Karen Robinson, unpublished data) 
 Dr Jody Winter, another member of the group, identified the major 
constituent proteins in the H. pylori secretome (unpublished data). To do this, 
equal amounts of protein from culture supernatants of the SS1 H. pylori strain 
and whole-cell lysates were resolved by SDS-PAGE. The result showed 
enrichment of certain proteins in the culture supernatant compared to the 
whole cell lysate. Next, using MALDI-TOF mass spectrometry peptide mass 

































Figure 2.2 The SDS-PAGE analysis of the protein constituents of H. pylori SS1 
whole cell lysate and its culture supernatant. Lane 1, prestained protein 
standard; Lane 2, H. pylori SS1 whole cell lysate; Lane 3, H. pylori SS1 culture 
supernatant containing the secreted components. From the peptide mass 
fingerprinting (MALDI-TOF), proteins were identified as shown above. 
 
Three of the most enriched proteins were selected for the study. Catalase 
(KatA, HP0875), - Glutamyl transpeptidase (GGT, HP1118), and Peptidyl prolyl 
cis-trans isomerase (PPT, HP1075) were selected for an initial investigation of 
their potential immunomodulatory properties. 
2.1.2 Catalase 
Catalase is one of the most conserved H. pylori factors with the 
approximately 98-100% amino acid sequence similarity among different strains 




which makes a haem-containing enzyme of 505 amino acids (Loewen et al., 
2004). In conditions of oxidation stress especially during H. pylori infection, 
KatA enzymes have been shown to be overexpressed account for 1% of the 
total H. pylori protein (Huang and Chiou, 2011, Wang et al., 2006, Alyamani et 
al., 2007). This ubiquitous enzyme is essential in the gastric colonisation of the 
bacteria (Hazell et al., 1991). Interesting, the catalase enzyme retains its 
activity at a lower pH of 3 compare to urease, another protective enzyme found 
in H. pylori, which its activity is deactivated at pH of 5 (Bauerfeind et al., 1997). 
Therefore, catalase is believed to be more essential to the survival of H. pylori 
in the lower pH environment such as the human gut (Ramarao et al., 2000).  
Schriner et al showed that the maximum life span of transgenic mice 
overexpressing human catalase in the peroxisome, the nucleus or 
mitochondria were maximal increased (Schriner et al., 2005). Similarly, other 
literature has shown that acatalasemia, an inherited deficiency of catalase 
activity which was originally thought to be an asymptomatic disorder, could be 
responsible for a number age-associated disease conditions such as diabetes 
mellitus, hypertension, anaemia, vitiligo, Alzheimer’s disease, Parkinson’s 
disease, bipolar disorder (Goth, 2001, Goth and Nagy, 2012, Nandi et al., 2019).  
During H. pylori infection, inflammatory responses by the immune cells 
produce reactive oxygen species in the gastric mucosa, which could be 
detrimental by triggering DNA damage and may lead cancer (Robinson et al., 
2007, Acheson and Luccioli, 2004). Hydrogen peroxide has been shown the act 
as a first messenger able to transmit cell-to-cell proinflammatory signals such 




demonstrated that incubation of human endothelial cells with mammalian 
catalase and then stimulating the cells with LPS, pro-inflammatory cytokines 
such as TNF-α, IL-1 and IL-6 were reduced by 90%, 21% and 42%, respectively 
(Siwale et al., 2009).    
H. pylori catalase (KatA) share about 50% amino acid sequence 
similarities with that of human and since mammalian catalase have been 
shown to have direct inhibition of proinflammatory cytokine. Consequently, 
there could be a possibility of catalase produced during the immune response 
against H. pylori infection directly playing anti-inflammatory function.  
 
2.1.3 -glutamyltranspeptidase (GGT)  
All strains of H. pylori constitutively express γ-glutamyltranspeptidase 
(GGT) and it has been demonstrated to be very important in colonization of 
the mouse gastric mucosa by the bacteria (Chevalier et al., 1999). The active 
enzyme is made up of two subunits, the 37 kDa large subunit and 20 kDa small 
subunit, processed from the originally synthesised 60 kDa pro-enzyme.  
Catalytically, GGT is known to catalyse the reactions involving the transfer of -
glutamyl moiety from -glutamyl compounds such as glutathione to amino 
acids or water (Chevalier et al., 1999). As in other organisms, the human 
version of this enzyme is known and it is routinely utilised in tests as an 
indicator of hepatic and biliary tract-associated diseases (Hanigan and Ricketts, 




et al., 2010), it is also known to generate ammonia from the hydrolysis of 
glutamine (Shibayama et al., 2007). Likewise, H. pylori GGT activity has been 
shown to independently control the growth of the bacteria in vitro, as isolate 
with higher GGT activities grows more profusely as against the ones with lower 
GGT activity (Gong and Ho, 2004). Although there have been mixed reports on 
the importance of H. pylori GGT in gastric pathogenesis of the bacteria, one 
report by (Chevalier et al., 1999), argued that it is essential for the colonisation 
of the gastric mucosa of mice. While using gnotobiotic piglets and C57BL/6 
mice (McGovern et al., 2001) reported a significant reduction in colonisation 
among the ggt-isogenic mutant infected animals as compared to the wild-type 
rather than total clearance of the mutant. Largely, both pieces of evidence 
project the importance of GGT in the H. pylori colonisation. GGT is found in a 
wide range of organisms from bacteria to mammals and performs a similar 
function of catalysing the transfer of a γ-glutamyl moiety from γ-glutamyl 
compounds to molecules such as amino acids and water (Boanca et al., 2006). 
However, analysis of the H. pylori GGT amino acid sequence shows a 
remarkable difference from its counterpart in other bacterial species such as 
Bacillus subtilis, E. coli and Pseudomonas aeruginosa with only 38%, 52.5% and 
47.7 % sequence identity, respectively (Chevalier et al., 1999).   
An investigation has shown the mixed role of GGT in the immune 
response to H. pylori infection, with the protein being reported as being both 
pro-inflammatory and anti-inflammatory. As pro-inflammatory, H. pylori GGT 
is known to induce IL-8 secretion in AGS and gastric epithelial cells through the 




reason for the rise in the chemokine, IL-8, during H. pylori infection(Fan et al., 
1995). Another report suggested that during H. pylori infections there is an 
increase in expression of cyclooxygenase-2 (COX-2) and corresponding 
prostaglandin E2, both of which are vital in proinflammatory response. 
 As an anti-inflammatory molecule, GGT is known to have direct 
immunosuppression effects on both T- cells and DCs. On T-cells it induces cycle 
arrest at the G1 phase by a mechanism described by Schmees et al. and 
disruption of Ras-dependent signal pathway (Schmees et al., 2007).  The 
mechanism by which GGT induces polarisation of DCs and subsequent 
induction of a Treg response is still not yet well understood. But it has been 
shown that GGT exposed DCs produce IL-10 and induce the FOXP3 and contact-
dependent differentiation of T-cells into CD4+CD25hiFOXP3+ regulatory T-cells 
while simultaneously preventing T helper 1 (Th1) and Th17 differentiation 
(Oertli et al., 2013a). 
2.1.4 Peptidyl prolyl cis-trans isomerase  
Peptidyl prolyl cis-trans isomerase (PPT) is another enzyme family that 
is evolutionary conserved and are expressed in a wide range of organisms 
ranging from bacteria to mammal. Their basic role is to catalyse slow the cis-
trans isomerization of proline imidic peptide bonds which is important in 
several biological processes such as protein folding, biomolecular assembly 
and molecular switch (Shaw, 2002). Due to the likelihood of the cis and trans 
conformation in the PPT backbone, the enzyme possesses a wide range of 




for immunosuppressive agents such as cyclosporine A (CsA), rapamycin and 
FK506 which are to known to bind immunophilins, a cytoplasmic receptor and 
member of PPT superfamily(Kim et al., 2010, Bertrand et al., 1999). There are 
three classes of PPTs, Cyclophilins, FKBP and parvilins. The first PPT member 
was isolated in 1984 from the porcine kidney cortex and is an 18 kDa cytosolic 
receptor known as cyclophilin and later an FKBP12, a 12 kDa FKBP class  
(Fischer et al., 1984, Rahfeld et al., 1994, Harding et al., 1989).  In bacteria PPT 
was discovered first in E. coli, a 10.1 kDa  PPT class, named parvulin (Rahfeld et 
al., 1994) which is similar to Par14 another member parvulin which is found in 
a lot of human tissues with PPT activities. 
 Tomb et al complete genome sequencing of H. pylori,   described as a 
gene which code for the protein designated HP0175 (Tomb et al., 1997). This 
protein is a ~30 kDa secretory protein with peptidyl-prolyl isomerase activity 
(McAtee et al., 1998). Since then several investigations to ascertain other 
activities of this protein have shown a tendency to induce the proinflammatory 
cytokines, apoptosis and autophagy (Halder et al., 2015, Basak et al., 2005). It 
is associated with severity gastritis, initiation gastric pathologic lesions which 
may progress to peptic ulcers or gastric cancer (Zhu et al., 2015). Some other 
reports inferred that the HP-PPT induces Th17 signature pro-inflammatory 
cytokines such as IL-17 and IL-21 by lymphocyte infiltration in the tumour from 
cancer patients (Amedei et al., 2014).  With the knowledge of the role of PPT 
in the cellular proliferation, concluded that it is the imbalance between the 
apoptosis and the cellular proliferation that could be promoting carcinogenesis 




between induced apoptosis and induced cellular proliferation that promotes 
carcinogenesis.  
To this end Basak et al, 2005 went on to show that in AGS cells, there is 
a direct and specific interaction between TLR4 and PPT and likewise that the 
signalling pathway activated by PPT is downstream of TLR4. This is in 
agreement with other studies which depict the upregulation of TLR4 and MD-
2 in the gastric mucosa in cases of H. pylori infection (Ishihara et al., 2004). 
Similarly, PPT was also demonstrated to interact with TLR 4 in a macrophage-
monocyte model, THP-1, and PBMC binding directly binding to the  ectodomain 
(ECD) of the TLR4.  Following this interaction, MAPK ERK and p38 MAPK 
signalling pathways are activated in P13K/Ras, Rac1-dependent manner and 
subsequently, activation of MSK1, which is important in NF-B activation 
(Pathak et al., 2006).   
It is also known to readily induce antigen-specific serum antibodies in 
an infected patient, making it a good marker for a non-invasive serology assay 
(Atanassov et al., 2002). Which also shows that PPT interacts with antigen-
presenting cell and adaptive immunity. 
Although the interactions of PPT with TLR4 are well-established, it’s not 
known whether PPT produces other effects on the immune cells order than its 
ability to trigger the caspase pathways leading to apoptosis in epithelial cells 
(Basak et al., 2005) and supposed IL-6 induction in macrophages (Pathak et al., 
2006). We hypothesis that H. pylori PPT might have a direct anti-inflammatory 













2.2 Hypothesis  
Data from humans and mouse models have shown that stronger Treg 
responses are linked to higher levels of H. pylori colonisation, and these cells 
also contribute to the persistence of the infection (Robinson et al., 2008, 
Robinson et al., 2005). Work from our group showed that H. pylori factors very 
potently stimulated human peripheral blood Tregs in vitro to express the anti-
inflammatory cytokine IL-10. However, IL-10 mediated immunoregulation is 
not the only path to regulation of immune response. Gebert et al reported that 
VacA, a H. Pylori factor, abolished the nuclear translocation of nuclear factor 
of activated T cells (NFAT) thereby downregulating IL-2 production in T cells 
(Gebert et al., 2003).   It was hypothesised that some other bacterial factors 
could exert direct suppressive effects on proinflammatory cytokine production 
by immune and epithelial cells. Aims of the research were therefore 
• To express katA, ggt and ppt genes in ClearColi® BL21 (DE3) competent 
cells to avoid LPS effects, and purify the recombinant proteins. 
• To examine the LPS contamination of recombinant protein 
preparations 
• To characterise the recombinant proteins and assess the catalase 
activity of rKatA. 
• To determine the ability of the recombinant proteins to suppress the 
production of cytokines by activated human T cells (IL-2), monocytes 









2.3 Materials and Methods 
2.3.1 Preparation of the Recombinant Proteins  
2.3.1.1 Gene cloning (carried out by Dr Jody Winter) 
The genes encoding the proteins Catalase (KatA), Gamma Glutamyl 
Transpeptidase (GGT) and Peptidyl Prolyl Transferase (PPT) were cloned into 
pET -41a (+) plasmid (Novagen) (Appendix Figure A ) expression vector that has 
a 6 x His- tag which is needed for the immobilized metal affinity 
chromatography protein purification. Polymerase chain reaction (PCR) was 
used to amplify the genes of katA, ggt and ppt (Appendix Table 1) according to 
the genomic DNA of H. pylori strain 26695 (complete genome (Tomb et al., 
1997). 
To confirm the amplification of the genes, the amplified genes were 
separated on a by 1 % agarose TAE gel with ethidium bromide which stains the 
DNA. Then using the QIAquick gel extraction kit (Qiagen), the DNA products 
were extracted, before ligation into the plasmid pJET1.2 vector, containing 
Ampicillin resistant gene, the ends of the purified DNA products were blunted 
using a blunting enzyme (Fermentas, CloneJet kit). Using heat shock, the 
resultant plasmids were transformed into a chemically competent E. coli (NEB 
5) which is then plated on to Luria Bertani (LB) agar plates containing 100 
g/ml Ampicillin as a plasmid selecting agent. To confirm the gene insertion a 




the 5 ml LB broth containing 100 g/ml Ampicillin. After overnight incubation 
at 37 C in a shaker, the cells were pelleted by centrifugation and the plasmids 
were purified using a GenElute Plasmid Miniprep Kit (Sigma). To ensure there 
was no introduction of mutations by the PCR, sequencing was performed on 
the plasmid. NdeI and KpnI restriction enzymes were used to subclone the 
genes into a pET-41a expression vector (Novagen), containing the kanamycin-
resistant gene. The presence of the subcloned genes was established by 
restriction digestion analysis and using heat shock (Kushner, 1978), the 
resultant plasmids were transformed into chemically competent E. coli B834 
(DE3). Although this E. coli strain is easy to manipulate for high protein 
expression and yield, it has the problem of purification as the purified proteins 
from the strain usually contains lipopolysaccharide (LPS) bound strongly to the 
protein. The LPS bound to the protein could easily trigger an endotoxic 
response in cell culture of human origin.  
 
2.3.1.2 Transformation into ClearColi®   
ClearColi® BL21 (DE3) competent cells are a commercially available 
genetically modified E. coli BL21 (DE3) strain which does not trigger the 
endotoxic response in human cells. This was created by deletion of two of the 
secondary acyl chains in a wild type hexa-acylated LPS thereby abolishing its 
endotoxicity in human cells. NF-B is activated when the six chains of acyl 
group of the LPS activate the Toll-like receptor 4(TLR4)-myeloid differentiation 




complex. But the deletion of 2 out these 6 acyl chains results in Lipid IVA which 
does not activate the formation of TLR4/MD-2 complex thereby not induce the 
endotoxic response. ClearColi BL21 (DE3) is most suitable for several 
applications since the plasmids or proteins purified from ClearColi does not LPS 
contain and the presence of the LPS in form of Lipid IVA does not elicit an 
endotoxic response in eukaryotic cells (Lucigen, 2019) 
E. coli B834 (DE3) transformed previously in section 2.4.1.2 were 
cultured in 5 ml LB broth supplemented with 30 g/ml kanamycin sulfate and 
grown overnight. The cells where harvested and the plasmids purified using a 
GenElute Plasmid Miniprep kit (Sigma). The katA-pET-41a, GGT-pET41a and 
PPT-pET41a recombinant plasmids were transformed into ClearColi® BL21 
(DE3) electrocompetent cells by electroporation as follows:  
The electroporation cuvettes (0.1 cm gap) and microcentrifuge tubes 
were placed on ice prior to the transformation. Aliquots of the E. coli strain 
BL21 (DE3) with modified non-stimulatory LPS (Lucigen) were removed from 
the -80 °C freezer and thawed completely on wet ice and 25 µl was pipetted 
into the microcentrifuge tubes. 1 µl of the extracted plasmid was added and 
the mixture stirred with the pipette tip. To the chilled cuvette, 25 µl of the 
cell/DNA mixture was added and electroporated at 25 µFD Capacitance, 200 Ω 
and 2.5 volts using a Gene Pulser (BioRad) and Pulse Controller (BioRad). 
Within a few seconds of the pulse, 975 µl of expression recovery medium 
(Lucigen) was added to the cuvette and pipetted up and down to mix. The cells 




shaking incubator for 1 hour at 37 °C. 100 µl was then spread onto LB plates 
containing 30 µg/ml kanamycin, which were incubated for 40 hours at 37 °C. 
The transformed and antibiotic selected colonies were picked and subcultured 
onto fresh LB plates with 30 µg/ml kanamycin. 
 
2.3.1.3 Confirmation of Transformation via Polymerase Chain Reaction 
To confirm the presence of the plasmid in the transformed cells, 
colonies from original LB plates as well as the subcultured plates were tested 
for the presence of the katA genes. The PCRs was carried out in 20 µl volumes 
and consisted of the appropriate volume of PCR buffer, dNTPs (0.2mM 
concentration each), 0.5U of a Taq green DNA polymerase mix (9:1) and 10-
100ng of the template DNA. The KatA primers used are shown in Table 3. The 
reaction was carried out in a PCR Express thermal cycler (Thermo Hybaid) using 
the following parameters: 95 °C for 10 min initial denaturation, followed by 95 
°C for 1 min denaturation, 50 °C for 30 seconds annealing and 72 °C for 2 min 
extension. A final extension period of 10 min at 72 °C was performed. The 
bacterial colonies shown to contain the plasmid were then frozen and stored 





2.3.1.4 Protein Expression  
A single colony of transformed ClearColi® BL21 (DE3) was inoculated 
into 40 ml Luria Bertani (LB) broth containing 30 g/ml kanamycin sulfate and 
supplemented with 0.5% (w/v) glucose and incubated at 37 C in a shaker 
incubator. Following overnight incubation, the 40 ml culture was inoculated 
into 1 litre LB broth supplemented with 30 g/ml kanamycin sulfate and 
incubated with shaking at 37 C until an OD600 of 0.6-0.8. Subsequently, a final 
concentration of 1 mM of isopropyl -D-1-thiogalactopyranoside (IPTG) 
Melford, Darmstadt, Germany) was used to induce a conformational change in 
the repressor to give access to T7 RNA polymerase together with other protein 
synthesis machinery in the cell for overexpression of the intended recombinant 
proteins. The cultures were placed in a shaker at 30 C for 4 hours and placed 
on ice for 10 minutes then the cells were harvested by centrifugation at 5,000 
x g for 10 minutes at 4 C. The pellets were resuspended in 20 ml binding buffer 
(20 mM Na3PO4, 0.5 NaCl, 10 mM imidazole pH 7.4) (GE Healthcare, life 
sciences) and stored in -20 C freezer.  
 
2.3.1.5 Protein Purification-First step purification 
The induced frozen cell suspensions were allowed to thaw completely, 
then a complete EDTA free protease inhibitor tablet (Roche) was added to 10 
ml of culture then vortexed to dissolve completely. Afterwards, the cells were 




break after each burst to avoid overheating and destruction of the 
recombinant proteins. The lysed ClearColi® BL21 (DE3) suspension was 
centrifuged on 9,000 x g at 4 C for 20 minutes, then the supernatants portion 
which contains the soluble proteins were loaded into  10 ml His GraviTrap 
Talon© (GE Healthcare, life sciences) prepacked gravity flow column pre-
equilibrated with 10 ml of the binding buffer (GE Healthcare life sciences) for 
an immobilised metal affinity chromatography. The flow-through contain the 
unbound constituent from the supernatants and column was afterwards 
washed with 3 x 10 ml binding buffer (GE Healthcare, life sciences) which 
washes off the weakly unbound materials. Lastly, the his-tagged recombinant 
proteins still left bound to the column resins were eluted using the 3 ml Elution 
buffer (20 mM Na3PO4, 0.5 NaCl, 500 mM imidazole pH 7.4) (GE Healthcare, life 
sciences). 
2.3.1.6 Further protein purification-Second step purification 
The eluted products were further purified to obtain a purer product and 
exchange the imidazole containing buffer. To do this, the GraviTrap Talon 
elution was first filtered using 0.2 m Minisart® NML Syringe Filters (Sartorius) 
and loaded onto a Hiload 26/60 s200, size exclusion chromatography column 
(GE Healthcare) pre-equilibrated with 50 mM Tris base pH 8.8, 200 mM NaCl. 
The system was run using an AKTA prime plus (GE Healthcare) at 0.5 ml/min 
and 5 ml fractions were collected. Then the fractions containing the 
recombinant protein were concentrated using Vivaspin 20, 50,000 MWCO PES 




determined using Pierce BCA protein assay kit (Thermo Scientific) following 
the manufacturer’s instructions. The proteins were then stored in the -80 C 
until required for various assays.  
2.3.1.7 Characterisation of the purified protein  
2.3.1.7.1 SDS-PAGE and PageBlue Protein Staining 
Following the method established by (Laemmli, 1970), the protein 
samples were resolved by denaturing sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE). Initially, the protein samples were heated to 
the temperature of 100 C for 5 minutes in a 1 x reducing SDS sample buffer 
(50 mM Tris-Cl, 100 mM DTT, 2% SDS, 0.1% bromophenol blue and 10% 
glycerol) and then 10 l of each of the samples loaded into the wells of the gel 
together with 3 l of Precision Plus Protein™ Prestained Standards (Bio-rad, 
UK). The prestained standard was used in assessing the approximate size of the 
proteins after separation by electrophoresis.  
The SDS-PAGE gel included the resolving gel which contained 15% 
polyacrylamide and the stacking gel which contained 3% polyacrylamide, the 
gel was cast in the Invitrogen™ Empty Gel Cassettes, mini, 1.5 mm 







Table 2.1 Composition of the Resolving gel and Stacking gel preparation for the 
SDS-PAGE.  
Resolving Gel (7.5 ml) for one gel Stacking gel (5 ml) for one gel 
-  2.5 ml of 30 % Bis-acrylamide 
solution: bis37:1 (Severn Biotech Ltd, 
UK) 
- 1.875 ml 1.5 M Tris HCL pH 8.8 
- 3.125 ml distilled H20 
- 0.1 µl 10% (w/v) SDS 
- 25 l of 10% Ammonium 
persulphate (APS) (SIGMA) 
- 5 l of TEMED (Melford) 
- 0.65 ml of 30 % Bis-acrylamide 
solution (37:1 (Severn Biotech Ltd, 
UK) 
- 1.25 ml 0.5 M Tris HCL pH 6.8 
- 3.05 ml distilled H20 
- 50 µl 10% (w/v) SDS 
- 25 l of 10% Ammonium 
persulphate (APS) (SIGMA) 
- 5  l of TEMED (Melford) 
  
The BioRad mini Protean II gel system (BioRad PowerPac 200/2.0) 
containing electrode buffer (5 x stock: 0.125 Tris, 0.95M glycine 0.4% SDS pH 
8.3) ran at 180 V constant voltage, was used to separate the proteins. At the 
end of the electrophoresis, the cassette was opened, and the gel transferred 
to a clean tray containing 100 ml of distilled water and heated gently to 65 C 
for 3 minutes. The water was removed and 20 ml of PageBlue Protein 
Staining Solution (Thermo Scientific) was added to visualise the protein bands 




with distilled water, then the gel was destained with 10 % acetic acid for 2 
hours, Molecular Imager Gel Doc XR+ Imaging system (BIO-RAD) was used 
to scan the gel. 
2.3.1.7.2 Western Blot analysis  
After the SDS-PAGE, the gel for the western blot was equilibrated in the 
blotting buffer (5.8g glycine, 11.6 g tris base, 7.4ml 10% SDS, 400ml methanol 
and 2L distilled water) for 10 minutes prior to transblotting. The nitrocellulose 
paper and a couple of Whatman filter papers cut to the same size as the gel 
(8.5 cm x 6.5 cm) were soaked in the blotting buffer. Together with the Scotch-
Brite pad, the gel, nitrocellulose paper and filter paper were assembled in a 
sandwich manner on a mini blotter cassette (BioRad) taking care no air bubble 
is trapped by rolling a pipette gently over the sandwich and the top of the gel 
align with the nitrocellulose.  The cassette was placed in the electrode 
assembly with the nitrocellulose facing the anode and frozen ice-pack inserted 
as the cooling unit all in the buffer. The cell was connected to the power pack 
(Bio-Rad) through the lid and ran at a constant current of 150mA for 60 
minutes. Proper transfer of the prestained molecular weight marker was used 






Figure 2.3 Gel nitrocellulose assembly for electrophoretic transfer cells. 
The blot was blocked for 1 hour on a shaker at room temperature with 
2% skimmed milk powder (Marvel) in PBS-Tween (500 l Tween20, 1X PBS tablet 
in 1L distilled water) (Blocking solution). Following blocking, the primary 
antibody (6x-His Tag monoclonal antibody) (ThermoFisher Scientific) was 
added at the dilution of 1:20000 and incubated overnight at 4 C on the shaker. 
After incubation, the blot was washed in PBS-Tween 3 x with 5 minutes shaking 
incubation in between each wash. The blot was placed in the 1:50000 dilution 
of the secondary antibody Anti-rabbit IgG-horseradish peroxide conjugate 
(Sigma), and incubated for 1 hour. Subsequently, the blot was washed 5x for 5 
minutes in PBS-Tween and 1 x in PBS.  
The chemiluminescent readout was accomplished using the enhanced 
chemiluminescence (ECL) substrate kit (ECL Western blotting detection 
reagent: GE Healthcare). The blot was incubated in the ECL for 1 minute and 
then placed in the autoradiography cassette. Working in the dark, the 




developed using the developer and replenisher (Carestream GBX) and fixer and 
replenisher (Carestream GBX). The film was washed with distilled water and 
allowed to dry.     
2.3.1.7.3 Catalase Assays 
2.3.1.7.3.1 Catalase activity 
Catalase activity was measured using Amplex Red Catalase Assay Kit 
(ThermoFisher Scientific) following the manufacturer's protocol described 
briefly as follows; The standard curve of 0 to 4.0 U/mL was prepared from the 
1000 U/mL catalase stock solution and 25 L of each of the standard as well as 
the sample (diluted in the 1X reaction buffer) were added to 96-well microplate 
with the negative control as 1X reaction buffer.  25 L of 40 M H2O2 was also 
added to each of the wells of the standards, samples and control and incubated 
at room temperature for 30 minutes. Following incubation, 50 L of  Amplex 
Red/HRP (containing 0.4 U/mL and 100 M Amplex red reagent in 1X Reaction 
buffer) was added to each of the wells of standard, samples and control and 
incubated for 30 minutes at 37 C away from light. The absorbance was 
measured in a microplate reader at 595 nm. The absorbance was reported by 
substracting the sample from the control without any catalase and catalase 
activities were interpolated from the standard. 
2.3.1.7.3.2 Catalase biochemical test 
To carry out the test, 5 L of the sample (rKatA) was dropped on a glass 




3 % H2O2 was added to each of the sample and the control. A positive result 
was considered by the rapid evolution of oxygen in the form of effervescence.  
2.3.2 Jurkat T Cell Suppression Assays 
The Jurkat T cell line was maintained in RPMI 1640 supplemented with 
10 % fetal bovine serum (FBS) and 100 g/ml and 100 U/ml of 
penicillin/streptomycin antibiotics and incubated at 37 C in an atmosphere 5 
% CO2. The 96 microwells flat bottom tissue culture plate (Thermo scientific) 
were pipetted with 200 l of the cell suspension at the density of 1 x 106 
cells/ml in triplicate. Then the cells were stimulated with increasing 
concentration (10, 25 and 50 g/ml in Tris buffer) of each of the purified 
recombinant KatA, GGT and PPT and incubated for 1 hour at 37 C. Then the 
cells were further stimulated with 50 ng/ml phorbol myristate acetate (PMA) 
and 1 M ionomycin, and incubated for an additional 24 hours. The 
supernatants were harvested after centrifugation to remove the cells. Finally, 
the resulting supernatants were stored in a – 80C freezer until assayed for the 
presence of IL-2 by ELISA as per the manufacturer’s instruction (ThermoFisher 
scientific). 
2.3.3 THP-1 Cell Suppression Assays  
THP-1 monocytic cells were maintained in culture media, RPMI 1640, 
supplemented with 10 % fetal bovine serum (FBS) and 100 g/ml and 100 U/ml 
penicillin/streptomycin antibiotics incubated at 37 C in an atmosphere of 5 % 




were pipetted with 200 l of the cell suspension at the density of 1 x 106 
cells/ml in triplicate. Then the cells were stimulated with increasing 
concentration of each of recombinant KatA, GGT and PPT (10, 25 and 50 g/ml) 
and incubated for 1 hour at 37 C. Then the cells were further stimulated with 
40 ng/ml LPS (mitogen) and incubated for an additional 24 hours. The 
supernatants were harvested by centrifuge to remove the cells. Finally, the 
resulting supernatants were stored away in the – 80 C freezer and assayed for 
the presence of IL-6 by ELISA as per the manufacturer’s instruction 
(ThermoFisher scientific). 
2.3.4 AGS Cell Suppression Assays  
AGS cells, a human adenocarcinoma cell line, were maintained in 
culture media, F-12 Ham, supplemented with 10 % fetal bovine serum (FBS), L-
glutamine and 100 g/ml and 100 U/ml incubated at 37 C in an atmosphere 5 
% CO2. The 24-well flat-bottom tissue culture plate (Thermo scientific) were 
pipetted with 200 l of the cell suspension at the density of 5 x 105 cells/ml in 
triplicate. Then the cells were stimulated with increasing concentration of each 
of recombinant KatA, GGT and PPT (10, 25 and 50 g/ml) and incubated for 1 
hour at 37 C. Then the cells were further stimulated with 40 ng/ml TNF- 
(mitogen) and incubated for an additional 24 hours. The supernatants were 
harvested after centrifugation to remove the cells. Finally, the resulting 
supernatants were stored away in the – 80 C freezer and assayed for the 





2.3.5 Cytokine ELISA Assays 
Human IL-2, IL-8 and IL-6 concentrations were measured in the 
supernatant from cell culture induction assays of Jurkat, AGS and THP-1 cells 
respectively, using Human IL-2, IL-8 and IL-6 ELISA kits (Invitrogen) following 
the manufacturer's protocol, with a detection limit <2 pg/ml. The optical 
densities of the 96 microtiter plate wells were measured using a plate reader 
(LabSystems iEMS reader MF) at dual wavelengths of 450 nm and 620 nm, and 
the data were analysed using Gen5 Data Analysis Software (BioTek). To 
calculate the cytokine concentration in each of the samples, a standard curve 
on each of the assay microplates (positive control) was used as the reference. 
Four control wells containing no cytokines were used to determine the assay 
sensitivity, calculated as the mean plus 3 times the standard deviation.  
 
2.3.6 Statistical analysis 
Graphs were prepared and statistical analysis was carried out using 
GraphPad Prism version 8.3 software. Data and error bars indicate the mean 
±SEM. Statistical significance was determined using a one-tailed Student T-test 
for data with a non-Gaussian distribution. Differences were considered 







2.4.1 Expression and purification of rKatA, rGGT and rPPT 
 
2.4.1.1 Cloning and Colony PCR of the katA, ppt and ggt genes to conform the 
transformation into ClearColi cells 
The recombinant plasmids containing the katA, ggt and ppt genes, 
made by Dr Jody Winter (Section 2.4.1.1) were purified and subject to 
transformation by electroporation into ClearColi. Transformed cells were 
plated on selective medium (LB agar containing 30 g/ml). After incubation, 
the resulting colonies were tested using colony PCR analysis, picking 6-7 
colonies from each plate. PCR products were analysed on an agarose gel. Gels 
were checked for the bands corresponding base pairs for each of the genes 
(katA, ggt and ppt genes,  in Figure 2.4 A; ppt in Figure 2.4 B; and ggt in Figure 






Figure 2.4 Confirmation of the transformation of Clearcoli competent cells with 
the recombinant plasmids.  A. 0.8 % (w/v) TAE agarose gel stained with 
ethidium bromide: Lane 1, 1kb DNA ladder; Lane 2, the purified katA DNA 
template as the positive control; Lane 3 -8 are 6 different colonies from the 
transformed LB plate; Lane 9, is the PCR prep without any DNA as the negative 
control. B. 0.8 % (w/v) TAE agarose gel stained with ethidium bromide: Lane 1, 
1kb DNA ladder; Lane 2, the purified ppt DNA template as the positive control; 
Lane 3; is the PCR prep without any DNA as the negative control; Lane 4-9 are 
6 different colonies from the transformed LB plate. C. Lane 1, 1kb DNA ladder; 
Lane 2, the purified ggt DNA template as the positive control; Lane 3 -7 are 5 
different colonies from the transformed LB plate; Lane 8, is the PCR prep 





2.4.1.2 Overexpression of the recombinant protein and purification by 
Immobilized metal affinity chromatography (IMAC) 
The expression of the three proteins in ClearColi was confirmed by 
analysing the pre and post-induction whole-cell samples by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The corresponding 
bands to the molecular weight for each of the recombinant proteins were 
visualised using PageBlue Protein Staining Solution. (rKatA in Figure 2.5 A; 







Figure 2.5 A typical SDS-PAGE showing the expression of the recombinant 
proteins rKatA, rPPT and rGGT. The ClearColi transduced with the his-tagged 
recombinant DNA were grown to the OD600 of 0.6-08, then induced with 1 mM 
IPTG and further incubated for 4 hours at 30 C in a shaker incubator. The cells 
were lysed by sonication on ice, then clarified by centrifuge to harvest the 
soluble fraction. Lane 1, prestained protein standard; Lane 2 Induced soluble 
lysate; Lane 3, the whole cells of IPTG induced ClearColi; Lane 4, pre-induction 
ClearColi whole cells. 
To aid purification of the proteins using immobilised metal affinity 
chromatography, the proteins were expressed in the ClearColi as a 
hexahistidine-tagged protein at the N-terminal. Then sonication was used to 
lyse the cells on ice in a binding buffer containing 20 mM Na3PO4, 0.5 NaCl, 10 
mM imidazole pH 7.4 with Protease Inhibitor Cocktail Tablets added. 
Afterwards, the lysates were separated by centrifugation and a sample of the 




PAGE and visualised using PageBlue Protein Staining Solution (rKatA in Figure 
2.5 A lane 2; rPPT in Figure 2.5 B lane 2; and rGGT in Figure 2.5 C lane 2). 
 
The supernatants containing the soluble proteins were then loaded 
onto 10 ml His GraviTrap Talon© columns for the first step purification and 
washed three times with the binding buffer containing 10mM imidazole to 
ensure the weakly bound impurities were washed off. Subsequently, the 
desired recombinant proteins are eluted in the elution buffer containing 
500mM imidazole. The purified eluted fractions were resolved by SDS-PAGE to 
ascertain the purity of the eluted purified product (rKatA in Figure 2.6 A; rPPT 








Figure 2.6 A typical SDS-PAGE analysis from the purification of rKatA, rPPT and 
rGGT. The induced ClearColi containing overexpressed recombinant proteins 
were lysed by sonication and centrifugation was used to separate the soluble 
fraction which was then applied to a prepacked His GraviTrap 1 ml TALON 
superflow chromatography. Lane 1, prestained protein standard; Lane 2, Final 
wash of the Talon; Lane 3; Final Talon elution. 
 
2.4.1.3 Further Purification of the Proteins by Size-exclusion Chromatography   
Size exclusion chromatography (SEC) also known as gel filtration, works 
with the principles of separating molecules based on the differences in the size 
following their movement through a column packed resin. This was employed 
to further purify the proteins after the metal affinity chromatography and to 
also carry out buffer exchange to remove the 500mM imidazole in the first 





contaminating proteins from the ClearColi host cells. To ensure that the 
purified proteins were collected at the correct molecular weight fraction, 
proteins standards were first to run in the SEC column and the resulting peaks 
from the calibration curve were used as a marker (Figure 2.7). 
 
A; Protein aggregate (void peak), B, Thyroglobulin 670 kDa-49 ml; C; -globulin 
158 kDa-63.8 ml; D; Ovalbumin 44 kDa – 80.45 ml; E; Myoglobin 17 kDa – 92.4 
ml; F; Vitamin B12 1.35 kDa -112.14 ml.  
 
 




2.4.1.4 rPPT purification by Size-exclusion chromatography 
The filtered rPPT samples from the first step of   His GraviTrap Talon© 
purification were loaded on to the SEC column and eluted into 5 ml fractions. 
Each of the fractions was resolved on 12% SDS-PAGE to confirm the presence 
of the desired protein in the eluted fraction, comparing the expected 
molecular weight from the calibration curve of the standard and the peaks 
from the purification run. The chromatogram below (Figure 2.8 A) shows 









Figure 2.8  A typical size exclusion (SE)/gel filtration chromatogram/ trace for rPPT 
purification. A. The vertical / X-axis indicates the level of absorbance downstream of 
the column measured by the UV detector in miliabsorbance units at 280 nm. The 
horizontal/Y-axis indicates the volumes separated by the system and collection in 
fractions of 5 ml. The fractions are indicated by rows of red lines with each peak 
representing the volume contain the proteins. The peak number 1 represents the 
larger aggregate of proteins also known as a void peak. Peak 2 represents the target 
protein rPPT and peak 3 represent the smaller molecular weight imidazole. B. A 
typical SDS-PAGE analysis of the fractions from the size exclusion purification of rPPT 
to confirm the presence of the target protein. Lane 1, prestained protein standard. 
Lane 2, a pool of fractions 4, 5,6, 7 and 8, Lane 3 is the concentrated fraction protein 





The SDS-PAGE analysis of the fractions showed that the recombinant protein 
was present in fractions 4, 5, 6, 7 and 8 according to the expected molecular 
weight of rPPT. The weak band at 34 kDa was due to dilution of the fraction 
from the SEC elution (Figure 2.8 B Lane 2). The protein in the pooled fractions 
was further concentrated (Figure 2.8 B lane 3) and the total protein 
concentration was measured using BCA assay. The SDS-PAGE analysis indicated 
an approximate 90% purity. The concentrated protein was aliquoted, 
subjected to a quick freeze in liquid nitrogen and stored in -80 C until needed. 
 
2.4.1.5 rKatA purification by Size-exclusion chromatography 
The chromatogram of rKatA samples subjected to purification by SEC 
column and collected in of 5 ml fractions (Figure 2.9 A). Each of the fractions 
was resolved on 10% SDS-PAGE gel to confirm the presence of the desired 
protein. Eluted fraction 6, 7 and 8, comparing the expected molecular weight 
from the calibration curve of the standard and the peaks from the purification 
run. The SDS-PAGE (Figure 2.9 B ) shows asymmetric rKatA elution, indicating 











Figure 2.9 A typical size exclusion (SE)/gel filtration chromatogram/ trace for rKatA 
purification. A. The vertical / X-axis indicates the level of absorbance downstream of the 
column measured by the UV detector in miliabsorbance units at 280 nm. The horizontal/Y-axis 
indicates the volumes separated by the system and collection in fractions of 5 ml. The fractions 
are indicated by rows of red lines with each peak representing the volume contain the proteins. 
The peak number 1 represents the larger aggregate of proteins also known as the void peak. 
Peak 2 represents the target protein rKatA and peak 3 represent the imidazole which is quit a 
smaller molecular weight. B. A typical SDS-PAGE analysis of the fractions from the size 
exclusion purification of rKatA to confirm the presence of the target protein. Lane 1, prestained 
protein standard, Lane 2, pooled fractions 6, 7 and 8, Lane 3 is the concentrated fraction 






2.4.1.6 rGGT purification by Size-exclusion chromatography 
The chromatogram of rGGT samples subjected to purification by SEC 
column and collected in of 5 ml fractions (Figure 2.10 A). Each of the fractions 
was resolved on 10% SDS-PAGE gel confirm the presence of the desired 
protein. Eluted fraction 6, 7 and 8, comparing the expected molecular weight 
from the calibration curve of the standard and the peaks from the purification 
run. The SDS-PAGE (Figure 2.10 B ) shows asymmetric rGGT elution, indicating 



















Figure 2.10. A typical size exclusion (SE)/gel filtration chromatogram/ trace for rGGT 
purification. A. The vertical / X-axis indicates the level of absorbance downstream of 
the column measured by the UV detector in miliabsorbance units at 280 nm. The 
horizontal/Y-axis indicates the volumes separated by the system and collection in 
fractions of 5 ml. The fractions are indicated by rows of red lines with each peak 
representing the volume contain the proteins. The peak number 1 represents the 
larger aggregate of proteins also known as the void peak. Peak 2 represents the 
target protein rGGT and peak 3 represent the imidazole which is the smaller 
molecular weight. B. A typical SDS-PAGE analysis of the fractions from the size 
exclusion purification of rGGT to confirm the presence of the target protein. Lane 1, 
prestained protein standard, Lane 3, a pooled fraction of 6 and 7, 8, Lane 2, is the 






2.4.2 Western Blot analysis of Size exclusion chromatography 
purified recombinant proteins. 
To confirm the identity of the three purified proteins (Section 2.4.1), 
each of the protein products from the second step of the purification process 
was resolved by SDS-PAGE and transferred on to a nitrocellulose filter and 
probed with an anti-hexahistidine-tagged antibody.  The bands were visualised 
using a chemiluminescent substrate and autoradiography film (Figure 2.11). 















Figure 2.11 His tag Immunoblot confirmation of purified of rKatA, rPPT and 
rGGT. ClearColi BL21(DE3) cells containing overexpressed recombinant 
proteins were lysed by sonication and the soluble fraction were subject to 
metal affinity purification on His Gravitrap Talon (GE Healthcare). Afterwards, 
the recombinant proteins were concentrated using a vivaspin concentrator 
and further purified by size exclusion chromatography. Lane 1, prestained 
protein standard; lane 2, rKatA; lane 3, rPPT; lane 4, metal affinity-purified rPPT 
(positive control); lane 5, rGGT. 
 
2.4.3 Catalase Assay  
2.4.3.1 Qualitative Catalase biochemical test 
Catalase is a very active enzyme that can degrade in the removal of 
peroxides such as hydrogen peroxide (H2O2). Catalase acts on H2O2 to releases 
oxygen bubbles in the form of effervescence. Therefore, the catalase produced 




adding 2µl of 3% H2O2 to the 2µl of Catalase solution on a clean glass slide. 
Effervescence was produced on the catalase slide depicting catalase activity, 
while no effervescence was observed on the control containing the rGGT 
produced above (Section 2.4.1.6).  Therefore, the purified recombinant KatA 
(catalase) retains its activity throughout the purification process.   
 
 
Figure 2.12 Qualitative Catalase biochemical test. The rKatA purified was 
placed on a glass slide (5 L) with 5 L of rGGT on another slide as control, 5 
L of 3 % H2O2 was added to each of the slides and prompt effervescence 
indicates presence and activity of the catalase. A. Contain the purified rGGT 
and produce no effervescence. B. Contain the rKatA and shows the presence 





2.4.3.2 Catalase activity 
To quantitatively measure the activity of the recombinant purified H. 
pylori catalase (KatA) (Section 2.4.1.6), a commercially available Amplex Red 
Catalase A standard curve was used to determine the level of activity in the 
sample. (Table 2.1) The assays determined that the purified recombinant 
catalase protein at the concentration of 317.849 µg/ml had an enzymatic 
activity of 3.572 U/g. 
Table 2.1.Catalase activity 
Protein concentration (g/mL)       Catalase activity (U/mL) 





2.4.4 Investigation of the role of KatA, PPT and GGT in 
Immunomodulation 
2.4.4.1 Analysis of the ability of rKatA, rGGT and rPPT to inhibit IL-2 production 
by activated Jurkat T cells 
To investigate the ability of the purified recombinant proteins to inhibit 
activation of T cells, a Jurkat T cell suppression assay, previously used by Gebert 
et al.(Gebert et al., 2003) was employed with a readout of IL-2 production.  
In a dose-dependent manner 10 g/ml, 25 g/ml and 50 g/ml of rKatA 
were used to treat Jurkat cell for 1 hour. To ensure the effectiveness of the Tris 
buffer (50 mM Tris base pH 8.8, 200 mM NaCl) in which the protein is stored 
did not affect the outcome of the investigation, control cells were treated with 
the buffer only. Subsequently, the cells were stimulated with 20 ng/ml PMA/ 1 
M ionomycin for 24 hours. The supernatants were harvested by 
centrifugation and the levels of IL-2 expression were measured by ELISA. 
The buffer alone was found not to have a significant detrimental effect 
on the cells (presented below in Figure 2.14). The results showed dose-
dependent reductions in IL-2 production, however, significant differences from 
the buffer control were found only with the highest concentration of rKatA (50 
𝜇g/ml) (P<0.05) (Figure 2.14A) and with only 50 𝜇g/ml rGGT  (P<0.05) (Figure 
2.14B). There was no significant difference for all concentrations of rPPT 






Figure 2.13 Effects of purified KatA, GGT and PPT on IL-2 secretion by Jurkat T 
cells. Effects of purified KatA, GGT and PPT on IL-2 secretion by Jurkat T cells. 
Jurkat cells were seeded in 96-well plates at 1 x 106 per well and were 
pretreated with purified rKatA, rGGT and rPPT at the indicated concentrations 
for 1 hour at 37°C and  5% CO2. The cells were then stimulated with phorbol 
myristate acetate (PMA) (50 ng/ml) and ionomycin (500 ng/ml). After 24 hours 
the cells were pelleted and the concentration of IL-2 in the supernatant was 





independent experiments. (A) Only the highest concentration of rKatA (50 
𝜇g/ml) significantly reduced the IL-2 response (P<0.05).  (B) Also, with only 50 
𝜇g/ml rGGT significantly suppressed IL-2 secretion (P<0.05). (C) rPPT did not 
have immunomodulatory activity on Jurkat cells.  
 
 
2.4.4.2 Analysis of the ability of rKatA, rGGT and rPPT in the inhibition 
of IL-6 production in monocytic THP-1 cells. 
Similarly, the ability of the H. pylori factors under investigation to 
suppress IL-6 production in Monocyte-macrophage cell model was also 
investigated.  
As shown in the Figure 2.15 A, B, C with all the concentration of 
proteins, rKatA, rGGT and rPPT, 10, 25 and 50 𝜇g/ml there was no significant 
suppression of IL-6 compared to the Tris buffer control. There were trends for 
changes in the level IL-6 with an increase in the concentration of the proteins, 





Figure 2.14 Effects of purified KatA, GGT and PPT on IL-6 secretion by THP-1 
cells. Effects of purified KatA, GGT and PPT on IL-6 secretion by THP-1 cells 
(monocyte-macrophage cell model).  THP-1 cells were seeded in 96-well plates 
at 1 x 106 per well and were pretreated with purified rKatA, rGGT and rPPT at 
the indicated concentrations for 1 hour at 37°C and  5% CO2. The cells were 




concentration of IL-6 in the supernatant was analysed by ELISA. Bars represent 
the means and standard deviations of three independent experiments. There 
was an inhibition of IL-6 with rKatA, rGGT and rPPT, but the difference were 
not statistically significant. 
 
2.4.4.3 Analysis of the ability of rKatA, rGGT and rPPT in the inhibition 
of IL-8 production in AGS cells 
Following a similar technique described in section---- used in for Jurkat 
cells IL-2 suppression assay, the ability of the proteins- rKatA, rGGT and rPPT 
to suppress IL-8 in epithelial cells were tested.  
In all the concentrations (10, 25 and 50 𝜇g/ml) of the recombinant 
proteins, rGGT and rPPT, there was no suppression of IL-8 secretion compared 
to the tris buffer (Figure 2.16 B and C). The plots rather showed an increase in 
IL-8. rKatA (Figure 2.16 A) at concentrations 10 and 25 𝜇g/ml exhibited no 
suppression of IL-8 secretion compared to the Tris buffer but only 50 𝜇g/ml 
concentration showed suppression of the cytokine but still significant to 








Figure 2.15 Effects of purified KatA, GGT and PPT on IL-6 secretion by AGS cells. 
Effects of purified KatA, GGT and PPT on IL-8 secretion by AGS cells monocyte-
macrophage. THP-1 cells were seeded in 24-well plates at 1 x 106 per well and were 
pretreated with purified rKatA, rGGT and rPPT at the indicated concentrations for 1 
hour at 37°C. The cells were then stimulated with TNf-. After 24 hours the cells were 
pelleted and the concentration of IL-8 in the supernatant was analysed by ELISA. Bars 
represent the means and standard deviations of three independent experiments. 
There was an inhibition of IL-8 with rKatA, rGGT and rPPT, but the difference were not 




independent experiments. There was an inhibition of IL-8 with rKatA, rGGT and rPPT, 






The ultimate aim of this study was to investigate the ability H. pylori 
factors that suppress inflammation by interacting with a variety of cell types. 
The main conclusion from the present results was that KatA and  GGT showed 
significant immunoregulatory activities by inhibiting IL-2 production T cell 
model, similarly KatA, GGT and  PPT showed a trend in in reduction  of IL-6 
production in macrophage-monocyte cell model with increase in concentration 
of the proteins. Present results point towards possible alternative ways utilised 
by the bacteria to down-regulate inflammation in the gastric mucosa. 
2.5.1 Recombinant proteins expression and purification   
Fitting to the purpose for which the proteins were to be tested, the 
recombinant proteins KatA, GGT and PPT were successfully expressed in 
ClearColiBL21 (DE3) electrocompetent cells but not without problem.  These 
all were used to avoid contamination of the protein by LPS. Unfortunately, 
ClearColi (DE3) is known to grow 50% slower than po most E. coli strains such 
as BL21 (DE3) (Lucigen, 2019)and B834. Thus, longer growth time is needed to 
reach the required optical density (OD) prior to the protein induction and as 
such protein yield at optimal exponential growth phase were low compared to 
the wild type. To overcome the low yield, several batches of the induced 
proteins are needed to obtain a concentration that could be purified using gel 




The recombinant protein was purified in a two-step purification process 
according to the features of the proteins, which are the hexahistidine at the N-
terminal and the sizes. This is deemed necessary as the purified product of 
metal immobilised affinity chromatography (the first step) could be 
contaminated by other E. coli proteins such as SlyD (29kDa). SlyD has   (Parsy et 
al., 2007). Hence, the second step, size exclusion chromatography (SEC) was 
used to ensure that purer proteins were obtained, this technique separates the 
proteins, based on the sizes of the constituent molecules. Regardless, there 
could still be the probability of having a contaminant of rich histidine domain, 
which might show affinity and the same size as the targeted recombinant 
proteins. For rKatA, a combination of quantitative and qualitative catalase 
enzyme assays helped to prove its biological activities. The anti-his-tagged 
Western Blot assay, which probes for the hexahistidine sequence at the N-
terminal of each of the protein using a monoclonal antibody provides extra 
assurance of the purity of the recombinant proteins. 
 The use of the ClearColi BL21(DE3) electrocompetent cells, 
commercially available cells, as the host for the recombinant plasmids, reduced 
the chances of common LPS contamination of a recombinant protein 
preparation from the host E. coli (Heumann and Roger, 2002, Mamat et al., 
2015). More than half of recombinant proteins in biopharmaceutical and 
research industries are produced in E. coli and stand a chance of being 
contaminated with the immunostimulatory molecule LPS(Huang et al., 2012). 




to entirely eliminate LPS from recombinant protein products (Wakelin et al., 
2006). Some of the few post expression LPS removal methods such as Triton X 
separation, adsorption on activated carbon, ultrafiltration, anion-exchange 
chromatography, IMAC and polymyxin B treatment are known to be inefficient 
and poor selectivity (Petsch and Anspach, 2000). LPS is a known agonist of TLR4, 
CD14 and MD-2 receptor complex which is present in several cells of the innate 
immune system (Triantafilou and Triantafilou, 2002). The recognition of the 
receptor complex enables the phosphorylation and recruitment of the cascade 
of intracellular adaptor kinases leading to NF-B activation and subsequent 
pro-inflammatory cytokine secretion (Palsson-McDermott and O'Neill, 2004, 
Rossol et al., 2011). In the light of these, instead of post-processing removal of 
LPS, the LPS was genetically modified to lipid IVA in a BL21 (DE3) background. 
This bacteria cell line was created to process uncontaminated recombinant 
proteins. This was achieved by seven genetic deletions (∆gutQ ∆kdsD ∆lpxL 
∆lpxM ∆pagP ∆lpxP ∆eptA) which alter the LPS to Lipid IVA and one additional 
mutation to preserve the viability of the cells with Lipid IVA. This newly created 
ClearColi cells lack the agonists for TLR4/MD-2 activation, therefore the signal 
from the ClearColi are reported to be far lower in magnitude compared to the 
wild-type. Similarly, recombinant proteins prepared from ClearColi are 
practically endotoxin-free with minimal purification (Lucigen, 2019, Mamat et 
al., 2015). To avoid extraneous contamination of preparations, all water 
sources used were commercially available endotoxin free, heat treat 




purchased, disposable pipette tips were used, and good laboratory sterile 
cleaning technique were the precautionary measures employed. 
Although using ClearColi® BL21 (DE3) afford purity and immunological 
advantages especially in that the proteins are free from LPS, there are a number 
of drawbacks in using this strain. ClearColi® BL21 (DE3) has a slow growth rate 
compared to wildtype and this, in turn, affects the overexpression of the 
protein.  
 
2.5.2   Investigation of the mechanism through which KatA, GGT 
and PPT contribute to immune regulation  
In this study the suppression assay was used to investigate any possible 
mechanism of KatA, GGT and PPT mediated regulation. The assay was 
suppression of IL-2 in T-cell model (Jurkat cells), IL-6 in the monocyte-
macrophage model (THP-1 cells) and epithelial cell model (AGS cells). With the 
exception of IL-8 secretion in AGS, GGT and KatA at high concentration 
suppressed significantly the expression of  the IL-2 and IL-6 in Jurkat and THP-1 
cells. The result offers a substantial optimism for the mechanistic study of 
secretion process of the protein in vivo and the mechanism of their interaction 




2.5.2.1 IL-2 suppression in Jurkat cells  
T cells has been shown to be vital in eradiction of bacterial infection 
(Ermak et al., 1998). However, H. pylori VacA protein was shown to block T cell 
proliferation and activation by arresting G1/S cycle following stimulation with 
phorbol 12-myristate 13-acetate (PMA) and ionomycin (Gebert et al., 2003, 
Torres et al., 2007). The report explained that VacA interferes with the T cell 
receptor/interleukin-2 signalling pathway by inhibiting the transcription factor 
NFAT leading to downregulation of IL-2 transcription. PMA is an analogue of 
diacylglycerol that stimulates Jurkat cell by diffusing into the cell and activating 
protein kinase C(PKC). It works synergistically with Ionomycin, a calcium 
ionophore, to elicits calcium release (Chatila et al., 1989).  
The result of this experiment showed that a high concentration of (50 
g/ml) KatA and GGT strongly suppressed IL-2 secretion by Jurkat cells (79.5% 
reduction with 50 g/ml, p<0.05), while PPT did not suppress IL-2 production 
in Jurkat cell. The potential and the mechanism through which GGT inhibits IL-
2 production could be associated to its capacity to block T-cell proliferation by 
induction of cell cycle arrest from G1 via suppression of G1 cyclin-dependent 
kinase activity(Gerhard et al., 2005) this is in similar fashion as the mechanism 
utilised by VacA (Sundrud et al., 2004, Sewald et al., 2011). This is in contrast to 
H. pylori KatA activity on which has no known direct immune-regulatory 
attribute on T cell prior to this research.  
In the past, most of KatA immunoregulatory properties have been in an 




(Seo et al., 2002). But with the result of this experiment showing that IL-2 is 
suppressed at the highest concentration of KatA, it is only logical to assume that 
KatA suppression of IL-2 is concentration-dependent and it is only at 50 g/ml 
that KatA is enriched enough to exact immunosuppression. The argument is 
deemed strong when compared to VacA, another H. pylori factor that is 
secreted via a type V auto-transport mechanism (Palframan et al., 2012) and 
therefore easily accessible to immune cells in enriched level sufficient to exact 
immunosuppression. On the other hand, KatA is a cytoplasmic protein with no 
known signal-protein sequence for translocation across the cell envelope. 
Although reports have shown the presence of this enzyme both in the 
periplasmic space and on the bacterial cell surface (Harris et al., 2003, Phadnis 
et al., 1996), a number of recent researches have reported the presence of KatA 
in the outer membrane vesicles (OMV) that are  constitutively shed by H. pylori  
(Wang et al., 2006, Mullaney et al., 2009). Surprisingly, till date, no other means 
of translocation of this protein is known, yet it is constantly found in abundance 
in the environment of H. pylori both in vivo and in vitro.  Furthermore, more 
than 7% of the OMV was shown to be KatA alone (Mullaney et al., 2009). 
Lekmeechai et al in their recent work showed that KatA is enriched in the OMV 
the compared with the outer-membrane of an intact bacterial cell, up to seven-
fold higher (Lekmeechai et al., 2018).  
With this knowledge, it could be speculated that the KatA 
immunosuppressive activity would be more pronounced in vivo where it is 




Additionally, as there has been no evidence of any known KatA receptor 
on any cell surface, it is suspected that KatA could probably  be binding to an 
internal receptor or molecule. Past studies have shown that the key mechanism 
bacterial OMV mediated inflammation is in its ability to penetrate non-
phagocytic cells and induce production of cytokines (Kaparakis et al., 2010, 
Bomberger et al., 2009, Chatterjee and Chaudhuri, 2011). While H. pylori, is 
known to be non invasive, nevertheless the bacteria, still could deliver factors 
into the host cells (Parker et al., 2010). 
Hence, we conclude that at high concentration, which is evidently 
possible in vivo, there is a possibility that KatA plays a role in the 
immunoregulatory function of H. pylori. 
  
2.5.2.2 IL-6 suppression in THP-1  
During almost every inflammation condition cytokines such as IL-1, TNF-
 and IL-6 are usually elicited and hence are been of the prominent targets for 
anti-inflammatory therapy (Scheller et al., 2011). IL-6 is a 21-28 kDa 
glycosylated protein which binds to the IL-6 receptor, IL-6R, (gp80) and type I 
transmembrane signal transducer protein (gp130).  To activate the JAK/STAT, 
ERK and P13K pathways, IL-6 binds to the IL-6R to form a complex which in turn 
binds to the two molecules of gp130, leading to signal transduction and this is 
called classical signalling (Oberg et al., 2006). In macrophages, neutrophils, 




present on most cells (Rose-John et al., 2007, J and S, 2006). But to complement 
the absence of IL-6R on most the cells surfaces there is soluble IL-6 receptor 
(sIL-6R) in the plasma, which complex with IL-6 to agonistically bind to gp130-
expressing cells (Rose-John and Heinrich, 1994, Rose-John et al., 2007). This 
activation by sIL-6R/IL-6 complex of cells expressing gp130 only, called trans 
signalling, is very important in inflammation especially for lymphocyte 
attraction into the area of inflammation and promotion of T cell proliferation 
(Chalaris et al., 2007, Chen et al., 2006). Consequently, turning off production 
IL-6 in THP-1 step using the rKatA, rGGT and rPPT will be steps toward 
therapeutic blockade of IL-6 effect.  
The result did not show a significant reduction in IL-6 production in THP-
1 cell stimulated with LPS. interestingly to see that there is a noticeable change 
in IL-6 level as the concentration of each factor increases.  GGT was most 
effective in suppressing IL-6 from THP-1 cells (68.07% reduction with 50 g/ml). 
 
2.5.2.3 IL-8 suppression in AGS cell  
IL-8, a member of the CXC chemokine family was formerly known as a 
neutrophil chemoattractant (Schroder et al., 1987, Walz et al., 1987). It is also 
known as CXCL8 and is known to play an important role in inflammation and 
defence mechanisms (Zlotnik and Yoshie, 2000). Further research has shown 
that IL-8 could perform other functions apart from being a chemoattractant for 




(GIT). The pool of IL-8 in the GIT is generally from both local cells such as 
epithelial cells, endothelial, fibroblasts, and migratory cells, such as monocyte 
and neutrophils. IL-8 expression can be acute, as in the case of microbial 
infection and reports have shown continuous IL-8 production in cancerous 
gastric epithelial cells. Dysregulation of IL-8 is hypothesized to play a part in the 
pathophysiology of the development of several diseases, and IL-8 could, 
therefore, be a target for therapeutic use as a potential biomarker (Cotton et 
al., 2015). H. pylori is known to induce IL-8 cytokine secretion in the gastric 
epithelial cell line in vitro in a sequence of events that culminates in activation 
tyrosine kinase activation and NF-κB pathway (Sharma et al., 1995, Sharma et 
al., 1998). Consequently most studies have focused on the induction of IL-8 by 
H. pylori in the mucosal especially in relation to cag PAI (Peek et al., 1995, 
Yamaoka et al., 2006, Crabtree JE, 1994, Yamaoka, 2010). 
An experiment was set up to investigate immunosuppression of one 
more pro-inflammatory cytokine, IL-8, by the H. pylori factors, GGT, KatA and 
PPT in AGS cells stimulated with TNF-α. Interestingly, the GGT results showed 
the opposite, raising the question of whether the molecules could be playing a 
role in proinflammation induction. KatA showed a noticeable trend in the 
reduction in IL-8 production at a concentration of 50 µg/ml which is not 
statistically significant, similar to result obtained with PPT. Conversely, GGT 
tends to show in the concentration of IL-8 with the increase in the 
concentration of the protein. Two studies reported the abrogation of IL-8 




PAI (Li et al., 1999, Sharma et al., 1998). Their results showed that IL-8 induction 
in AGS is mainly abrogated by molecules exhibiting protein tyrosine kinase 
inhibitors. While Segal et al using kinase inhibitors, staurosporine and genistein, 
reported that besides of tyrosine phosphorylation of the cellular 145 kDa 
protein with inhibition in IL-8, there could be other ways of IL-8 inhibition which 
is independent of tyrosine phosphorylation (Segal et al., 1997).  
In several studies, IL-8  expression down-regulation has been widely 
reported in epithelial and endothelial cells in a redox responsive transcriptional 
manner (DeForge et al., 1993, Roebuck, 1999, Lakshminarayanan et al., 1997, 
Lakshminarayanan et al., 1998, Vlahopoulos et al., 1999). But it was Lekstrom-
Himes et al that showed that catalase specifically has the ability to significantly 
suppress IL-8 expression by suppression the IL-8 mRNA transcription (Lekstrom-
Himes et al., 2005). They reported that catalase performs this function by acting 
as hydrogen peroxide scavenger. Hydrogen peroxide is to chemically inhibit the 
activities NADPHnoxidase activity thereby stimulating the increase in IL-8 
mRNA production in cells. Nevertheless, the result of this experiment failed to 
establish any of this with H. pylori KatA. 
2.6 Conclusion   
• KatA and GGT at high concentration of 50 µg/ml significantly 
inhibit IL-2 in T  cells model and could be deemed to have had 
direct immunosuppressive activities. 




• The three H. pylori factors do significantly suppress IL-6 
production in a monocyte-macrophage cell model, although 
there were trends on decrease cytokine production with the 
increase in the concentration of the proteins. 
•  IL-8 production in epithelial cell model was not significantly 
suppressed by any of the factors but KatA and PPT showed a 
trend in reduction of the cytokine production. Conversely, GGT 





Chapter 3  
 
In vivo investigation of 
immunoregulatory properties of Helicobacter 









3.1 Introduction  
Originally, the virulence factor, VacA was primarily known by its 
vacuolating activity in the eukaryotic cytoplasm (de Bernard et al., 1997). In 
recent decades, VacA researches have revealed so many other functions of the 
protein, one of which is immunomodulatory activities. This activity of VacA on 
the immune cells could be perceived to be a very important step towards the 
understanding of the colonisation ability of the bacteria.  In mouse models, 
Salama et al reported that the wild type strains expressing VacA readily 
outcompete the mutant strains lacking VacA in a mixed infection of the mouse 
stomach: showed that a VacA plays a role in the establishment of infection 
hence, in a single infection, the ID50  of the wild type was two times higher than 
the mutant (Salama et al., 2001a). Oertli et al working on VacA and GGT 
established a similar result of the inefficiency of vacA mutant to colonise 
compare to the wild type (Oertli et al., 2013a). It has been revealed also that 
most of the human isolates are positive for vacA-positive, although there is 
variation in the alleles and expression level (Xiang et al., 1995).  A study by 
Winter et al on the allelic differences revealed that H. pylori producing the less 
active type s2i2 form of VacA promote colonisation the mice gastric efficiently 
than the VacA deficient isotype or the more active s1i1 form. On the other 
hand, the more active form of VacA was implicated in the study for induction 
of extensive metaplasia and inflammation in mouse compared to the less active 
form (Winter et al., 2014).  Other studies were also in agreement with finding, 




gastric cancer and premalignant lesions (Rhead et al., 2007, Basso et al., 2008). 
The inference from these reports answers the question of why H. pylori strains 
would actively be producing a supposedly “not needed molecule” – the 
nonactive toxin? Which could go on to explain that it largely performs other 
functions different from the toxin activities. Hence, cytotoxic activities and 
immunological activities are divergent and unrelated. 
The immunomodulation effect of VacA has been well studied to shed 
light on a number mechanism through which this is achieved. These include 
interference with phagosome maturation and intracellular trafficking in 
macrophages (Allen et al., 2000), interference with T-cell receptor/interleukin-
2 signalling pathway through the Ca2+/calmodulin-dependent phosphatase 
calcineurin which culminates in VacA inhibition of T-cell proliferation and 
finally, promotion of differentiation of regulatory T-cell by hijacking the 






One of the profound effects H. pylori on the immune system, both in 
vivo and in vitro, is its ability to reprogram of the DC towards tolerogenic 
phenotype, and consequently the bacteria colonisation (Wang et al., 2010). 
Downstream, the reprogrammed DC is skewed towar5ds priming the 
regulatory T-cell instead of the effector T-cells (Th1 and TH17) thereby 
favouring an anti-inflammatory immune response over a pro-inflammatory 
response (Oertli et al., 2012). A study by Oertli et al on the immunomodulatory 
effect of VacA prove similar effect as the H. pylori itself. They demonstrated 
that DCs isolated and purified immunomagnetically from mice infected with 
wild-type (VacA-proficient) H. pylori strains and those from the uninfected mice 
or VacA mutant infection exhibit a remarkable difference in the type of T-cell 
response. They showed induction of regulatory T-cell response by DCs from the 
wild type as opposed to the DCs from either uninfected or VacA mutant (s1i1) 
infected mice, which exhibited proinflammatory responses characterised by a 
higher number of Th1, Th17, their associate cytokine; IFN- and IL-17 as well as 
low numbers of  Foxp3+ CD25+ regulatory T-cells. In addition to these, they also 
confirmed the lower colonisation level among the VacA mutant compared to 
the wild type(s2i2) (Oertli et al., 2013a).  
This study and many other similar studies failed to provide information 
on the difference in regulatory T-cell induction by various VacA variants. But 
since it has already been proven that less vacuolating cytotoxic form promotes 




2014), we hypothesis that the non-cytotoxic VacA type, s2i2 promotes the 
induction of CD4+CD25hiFoxp3+ Treg more efficiently than the toxic VacA type. 
Therefore, the following objectives were set out. 
• To compare the CD4+ T lymphocyte frequencies in the spleens 
of uninfected and H. pylori-infected mice at different time 
intervals of 3, 6 and 9 weeks. 
•  To quantify the fraction of this CD4+ T lymphocyte exhibiting 
Treg properties of CD4+CD25hiFoxp3+ and signature cytokine IL-
10. 
•  To compare the difference in CD4+CD25hiFoxp3+ Treg 
frequencies in mice infected with different forms of VacA 
expressing H. pylori 
•  To compare the suppressive potential of Treg from the spleen 




3.3 Materials and Methods 
3.3.1 Study team and organisation 
This experiment was carried out as part of multidisciplinary researches 
in the Helicobacter pylori research group of the Nottingham Digestive Disease 
Centre. This comprises of the Molecular microbiology team, Immunology team 
and PhD students lead by Dr Karen Robinson, Dr Darren Lentley, Dr Kazuyo 
Kaneko, Mrs Jo Rhead, Dona Reddiar and yours sincerely. The experimental 
procedures were carried out under Home Office project licence number 
30/3298, with ethics approval and in line with institutional guidelines on animal 
welfare.  
3.3.2  Infection of mice with H. pylori 
The 6 weeks old female C57BL/6 mice were obtained from Charles 
River. They were housed and feed appropriately and allowed to acclimatise one 
week before the experiment began.  
Groups of 18 female 6-week-old C57BL/6 mice were infected with H. 
pylori by administering oral doses of 100 µl of Brucella broth (Difco 
Laboratories) containing 1 x 109 bacteria of the SS1 strain (either the wild type 
expressing the s2/i2 form of VacA or a mutant strain expressing the s1/i1 form 
of VacA). Doses were administered on three alternate days.  A further 18 mice 
received oral doses of plain Brucella broth as a placebo control. At 3 weeks, 6 




terminated. Colonization densities and histological parameters were assessed 
from stomach tissue and spleens were removed for comparative analyses of 
the immune response. 
3.3.3 Splenocyte preparation  
Spleens were removed and rubbed through a 40 µm cell strainer (BD 
Biosciences Oxford, UK) using a sterile disposable 1 ml syringe. The splenocyte 
suspensions were washed and a sample was removed and mixed with 3% acetic 
acid with methylene blue (Stemcell Research) for counting using a 
haemocytometer. The cell concentration was then adjusted to 1 x 107 per ml, 
suspending the cells in culture medium (RPMI with 10% foetal calf serum 
(FCS)/100U/ penicillin G/100 µg/ml streptomycin sulphate). 
 
3.3.4 Quantifying Tregs amongst splenocytes 
1ml of each splenocyte suspension (containing 1 x 107 cells) was 
centrifuged at 300 x g for 3 minutes and resuspended in 1 ml red blood cell 
lysing buffer (Sigma Aldrich). After 1 minute 10 ml of culture medium was 
added and the cells were washed twice, spinning the tubes at 300 x g for 3 
minutes. Finally, the cells were resuspended in 10 ml of culture medium. 
130 µl of phorbol myristate acetate (PMA) / lipopolysaccharide 
(LPS)/ionomycin stimulation cocktail was added to 1 ml of the cell suspensions 




for 1 hour. 10 µl Brefeldin A Solution (BFA) was added to the tubes to give a 
final concentration of 1 x 106 per ml and incubated at 37°C for a further 5 hours. 
Unstimulated controls were prepared from each cell suspension. These 
were stored in the cold room at 4°C. 
 
3.3.5 Cell staining and flow cytometry 
Following incubation, the cells were pelleted at 300 x g for 5 minutes 
before staining with the appropriate combination of fluorochrome-conjugated 


















Biolegend 100566 1 µl RM4-5 
CD25 BV421 Anti-
mouse CD25 
Biolegend 102043 0.5 µl PC61 





1 µl FJK-16s 
IL-10 AF647 Anti-
mouse IL-10 
Biolegend 505016 0.5 µl JESS-16E3 
Isotype controls 
 Iso-CD25 BV421 anti-
mouse IgG1 
Biolegend 401911 0.5 µl GO114F7 
 Iso-Foxp3 FITC anti-
mouse IgG2a  
Biolegend 400505 1 µl RTK2758 
 Iso-IL-10 AF647 anti-
mouse IgG2b 
Biolegend 400626   0.5 µl RTK4530 
     NB: PE, phycoerythrin;  
FITC, fluorescein isothiocyanate; 





 Antibodies against CD4 and CD25 were added and the tubes were incubated on ice 
for 30 min. The cells were then washed twice with 1 ml PBA buffer (phosphate-buffered saline 
(Oxoid) containing 2% bovine serum albumin (BSA) (Sigma) and 0.1% sodium azide (Sigma)), 
before fixing in 0.5 ml fixation buffer (Biolegend) at room temperature for 20 mins in the dark. 
Cells were then washed with 1 ml PBA and permeabilized by washing first with 1 ml 
PBA-saponin (PBA with 0.1% saponin (Sigma), and then with 1 ml PBA-saponin/10% FCS.  The 
cell pellet was then stained with the IL-10 antibody conjugate according to a previously 
described protocol (Biolegend), incubating for 2 hours at 4oC with periodic gentle mixing. At 
the end of the incubation, the cells were washed with 1 ml PBA-saponin and then with 1 ml 
1x Perm buffer (Biolegend), before adding 1 ml 1x Perm buffer and incubating at room 
temperature for 10 min in the dark. The cells were pelleted, and Foxp3 antibody conjugate 
was added directly to the pellet and incubated at room temperature for a further 30 min in 
the dark. After the incubation, the cells were washed twice in 1 ml PBA and finally 
resuspended in 0.5 ml PBA. 
Data on 200,000 events were acquired using a MoFlo Astros EQ flow cytometer 
(Beckman Coulter). Controls consisted of unstained cells, cells stained with a single 
fluorochrome-conjugated antibody and the staining antibody combinations minus one. These 
were included to optimise compensation settings. Data analysis was performed using Kaluza 




3.3.6 T cell isolation 
CD4+ CD25+ T regulatory (Treg) cells and CD4+ CD25- T effector cells (Teff) were purified 
from the splenocyte suspensions from the treatment groups using a magnetic bead 
separation kit (Miltenyi Biotec). Because of the requirement for large numbers of cells for this 
process, 5 x 107 cells from each of the two samples were combined. Each group of six 
splenocyte suspensions, therefore, resulted in three purifications per group. CD4+ CD25- 
splenocytes from a further two untreated animals were also purified in the same way to 
generate a single pool of CD4+ CD25- T responder (Tresp) cells for functional suppression 
assays.  
Each spleen cell suspension was passed through a pre-separation filter (Miltenyi 
Biotec, cat. 130-041-407) to remove clumps and then centrifuged for 3 minutes at 200 x g. 
The supernatant was removed completely, and the cells were suspended in 400 µl of MACS 
buffer (2.5 ml MACS BSA Stock Solution and 50 ml MACS rinsing solution, Miltenyi Biotec). 
Then 100 µl CD4+CD25+ regulatory T cell biotin-antibody cocktail was added, and the tubes 
were incubated for 10 minutes at 4oC. 
The cells suspension was then applied to an LD column in a midiMACS separator 
(Miltenyi Biotec) which negatively separated the CD4+ cells. These cells, which were not 
retained on the column, were spun down and re-suspended in 900 µl of MACS buffer (Miltenyi 
Biotec). Then 100 µl anti-PE microbead cocktail (a mixture of 300 µl MACS buffer + 200 µl anti-
biotin microbeads + 100 µl CD25-PE antibody) was added to the cells and incubated for 15 




At the end of the incubation, the cell suspension was applied to an MS column in a 
miniMACS separator (Miltenyi Biotec), for positive selection of CD4+CD25+ cells on the column 
whilst CD4+CD25- cells flowed through. The CD4+CD25+ cells were collected by removing the 
column from the magnetic separator, applying 1 ml of MACS buffer and using the column 
plunger to expel the cells. To ensure high purity of CD4+CD25+ cells the collected cells 
underwent a further purification cycle, applying the suspension to a new MS column. 
The purified CD4+CD25- Tresp and Teff cells and CD4+CD25+ Treg cells were spun down 
at 200 x g for 3 minutes and re-suspended in a culture medium, counted and adjusted to 1 x 
106 cells/ml. 
 
3.3.7 Carboxyfluorescein succinimidyl ester (CFSE) labelling of Tresp cells 
To investigate the Tregs functional suppression assay, the CD4+CD25- Tresp cells 
isolated from uninfected mice were spun down at 200 x g for 3 minutes. The pellet was 
resuspended in 4.5 ml of CFSE (10 µl of 5mM CFSE stock solution in 5 ml 0.1% BSA/PBS) and 
incubated at 37°C for 10 minutes. At the end of the incubation, 20 ml of culture medium was 
added, and the cells were retained on ice for 5 minutes. The cells were then washed three 
times and finally re-suspended in 4.5 ml culture medium (1 x106 per ml). 
3.3.8 Treg functional suppression assay 
A volume 50 µl aliquots of the CFSE labelled Tresp cells were placed in 96 well plates. 
50 µl of four dilutions of Tregs (1 x 106/ml, 0.5 x 106/ml, 0.25 x 106/ml and 0.125 x106/ml) 




CD3/CD28 beads (5 x 105 beads/ml; Cat 11452) was added to all wells.  Unlabelled Tresp only 
labelled Tresp only and labelled Tresp with CD3/CD28 beads were included as controls. The 
plate was incubated at 37°C for 72 hours. 
At the end of the 72 hours incubation period, the cells were collected into FACS tubes, 
fixed and re-suspended in 0.5 ml PBA.  
Data on 50,000 events were acquired using Coulter FC500 flow cytometry (Beckman 
Coulter). Unlabelled cells, cells labelled with CFSE and stimulated, and cells labelled but not 
stimulated were included as controls. Data analysis was performed using Kaluza analysis 1.5a 
(Beckman Coulter). 
3.3.9 Gating strategy  
A gating strategy used to identify CD4+ T -cells, CD4+CD25hiFoxp3+ Treg and IL-10 
producing T lymphocyte was prepared and was used for identifying the cells from the spleen 
samples as shown in Figure 3.2. 
3.3.10 Statistical analysis 
Graphs were prepared and statistical analysis was carried out using GraphPad Prism 
software. Data are shown with mean ±SEM. Statistical significance was determined using a 
one-tailed Student T-test for data with a non-Gaussian distribution and ordinary one-way 





3.4.1 Effect of H. pylori VacA mutant SS1s1i1 and VacA wild-type 
SS1s2i2 strains on Gastric colonisation  
Previously, VacA has been shown to promote gastric mucosa 
colonisation in infected mice (Raju et al., 2012). In this experiment, we use SS1 
VacA mutant strain (SS1s1i1) expressing s1i1 VacA type and   SS1 VacA wildtype 
(SS1s2i2) expressing s2i2 VacA type and reinvestigated the previous finding on 
the difference in the role of VacA a type in the colonisation of the bacteria. Our 
result was consistent with the earlier finding by Winter et al, who showed that 
SS1s2i2 strain was better able to colonise better than SS1s1i1 (Winter et al., 2014). 
There was a significant difference in the colonisation of mutant SS1s1i1 and 
wildtype SS1s2i2 with the average colonisation of the wildtype being increased 
by approximately one order magnitude compared to the mutant H. pylori at 3 





Figure 3.1 Colonisation density in the stomach of mice infected with two strains 
of H. pylori expressing different VacA type. The mice C57BL/6 were divided into 
two groups, one group were orally dosed with H. pylori SS1 wildtype (SS1s2i2, in 
blue) and the other H. pylori SS1 mutant (SS1s1i1, red) for 3 and 9 weeks. The 
colonisation density was measured at 3- and 9-weeks post-infection. The 
differences were considered significant at p<0.05. 
 
3.4.2 Comparison of the IL-10-secreting T cell and Treg response to 
H. pylori infection in mice, and the impact of the vacA type  
To investigate Treg and IL-10+ T cells levels in the spleens of 3 mice 
groups (broth placebo-dosed, SS1 wild-type strain-infected(s2i2 vacA) and SS1 
(s1i1 vacA) mutant-infected group) at 3, 6 and 9 weeks post-infection, the cell 




left unstimulated. The cells were then stained with fluorochrome-conjugated 
antibodies and analysed by flow cytometry. 
As shown in the representative gating strategy (figure 3.2), after gating 
from forward scatter and side scatter plots for the lymphocyte population, the 
percentage frequency of the CD4+ CD25hi, CD4+ Foxp3hi, and CD4+ IL-10+ among 
the total lymphocyte population was calculated. Of the CD4+ lymphocytes, the 
percentage frequency of the CD4+ CD25hi IL-10+ and CD4+ CD25hi Foxp3hi were 






Figure 3.2 Representative flow cytometry plots depicting the gating strategy for 
quantification of regulatory T cells amongst stimulated (A) and unstimulated 
(B) spleen cells. Cells were stained with fluorochrome-conjugated antibodies as 
follows: anti-CD4-PE/Dazzle, anti-CD25-BV421, anti-Foxp3-FITC and anti-IL-10-
AF647 and including respective isotype control reagents. (A) The lymphocyte 
population was gated based on forward scatter (FSC) and side scatters (SSC) 
plots. (B) CD4+CD25hi events were then identified from the lymphocyte gate. (C) 
Quadrant settings for identification of the CD4+Foxp3+ population from gated 




identification of the CD25hiIL-10+ population from gated lymphocytes (B), 




3.4.2.1 Higher percentage frequency of CD4+ CD25hi among 
unstimulated than stimulated spleen lymphocytes 
Among the lymphocytes, a higher percentage frequency of CD4+ CD25hi 
cells was observed in both H. pylori-infected groups, when the cells were left 
unstimulated compared to those that had been stimulated with mitogen. As 
shown in Figure 3.3 for 3 weeks, 6 weeks and 9 weeks post-infection there was 
a general decrease in the frequency of CD4+CD25hi lymphocytes following 
stimulation.  At 3 weeks post-infection there was a 2.6-fold difference (p= 
0.0003) in cells from the wild-type infected group and a 2.1-fold difference (p 
<0.0001) in cells from those infected with mutant strain. At 6- and 9-weeks 
post-infection, there were also significant differences in cells from those 
infected with the wild-type strain (p= 0.0005, p <0.0001 respectively) and 
mutant (p <0.0001, p <0.0001 respectively). At 6 weeks the unstimulated wild-
type 1.6-fold higher than the stimulated and 1.5-fold for the mutant. While at 
9 weeks the fold difference was 2.6 with the wild-type and 2.6 with the mutant. 
There was no statistically significant difference in the frequencies of 
CD4+CD25hi lymphocyte between the groups of mice infected with the wild-
type and mutant strains, at any of the time points post-infection (Figure 3.3). 
This was observed whether the cells had undergone mitogen stimulation 









Figure 3.3. CD4+ CD25hi cell frequency in the spleen of groups of 3 mice 
treated with H. pylori or plain Brucella broth as placebo. Cells were stained with 
fluorochrome-conjugated antibodies as follows: anti-CD4-PE/Dazzle, anti-
CD25-BV421, anti-Foxp3-FITC and anti-IL-10-AF647 and including the 
respective isotype control reagents. The percentage of CD4+CD25hi cells in the 
total lymphocyte population was determined for each sample (A), (B) and (C) 




infection respectively. The horizontal bar represents median values Statistical 
significance was determined using a paired t-test. Differences were considered 
significant at p<0.05. **** P<0.0001, ***P=0.005. 
 
 
3.4.2.2 Higher percentage frequency of CD4+ Foxp3hi cells among 
unstimulated compared to mitogen-stimulated splenic lymphocytes. 
Comparing the frequencies of CD4+ Foxp3hi cells among the three 
treatment groups (Figure 3.4) showed that there was higher frequency 
amongst unstimulated rather than stimulated cells from the wild-type infected 
group by  3.5-fold (p=0.0009) for 3weeks, 5.3-fold (p=0.0002) for 6 weeks and 
2.4-fold (p <0.0001) for 9 weeks post-infection). A similar observation was 
made when analysing cells from the group mutant strain infected 3 weeks 2.6-
fold (p=0.0003), 6 weeks 4.1-fold p=0.0012 and 9 weeks 2.9-fold (0.0001). 
  
When comparing data from the stimulated cells, there were no 
significant differences in the frequencies of CD4+ Foxp3hi cells between the 
wildtype and mutant infected groups at any of the time's post-infection (Figure 
3.4). Unstimulated cells showed the same result at 3- and 6-weeks post-
infection, however, there was a significant 1.2-fold difference in CD4+ Foxp3hi 






Figure 3.4. CD4+ Foxp3+ cell frequency in the spleen of groups of 3 mice treated 
with H. pylori or plain Brucella broth as a placebo. Cells were stained with 
fluorochrome-conjugated antibodies as follows: anti-CD4-PE/Dazzle, anti-
CD25-BV421, anti-Foxp3-FITC and anti-IL-10-AF647 and including the 
respective isotype control reagents. The percentage of CD4+Foxp3hi cells in the 
total lymphocyte population was determined for each sample (A), (B) and (C) 
depict the frequency of CD4+ Foxp3+ cells at 6 weeks and 9 weeks post-





Statistical significance was determined using a paired t-test. Differences were 
considered significant at p<0.05. 
 
3.4.2.3  Mitogen stimulated splenocytes contained higher frequencies of IL-
10+ CD4+ T cells. 
As expected from previous work done by the group significantly higher 
frequency of IL-10 producing CD4+ T lymphocytes was observed following the 
stimulation splenocytes. This was found at all three-time points (Figure 3.5), At 
3 weeks 13-fold (p=0.0001) for the wild-type and 13-fold (p=0.0001) for the 
mutant, 6 weeks 10.6-fold (p=0.0019) for the wild-type and 11.3-fold 
(p=0.0012) for the mutant and at 9 weeks 11.3-fold (p<0.0001) for the wild-
type and 12.2-fold (p=0.0001) for the mutant. 
At the 3- and 6-week time points, there were no differences in the 
proportions of IL-10+ CD4+ T cells between the mice infected with the mutant 
and wild-type strains. At 9 weeks post-infection, however, mice infected with, 
the mutant (expressing the active s1i1 VacA) had a 1.6-fold higher percentage 








Figure 3.5. CD4+ IL-10+ cell frequency in the spleen of groups of 3 mice treated 
with H. pylori or plain Brucella broth as placebo. Cells were stained with 
fluorochrome-conjugated antibodies as follows: anti-CD4-PE/Dazzle, anti-
CD25-BV421, anti-Foxp3-FITC and anti-IL-10-AF647 and including the 
respective isotype control reagents. The percentage of CD4+IL-10+ cells in the 
total lymphocyte population was determined for each sample (A), (B) and (C) 
depict the frequency of CD4+ IL-10+ cells at 3 weeks, 6 weeks and 9 weeks post-
infection respectively. The horizontal bars represent median values. Statistical 
significance was determined using a paired t-test. Differences were considered 
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3.4.2.4  Comparison of Foxp3-expressing CD4+CD25+ T cell frequencies 
To discover potential differences in the Treg response to infection, the 
proportions of CD25hi and Foxp3+ events amongst gated CD4+ cells were 
analysed.  The results were consistent with the previously described CD4+ 
CD25hi data at all of the time points (Figure 3.6). Stimulation of the lymphocytes 
increased the proportion expressing Foxp3; but comparing the stimulated and 
unstimulated groups there was a decrease, for the wild-type, there was 13-fold 
(p<0.0001) decrease at 3 weeks, 10.8-fold (p=0.0002) at 6 weeks and 11.6-fold 
(p=0.0195) while amongst the mutant, at 3 weeks, 9.1-fold (p<0.0001) 
decrease, 10-fold (p=0.001) at 6 weeks and 10.4 (p=0.0144) at 9 weeks,   but 







Figure 3.6. CD4+ CD25hi Foxp3+ cell frequency in the spleen of groups of 3 mice 
treated with H. pylori and plain Brucella broth as placebo. Cells were stained 
with fluorochrome-conjugated antibodies as follows: anti-CD4-PE/Dazzle, anti-
CD25-BV421, anti-Foxp3-FITC and anti-IL-10-AF647 and including the 
respective isotype control reagents. The percentage of  CD4+ CD25hi Foxp3+  
cells in the total lymphocyte population was determined for each sample (A), 
(B) and (C) depict the frequency of  CD4+ CD25hi Foxp3+ cells at 3 weeks, 6 weeks 
and 9 weeks post-infection respectively. the horizontal bar represents median 
values. Statistical significance was determined using a paired t-test. Differences 












































































































































































3.4.2.5  Comparison of IL-10-producing CD4+CD25+ T cell frequencies 
 To ascertain the proportions of CD25hi and IL-10+ events amongst 
gated CD4+ cells were analysed.  Analysis of the intracellular IL-10 in CD4+ T 
CD25+ T cell both for the stimulated and unstimulated situation, the result was 
consistent with previous findings in the group, a significant increase in the IL-
10+ following stimulation (Figure 3.7).with 3.3-fold (p=0.0014) increase 
amongst the wild-type 3 weeks, 3.8-fold (p=0.0001) at 6 weeks and 2.3-fold 
(p<0.0001) at 9 weeks. Comparing the mutants, at 3 weeks there was 4-fold 







Figure 3.7. CD4+ CD25hi IL-10+ cell frequency in the spleen of groups of 3 mice 
treated with H. pylori and plain Brucella broth as placebo. Cells were stained 
with fluorochrome-conjugated antibodies as follows: anti-CD4-PE/Dazzle, anti-
CD25-BV421, anti-Foxp3-FITC and anti-IL-10-AF647 and including the 
respective isotype control reagents. The percentage of CD4+ CD25hiIL-10 + cells 
in the total lymphocyte population was determined for each sample (A), (B) and 
(C) is the frequency of CD4+ CD25hi IL-10 +cells at 3 weeks and 9 weeks post-
infection respectively. The horizontal bars represent median values, and the 
statistical significance was determine using a paired t-test. Differences were 




3.4.3  Investigation of whether H. pylori infection influences the 
functional suppressive activity of regulatory T cells  
To measure the suppressive function of CD4+ CD25hi Treg cells isolated 
from the spleens of mice infected with the SS1 H. pylori strain or given plain 
broth as a placebo, they were mixed with CD4+ CD25- T responder (Tresp) cells 
from untreated mice at different ratios (1:1, 1:2, 1:4 and 1:8) varying only the 
numbers of Tregs. The Tresp cells were labelled with the fluorescent dye CFSE 
and activated with anti-CD3/CD28 beads before adding the Treg and the cells 
were cultured for 96 hours. 
To assess the suppressive capacity of the Treg cells, data on the 
percentage of Tresp cells that are suppressed response to the activation beads, 










Figure 3.8. The Representative flow cytometry plot gating strategies for Treg 
suppression assay. The responder T (Trep) cells (CD4+CD25-) isolated from two 
untreated mice were labelled with CFSE, the labelled cells were cocultured 
with four dilutions of regulatory T(Treg) cells (CD4+ CD25hi) and stimulated anti-
CD3/CD28 beads. (A) Lymphocytes were selected based on the forward scatter 
(FS) and side scatters (SS) as measures of size and granularity, respectively. (B) 
The histogram plot of the unlabelled Tresp negative control. (C) Histogram plot 
of labelled Tresp but unstimulated with anti-CD3/CD28. (D) Stimulated Tresp 
with no Treg. (E) Stimulated Tresp with the 1:1 Tresp: Treg ratio. (F) 1:2 Tresp: 
Treg ratio. (G) 1:4 Tresp: Treg ratio. (H) 1:8 Tresp: Treg ratio. (I) The 
corresponding dot plot of CFSE and FS for 1:1 Tresp: Treg ratio. (J) 1:2 Tresp: 












3.4.3.1 The percentage of cells suppressed by Treg 
This is the measure of the percentage of the Tresp cell stimulated will 
divide at least once with minimal suppression of the Treg. It is used in 
determining the fraction of the original population that divided least once 
during the culture period. As shown in Figure 3.8, the graph showed increases 
in the percentage of cells dividing with decreases in numbers of Tregs present 
in the coculture. However, there was no statistically significant difference in 
function between the suppressive ability of the Tregs isolated from the spleens 






Figure 3.9. Group of six mice were infected with the SS1 strain of H. pylori in 
Brucella broth or administered plain broth as a placebo. 6 and 9 weeks later 
the mice were killed and the splenic CD4+ CD25hi Treg cells isolated using 
magnetic bead isolation. Cells from two mice were combined to ensure 
sufficient recovery of cells. CD4+ CD25- Tresp were also purified from the 
spleens of untreated mice and labelled with CFSE before stimulation using anti-
CD3/28 beads. The suppressive activity of the Tregs cells from infected and 
placebo-treated mice was compared, co-culturing Treg and Tresp cells in a 
range of ratios for 96 hours. Effects on the Tresp cells expansion was assessed 













































using flow cytometry. Data show the mean and the standard deviation from 
the three replicates.  
3.4.3.2 Fold expansion of Tresp cell 
Fold expansion examines the ratio of final cell count to starting cell 
count during the culture. In this case, the fold expansion of the Tresp was 
calculated for both treatments and the result as shown in Figure 3.9   The 
overall fold expansion for each of the three-time points also showed increases 
in Tresp expansion when the numbers of Tregs in the coculture were reduced. 
As there was no statistically significant difference between Tregs from the 
spleens of infected or placebo-treated mice.   
Furthermore, to assess the trend according to the three points, a plot 
the percentage cell divides and overall fold expansion for 1:4 Treg: Tresp for 
the 3 time points were made   (Figure is shown in the appendix). There was no 











Figure 3.10. Group of six mice were infected with the SS1 strain of H. pylori in 
Brucella broth or administered plain broth as a placebo. 6 and 9 weeks later 
the mice were killed and the splenic CD4+ CD25hi Treg cells isolated using 
magnetic bead isolation. Cells from two mice were combined to ensure 
sufficient recovery of cells. CD4+ CD25- Tresp were also purified from the 
spleens of untreated mice and labelled with CFSE before stimulation using anti-
CD3/28 beads. The suppressive activity of the Tregs cells from infected and 
placebo-treated mice was compared, co-culturing Treg and Tresp cells in a 
range of ratios for 96 hours. Effects on the Tresp cells expansion was assessed 
using flow cytometry. Data show the mean and the standard deviation from 





3.5 Discussion  
The aim of this study was primarily to access the immunoregulatory 
potential of  the H. pylori protein, VacA. Several studies have shown that VacA 
is an effective immunomodulatory molecule (Oertli et al., 2013b, Kao et al., 
2010), but there is very little information on the relative effects of the different 
types of toxin. This study used two strains of the Sydney Strain 1 (SS1) mouse-
adapted model of H. pylori, which expressed the s2i2 and s1i1 forms of VacA. 
The SS1s2i2 strain is the wild-type, and this form is without vacuolating activity, 
whilst the SS1s1i1 mutant expressed active VacA (Day et al., 2001, Winter et al., 
2014). 
Although only a few H. pylori strains  are capable of  effectively 
colonizing mice to enable studies of this manner.  SS1 strain was shown to 
consistently colonise several mouse strains including C57BL/6 mouse at  high 
level with persistent infection that could last for months making it suitable for 
studies in immune system and effect of  virulence factors (Lee et al., 1997). The 
SS1 strain used in this investigation is known to lack cagPAI functionality but 
expresses the nontoxigenic form of VacA (s2i2) (Arnold et al., 2011b). However, 
most human studies have demonstrated the association between active form 
of VacA (s1i1) and disease.  Therefore, SS1s1i1  isogenic mutant expressing the 
toxigenic VacAs1i1 form was  used in this study. The wild type  SS1s2i2 H. pylori  
and the mutant SS1s1i1 H. pylori   have been used extensively in investigation of 
VacA-specific experiments. The colonisation result in the experiment showed 




mutant compare to the SS1s2i2 wild-type. This result is consistent with the 
findings by  Winter et al, in which they showed that the strains producing s1i1 
and s1i2 VacA has reduced colonisation densities while those of s2i2 readily 
colonised the mouse stomach (Winter et al., 2014).  However, the result of the 
difference in colonisation is not expected to influence the overall outcome this 
studies since the same study by Winter et al as showed that there is no 
significant correlation between colonisation density and production of gastric 
pathology in mice infected with SS1s1i1  producing toxigenic form of VacA or 
SS1s2i2 nontoxigenic form of VacA. 
The group and other literatures have previously shown that VacA is 
capable of suppressing the immune response in vitro and could be very 
important in the establishment of persistent colonization by H. pylori 
(Greenaway, 2014, (Salama et al., 2001b, Winter et al., 2014). Preliminary 
evidence from the group indicated that one of the mechanisms through which 
VacA achieves an immune regulatory function is the induction of Treg 
responses. It was shown that there was an increase in Foxp3 expression in 
PBMCs isolated from healthy patients with VacA-active strain compared to 
those with an inactive VacA strain (Greenaway 2014). This evidence serves as 
an indicator that VacA may be important in Foxp3 induction. 
Furthermore, the group also had already shown that VacA also 
influenced the amount of IL-10 expressed by mouse splenocytes. The type of 





Therefore, in this present research, the hypotheses were that 
Splenocytes from the mice infected with H. pylori expressing active s1i1 VacA 
would respond better to mitogen stimulation than cells from mice infected 
with H. pylori expressing the s2i2, the inactive form of VacA.  This would occur 
due to the presence of memory T cells which confers on it more 
responsiveness.  
There would be higher proportions of Foxp3+ CD4 cells among the 
lymphocytes from mice infected with the SS1s1i1 strain expressing s1i1  VacA 
form compared to the SS1s2i2 strain expressing s2i2  VacA form.  
There would be higher proportions of IL-10+ CD4 cells among the 
lymphocytes from mice infected with the SS1s1i1 strain compared to the SS1s2i2  
strain.  
Interestingly, mitogen-stimulated cells from all the groups showed a 
decrease in the proportion of Foxp3+ cells compared to their paired 
unstimulated cell preparations. However, there was no significant difference 
between the levels of FOXP3 expression when comparing the splenocytes from 
active VacA infected, non-active VacA infected or placebo-treated mice. This 
may be because VacA may not entirely be the only driving factor in FOXP3 
expression and immunoregulation other H. pylori proteins such as GGT, PPT 
and KatA have been reported to have some immune regulatory functions 





Similarly, IL-10 expression by the splenocytes was analysed and showed 
that there was an increase in IL-10 expressing cells following stimulation. 
However, again the active VacA H. pylori strain made no difference. This agrees 
with the point made above, that infection with H. pylori could influence the 
induction of immunomodulatory cells but VacA alone may not be the sole 
factor. On the hand, a long-standing suggestion is that VacA is essentially 
pleiotropic may be in effect in this study (Isomoto et al., 2010). 
 
Using CFSE suppression assay as described by Collision and Vignali 
(Collision and Vignali, 2011), the differences in the immunosuppression 
activities of Treg isolated from a group of mice infected with active H. pylori 
with active vacA gene and placebo-treated mice were investigated. The study 
here investigated whether the active VacA possessing H. pylori strain in mice 
induced a better Treg immunosuppressive activity compare to that of placebo-
treated mice. The results from this experiment indicated obvious activities by 
Tregs on the Tresp cells, but there was no difference in the suppression 
activities between Tregs from the H. pylori and placebo groups. Research in the 
past by Boncristiano et al. and Sundrud et al. had shown that VacA activities 
have inhibited the clonal expansion of activated T cell. They showed that VacA 
is capable of inhibiting IL-2 in Jurkat cells in vitro. IL-2 is produced by T-cell in 
response to mitogenic stimulation and is required for T-cell 
proliferation(Boyman and Sprent, 2012, Boncristiano et al., 2003). Early 




have decreased Foxp3 expression compare to that of VacA-positive patients, 
showing that VacA could be important Foxp3 induction (Greenaway, 2014 
unpublished). Both results go on to suggest that VacA could have 
immunoregulatory activity in vivo and in vitro. 
 The result raises the concern on whether mechanism through which 
molecules of VacA inhibit T cell proliferation differ from the secreted VacA 
from H. pylori. There is also the case of the suitability of the laboratory animal 
in the simulation of the human infection. Mice are the natural host for H. pylori 
and may require a large dose of the bacteria for proper simulation. Infection in 
a human subject in most case occurs at an early age when the immune system 
is developing this is different for 6-8 weeks mice which have fully developed 
immune system. Another reason is that mice stomachs have a very dense 
microbial flora in a less-acidic mucosa compare to that of human. 
The acidity in mice stomach is usually constant compare to human, 
which changes throughout the day.  Finally, the difference between human and 
mice immune system can also influence the out of the experiment. For 
example, lack of IL-8 in mice. And better still mouse model and/or mouse-
adapted strain of VacA-positive may not be a good model for this investigation 






• There were no differences in the frequencies of Tregs in the spleen 
between the groups infected with H. pylori expressing s1/i1 or s2/i2 
forms of VacA. 
• There was a significantly increased frequency of Foxp3+ cells in the 
stomach of infected mice compared to the uninfected group   
• VacA type did not significantly affect the frequencies of Tregs in the 
spleen or gastric mucosa 
• The infection did not influence the functional suppressive activity of 
Tregs from the spleen 
• There was only a very small increase in Tregs in mice infected with the 
SS1 strain of H. pylori. This is possibly due to them being infected at 6 
weeks of age (rather than as neonates), and the relatively short 




Chapter 4  
Serum Helicobacter pylori KatA, GGT. 









Although the effect of H. pylori-specific antibody on the extent of 
bacterial colonisation is still debatable, studies have shown that H. pylori 
infection almost constantly induces robust mucosal and systemic antibody 
production (Czinn et al., 1993, Akhiani et al., 2004). In most epidemiological 
research studies, serological testing has remained the most important 
approach; as illustrated in most gastric cancer cases where the studies showed 
a significantly higher prevalence of H. pylori specific antibodies among patients 
compared to normal controls (Gao et al., 2009a).  Helicobacter pylori infection 
is the major cause of a number of gastrointestinal tract diseases, such as 
chronic gastritis, peptic ulcer and gastric cancer (Suerbaum and Michetti, 
2002). It is also known that over 50% of the world population is infected with 
H. pylori. Primarily, 85 % of those infected experience no symptoms or mild 
symptoms such as mild asymptomatic gastritis. In cases of more severe 
outcomes, 10-15% can develop peptic ulcer disease (PUD), 5%  can develop 
atrophic gastritis and about 1-2% can develop gastric cancer(Amieva and El-
Omar, 2008, Conteduca et al., 2013).  Factors such as host factors and diet have 
been shown to be contributory to the risk of disease outcomes but researchers 
have also shown that bacterial virulence factors are a major independent 




2010). Virulence factors such as CagA, VacA, GGT, KatA and PPT  among others 
are all recognized to play crucial roles in H. pylori pathogenicity  (Atherton, 
2006) and the serum antibodies to these H. pylori factors could serve as 
noninvasive  biomarker for early detection of H. pylori diseases.  
   
4.1.1 Anti-cytotoxin-associated gene A (CagA) antibodies 
CagA is the most researched H. pylori virulence factor and as such 
possibly the most important virulence factor in the bacterium (Shiota et al., 
2013). CagA positive H. pylori strains have been implicated in serious clinical 
sequellae, with damaging effects mediated directly by CagA (Kuipers et al., 
1995, Huang et al., 2003). Parsonnet et al examined the serum of 179 infected 
and 63 uninfected individuals in a case-control investigation looking at the 
serum anti-CagA IgG response. Their results showed a more than a 5-fold 
increased risk of developing gastric cancer in individuals with CagA-positive H. 
pylori strains, compared to uninfected subjects. They also showed that subjects 
infected with CagA-negative H. pylori are not significantly more likely to 
develop gastric cancer than uninfected individuals (Parsonnet et al., 1997). 
Similarly, Gao et al investigated the association between chronic atrophic 
gastritis and serological status of antibodies to 15 H. pylori proteins using a 
novel multiplex serology method. Here, 534 cases of chronic atrophic gastritis 
and 1068 control subjects were examined for seropositivity for the 15 proteins. 




(HcpC) and the chaperonin GroEL was shown to have a strong association with 
chronic atrophic gastritis (Gao et al., 2009b). Equally, another group 
investigated the seroprevalence of CagA, VacA, GroEL, Urease subunit (UreA), 
GGT and HcpC and its’ relationship with gastric lesions, a precursor lesion of 
gastric malignancy, using the recomLine H. pylori test system. Their results 
showed that amongst the factors studied, only CagA and GroEL could be 
considered as an independent predictor for the development of gastric lesions 
(Pan et al., 2014).  
4.1.2 Anti-vacuolating cytotoxin A (VacA) antibodies 
VacA is another very well studied factor of H. pylori. The vacA gene is present 
in all strains but only the s1/i1/m1 allelic variant is regarded as encoding an 
active toxigenic form of VacA. The s1/i1 form of VacA is associated with severe 
disease outcomes such as peptic ulceration and gastric cancer (Atherton et al., 
1995, Miehlke et al., 2000). Although known for its induction of vacuolation in 
gastric cells (de Bernard et al., 1997), VacA has also been implicated to cause 
disruption of mitochondrion functions, T-cell proliferation inhibition and 
induction of apoptosis (Gebert et al., 2003, Isomoto et al., 2010). Other reports 
also showed that VacA could be important in mediating the colonisation of H. 
pylori (Salama et al., 2001b, Salama et al., 2001a).  There have been several 
mixed reports on the seroprevalence of VacA antibodies and its link with 
disease outcome. One report found 73.91% VacA seropositivity among gastric 
cancer patients (Suriani et al., 2008), and another reported an odds ratio of 




progression of chronic atrophic gastritis (Gao et al., 2009b).   Pan et al reported 
a 38.9 % seroprevalence among patients with gastric lesions (Pan et al., 2014). 
The conflicting reports paved the way for our investigation, using a protein 
array method to ascertain the differences in the prevalence of VacA-specific 
antibody between H.pylori-positive and H.pylori-negative individuals. 
 
4.1.3 Catalase (KatA) 
Catalase is an enzyme present in all life forms that neutralizes extracellular 
hydrogen- peroxides. In H. pylori catalase, KatA,  the enzyme protects the 
bacteria from oxidative damage in hostile immune environments which could 
have direct damaging effects on their genomic DNA (Harris et al., 2002, Wang 
et al., 2006, Wang et al., 2005). Therefore, KatA plays a vital role in H. pylori 
colonisation of the gastric mucosa (Hazell et al., 1991). KatA readily induces 
antibodies in H. pylori-infected individuals. Antibodies levels are similar in 
individuals from H. pylori -high-risk areas and in those residing in low-risk areas 
(Camargo et al., 2015), Camargo et al also reported associations of KatA with 
gastric diseases, showing it to be independent of other virulence factors such 
as CagA and VacA. Similarly, Zhang et al reported an association with gastric 
cancer and 14.59-fold increase in the risk of gastric cancer among those who 
were seropositive for KatA antibodies (Zhang et al., 2016). Their investigation 




group acknowledged could lead to nonspecific signals from cross-reactivity. 
This problem could easily be eliminated by the protein array.  
Although Kotiw et al reported that KatA-specific antibodies are readily induced 
in the serum of infected individuals, they still doubted the protective role of 
these antibodies (Kotiw et al., 2012). But earlier vaccine studies on rodents 
reported the opposite, demonstrating how anti-catalase antibodies could 
protect against a subsequent  H. pylori infection (Chen et al., 2003).  
4.1.4 -Glutamyltranspepetidase (GGT) antibodies 
 GGT is expressed by all strains of H. pylori. The enzyme contributes hugely in 
bacterial pathogenesis (Chevalier et al., 1999, Wustner et al., 2017). The 
activities of this enzyme alone, which include the utilisation of glutamine to 
generate glutamate and ammonia, conversion of glutathione to 
cysteinylglycine and by-products such as ammonia and reactive oxygen 
species, tend to have a massive effect on the surrounding host cells (Ricci et 
al., 2014). These effects contribute to final disease outcomes such as peptic 
ulcer and gastric cancer (Gong et al., 2010, Rimbara et al., 2013). 
Pan et al demonstrated the virulence activities of GGT in promoting bacterial 
and cell apoptosis but failed to establish a relationship between GGT 
seropositivity and gastric cancer (43.3 %). In fact, they reported an inverse 
association with the presence of preneoplastic lesions. They speculated the 
anti-inflammatory effect is produced by the interference of GGT-specific 




4.1.5 Peptidyl prolyl cis trans isomerase (PPT) antibodies  
 PPT (also known as PPIase) is another enzyme possessed by both 
eukaryotic and prokaryotic cells, which catalysis the folding of proteins by 
cis/trans isomerisation of peptide bonds with prolyl residues. (Gothel and 
Marahiel, 1999). H. pylori PPT (product of gene HP0175) is one of the secreted 
proteins that the bacteria utilise in colonisation and pathogenesis (Basak et al., 
2005). Studies of this protein in E. coli revealed that the protein perform more 
isomerase function but can equally independently perform chaperonin 
function (Ramm and Plückthun, 2001).  The protein has been observed to bind 
TLR4 in the AGS human gastric adenocarcinoma cell line, triggering apoptosis 
and therefore it is also known as H. pylori cell-binding factor 2 (HpCBF2). This 
was demonstrated by antibody blockade of TLR4, which abrogated apoptosis 
on incubation with PPT. The level of cell death observed with PPT was 
significantly more than with other H. pylori virulence factors (Basak et al., 
2005). TLR4 links innate immunity to adaptive immune responses, although the 
agonist widely known to associate with this PRR is bacterial (but not H. pylori) 
LPS. As PPT interacts with TLR4 in a similar way to LPS, it could follow a similar 
pattern of cell signalling pathway activation.  
 Atanassov et al, using PPT isolated from two strains of H. pylori; H. 
pylori HP141 and H. pylori ATCC 43579, showed the presence of PPT-specific 
antibodies by ELISA in H. pylori-infected individuals. They went further to show 
anti-PPT seropositivity value for gastroduodenal ulcers (GDU)patients of 33(60) 




respectively and 8(27) and 7(23) with non-ulcer dyspepsia NUD. These values 
which are not sufficient to be a sole predictive biomarkerfor ulcer diseases but 
report that antibody frequency to PPT together VacA and  β-ketoacyl-ACP S 
could make it possible to differentiate between the NUD and ulcer patients 
(Atanassov et al., 2002).  
 
4.1.6 H. pylori 60190 and H. pylori Tx30a  
Only a small percentage of H. pylori-infected individuals develop gastric cancer. 
This is known to be as a result of multiple factors which include, the host 
response to the infecting bacteria, the interaction between the host and 
bacteria and essentially the differing expression of the strains virulence factors 
(Blaser, 1997). One of the first virulence factors to be identified in the H. pylori 
was CagA, it is present in approximately 50% of bacterial isolates and is a 
constituent of the cag pathogenicity island (cagPAI) gene cluster (Covacci et 
al., 1993, Akopyants et al., 1998). The cagPAI encodes homologues of type IV 
bacterial secretion proteins (Censini et al., 1996). Several investigations have 
shown that individuals infected with CagA-positive strains are at a higher risk 
of developing disease outcomes, notably, gastritis, atrophic gastritis, peptic 
ulcer disease and gastric cancer (Kim et al., 2013a, Kuipers et al., 1995, Peek et 
al., 1995, Blaser et al., 1995) compared to those with CagA-negative strains 




Another vital virulence factor possessed by the strains is VacA, which is 
associated with disease (Atherton, 2006). Almost all strains possess the vacA 
gene, but only about half of the isolates express the active form of the protein. 
Allelic diversity in three main regions of the gene, which include the signal (s), 
the intermediate (i) and the middle (m) regions, results in different degrees of 
vacuolating activity (Atherton et al., 1995, van Doorn et al., 1998). For a long 
time, vacA s- and m- regions remained the two most important polymorphic 
regions associated with disease progression (Atherton et al., 1995, Blaser and 
Atherton, 2004, Sugimoto et al., 2009). Later, the i-region was recognised as 
the third determinant of vacA polymorphism, and shown to be a better 
predictor of disease severity (Rhead et al., 2007). Based on the amino acid 
sequence of each region it showed there could two more variants for each 
region: the s-region has two variants s1 and s2, the i-region has three variants 
i1, i2 and i3 while the m-region has two regions m1 and m2. (Atherton et al., 
1995, van Doorn et al., 1998, Van Doorn et al., 1999). Studies have shown the 
effect of different genotypes emanating from the combination of the variants 
is the determinant of the pathogenesis of a strain rather than possession of the 
vacA gene. Similarly, different VacA genotypes also influence the vacuolating 
activity. As the case may be, vacA s1 encodes a vacuolating active protein while 
vacA s2 encodes a variant which does not have a vacuolating activity. It has 
also shown that the protein encoded by the latter has a different signal peptide 
cleavage site which produces an extension, of 12 -amino acid long and is 
probably the reason for vacuolation inhibition (McClain et al., 2001). Likewise, 




cell types than the m2 (Atherton et al., 1995). The i1 variant shows the highest 
vacuolating activity compared with i2, while i3 is thought to be rare (Rhead et 
al., 2007, Ferreira et al., 2012). Again the H. pylori 60190 and Tx30a used in this 








The European Helicobacter Pylori Study Group (EHPSG) recommended 
serology assays and tests as one of the non-invasive means of H. pylori 
diagnosis (Malfertheiner et al., 1997). Several studies have shown that several 
H. pylori  virulence factors elicit strong antibodies both in the blood and in the 
gastric mucosa(Mattsson et al., 1998, Lee et al., 1995). These antibodies are 
relatively associative rather than of being protective against H. pylori 
infections(Tiwari et al., 2007).  Studies among certain gastroduodenal patients 
ulcers have shown that these serum antibodies against the factors 
preferentially recognize H. pylori antigens and this could be useful in 
differentiating one H. pylori disease from another (Atanassov et al., 2002).  
Here, five H. pylori factors KatA, GGT, PPT, CagA and VacA were selected based 
on their relative prominence during H. pylori infection. We hypothesis that the 
level of antibody against H. pylori factors is an important indicator of the 
disease severity. 
To test this hypothesis, we set the following objective  
1. To establish the differences in levels of antibodies against H. pylori 





2. To investigate whether a strong antibody response to each of the 






4.3 Materials and Methods  
4.3.1 Biological samples collection 
Peripheral blood samples were donated by 188 patients undergoing a 
routine upper gastrointestinal endoscopy at the Queen’s Medical Centre, 
Nottingham. The most common reason for this was chronic dyspepsia. A 
combination of biopsy urease test, bacterial isolation and culture, histology 
and PCR results were used to determine the H. pylori infection status of each 
patient (Table 4.1). All samples were collected with approval from Nottingham 
Research Ethics Committee 2 (ref 08/H0408/195) and informed written patient 
consent. Blood samples were not collected from patients who had taken 
antibiotics and/or frequently on non-steroidal anti-inflammatory drugs 
(NSAIDs) and/or proton pump inhibitors (PPI) in the last 4 weeks prior to the 
sample collection. EDTA anticoagulant containing vacutainer tubes were used 
to collect the blood samples and the plasma was separated by centrifugation 





Table 4.1. The demographics of the patients 
H. pylori status  Average age 
(years) 
Female to Male 
Ratio 
Disease status  
94 infected  52.2 (17-86) 51:43 35 duodonal 
ulcer 
6 gastric ulcer 
2 duodonal ulcer 
+ gastric ulcer 
51 No ulceration  
94 uninfected 51.8(20-89) 57:37 No ulceration 
 
4.3.2 Bacterial lysate preparation 
H. pylori strains 60190 and Tx30a graciously provided by Dr Karen 
Robinson towards this experiment were prepared as follows: Briefly, H. pylori 
strains 60190 and Tx30a were cultured on blood agar plates in duplicate 
(Oxoid) and incubated in microaerophilic incubator, MACS VA500 
microaerophilic workstation (DW Scientific) at 37 C in a 10% O2 and 5% CO2 




in ice-cold sterile phosphate-buffered saline (PBS) (Oxoid). The suspended 
bacterial cells were lysed on ice using the Soniprep 150 sonicator (SANYO, 
Watford, UK) at 4 x 10 seconds bursts at an amplitude of 10 microns with 30 
minutes break time in between each sonication process. The concentration of 
the protein contents was measured using a BCA (Bicinchoninic Acid) Protein 
Assay and the concentrations were adjusted to a working concentration of 100 
g/ml. 
4.3.3 Protein Sample preparation  
The 3 protein samples (rKatA, rGGT and rPPT) prepared in Chapter 3, 
rVacA(s1m1i1 type), and lysates of two strains of H. pylori 60190 and Tx30a, 
were adjusted to the concentration of 100 g/ml. 10 l of each of the samples 
were aliquoted into a 96 well V-bottomed plate (Eppendorf) in quadruplicate. 
Candida albicans lysate was included as positive control as it is one of the 
commonest infection found in human (Hernday et al., 2010, Hernday et al., 
2013) and landing light (2 l/ml) was used as the edge marker on the slide. 
4.3.4 Spotting of slide surface- contact printing  
To print even protein spots on the surface of flat glass slides, a choice of the 
most suitable slide surface was made between amino-silane and epoxy-silane. 
The 8 headed solid pins were used, in a matrix of 2 columns and 4 rows, to 
print 16 pads, 2 columns by 8 rows on each of the 25 x 75 mm amino-silane or 
epoxy-silane activated glass slides which had been prepared in house. Briefly, 




compartment of the BioRobotics Micrograd II microarray machine, the 
microspot solid pins were used to make double spotting to each array feature 
in a layout shown in Fig 4.1 at the humidity of 71-75 %. After spotting, the slides 
were removed and stored under vacuum until required. 
 
Figure 4.1. The design of the protein array. All of the 4 recombinant proteins 
(rKat, rGGT, rPPT and rVacA), a CagA peptide, 2 H. pylori whole cell lysates 
(strains 60190 and Tx30a) and 1 Candida albicans lysate (positive control) were 
spotted on each of the 16 fields on the slide while the empty spots were the 






4.3.5 Array processing  
The microwell gasket was assembled on the spotted glass slides, to 
allow testing of plasma samples from up to 16 patients. The surface of each 
slide was blocked with 240 l of 3 % BSA, overnight at 4 C. Following this, the 
microwells on the glass slides were washed sequentially for 3 x 1 min with PBS-
Tween (0.05 % Tween 20 in phosphate-buffered saline) and 100 l each of 
1:100 dilutions of the plasma samples in LowCross-Buffer® (Candor) were 
added to the wells. Diluent only was added to one of the wells, a negative 
control.  The slides were incubated on a shaker for 1 hour and then washed 3 
x 1 min with PBS-Tween. 
The slides were then probed with 100 l of 1:10000 dilution of anti-
human IgG-IR680 detection antibody (LI-COR Bioscience) diluted in LowCross-
Buffer® (Candor) and incubated for 45 min on a shaker at room temperature. 
The detection antibodies were washed 5 x 1 min with PBS-Tween, rinsed with 
distilled water and then spun to dry using a microarray slide spinner (Labnet). 
4.3.6 Fluorescence scanning 
After staining the slides were scanned with a fluorescence imaging 
system LI-COR Odyssey SA (LI-COR Bioscience) at a resolution of 20 m, focus 
of 3.1 nm and intensity of 11.5. The GenePix ProMicroarray Image Software 
package was used to acquire the data. To determine the fluorescence signal 




the replicates were obtained. Furthermore, the signal-to-noise ratio was 
determined from the test samples and background control tests. 
4.3.7 Data Analysis 
The signals obtained from the reaction of plasma samples to 
immobilized antigens were compared using a Kruskal-Wallis test on GraphPad 
prism 8 software. A p value of less than 0.05 was considered statistically 











4.4 HBJM Results 
4.4.1 Influence of slide surface on the protein array  
CagA peptide, recombinant proteins VacA, KatA, GGT PPT and lysates 
of H. pylori strains 60190 and Tx30a were spotted onto two different surface 
chemistries and then the biochemical activities were evaluated. Aminosilane 
coated glass slides did not allow the sensitive detection of these proteins using 
serum samples from one H. pylori-posit 
ive patient and  H. pylori-negative patient (Figure 4.2 A). In contrast, the 
assays performed much better on epoxy silane coated slides, where there were 
brighter fluorescent signals (Figure 4.2 B). Hence, the epoxy silane coated 





Figure 4.2. Evaluation of suitability of aminosilane and epoxysilane surface coatingsfor the slide for the protein microarrays. The proteins rVacA, 
rKatA, rGGT rPPT and the  cell lysate (H. pylori 60190 and Tx30a) were spotted on an Aminosilane and epoxy-silane coated glass slide using 
BioRobotics Micrograd II microarray machine with solid microspot pins. The lysate and purified protein spots were blocked and assayed with a 
infected (confirmed H. pylori positive) and an uninfected (confirmed H. pylori negative) patients’ serums and probed anti-human IgG-IR680 
detection antibody (LI-COR Bioscience). The fluorescence signal readout was carried out using a fluorescence imaging system LI-COR Odyssey SA 



































































































































































































































































































4.4.2 Spotting of the proteins, CagA, VacA, KatA, GGT and PPT and 
H. pylori 60190 and Tx30a lysates 
To analyse the serum antibodies against the recombinant proteins 
VacA, KatA, GGT and PPT, together with the two lysates of the H. pylori strains, 
60190 and Tx30a, and CagA peptide, the concentrations of the molecules were 
adjusted to 100 g/ml. A whole-cell lysate of the common yeast Candida 
albicans was included as a positive control antigen that the vast majority of 
individuals are exposed to. These were spotted on epoxysilane coated glass 
slide using a BioRobotics Micrograd II microarray machine with microspot solid 
pins. The spotted slides were incubated with serum samples from H. pylori-
positive and H. pylori-negative patients, followed by anti-human IgG-IR680 
conjugate and signals were visualised using a fluorescence imaging system. As 
shown in Figure 4.3 A after incubation with H. pylori-positive serum, 
fluorescence was detectable for almost all antigens spotted on the coated 
slide. In Figure 4.3 B, however, when slides were incubated with H. pylori-












Figure 4.3. . Representative fluorescence image obtained from the protein 
array spotted with 100 g/ml antigens, incubated with serum from patients, 
probed with anti-human IgG-IR680 detection antibody and then visualised 
using the LI-COR Odyssey SA (LI-COR) fluorescence imaging system. A. depicts 
fluorescence signals following incubation with serum from a typical H. pylori-
positive patient. B. depicts the fluorescence signals after applying serum from 
an H. pylori-negative patient, where reactivity was detected only to the control 





4.4.3 Analysis of serum antibodies against H. pylori 60190 and 
Tx30a lysates in H. pylori-positive and H. pylori-negative 
patients 
The first step was to ascertain the level reactivity of serum antibodies 
in H. pylori-positive and negative patients to two strains (60190 and Tx30a). 
The 60190 strain is CagA-positive and expresses the active s1/i1/m1 type of 
VacA, whilst the Tx30a strain is CagA-negative and expresses the least active 
s2/i2/m2 VacA type (Camorlinga-Ponce et al., 2004, Braga et al., 2014). Both 
strains are known to express GGT, KatA and PPT activities. To investigate the 
correlation between antibodies against H. pylori strain 60190 antigens and H. 
pylori strain Tx30a antigen, the lysates strains were spotted on epoxysilane 
coated glass slides and incubated with the 1:200 dilution of 94 H. pylori-
positive and 94 H. pylori-negative patient’s serum and further probed with the 
anti-human IgG-IR680 detection antibody. The fluorescence signals were 
measured using the fluorescence imaging system.  
The data presented in Figure 4.4 show significant differences between 
sera from H. pylori-positive and -negative patients. This seems to suggest that 
antigens present in both lysates induce an antibody response that reacts with 
both types of bacteria.  Analysis with a Kruskal-Wallis test showed  6.95- 
(p<0.0001) and 3.93-fold (p=0.0006) higher concentrations of antibodies 
against H. pylori 60190 and H. pylori Tx30a lysates respectively, in sera from H. 







Figure 4.4. Seroprevalence of serum antibodies against H. pylori strains 60190 
and Tx30a antigens H. pylori-infected and uninfected patients. The cell lysate 
H. pylori 60190 and Tx30a were spotted on an epoxy-silane coated glass slide 
using BioRobotics Micrograd II microarray machine with solid microspot pins. 
The lysate spots were assayed with a total of 188 (94 infected and 94 
uninfected) patients’ serums and probed anti-human IgG-IR680 detection 
antibody (LI-COR Bioscience). The fluorescence signal readout was carried out 
using a fluorescence imaging system LI-COR Odyssey SA (LI-COR). The 
horizontal bars represent median responses and statistical significance was 
calculated using the Kruskal-Wallis test on GraphPad Prism 8 software. (A). H. 



























































































Further investigation with Pearson’s Statistical correlations analysis of the 
fluorescence signal of the H. pylori-positive for the lysates H. pylori 60190 and 
Tx30a strains. As shown in Figure 4.5 there was a correlation between the 
antibodies against the antigens present in lysates of both strains (P< 0.0001 r= 
0.813). Which further suggests that, although Tx30a strains lacks CagA and 
express s2i2m2 VacA campare to 60190 strains which are cagA positive and 
express s1i1m1 VacA, there are similarities in the antigen responsible for the 





Figure 4.5. Positive Pearson’s rank correlation between relative seropositivity 




persons. The cell lysate H. pylori 60190 and Tx30a were spotted on an epoxy-
silane coated glass slide using BioRobotics Micrograd II microarray machine 
with solid microspot pin. The lysate spots were assayed with a total of 94 
infected patients’ serums and probed anti-human IgG-IR680 detection 
antibody (LI-COR Bioscience). The fluorescence signal readout was carried out 
using a fluorescence imaging system LI-COR Odyssey SA (LI-COR). Pearson’s 
Statistical correlations were analysed using Minitab 7 software. (p< 0.0001 r= 
0.813). 
 
4.4.4 Evaluation of serum antibodies against H. pylori molecules, 
CagA, VacA, GGT, KatA and PPT 
In the previous section, it was shown that there was an increase in 
antibodies against H. pylori lysates from strains 60190 and Tx30a in the serum 
of H. pylori-positive patients. It was hypothesized that bacterial factors such as 
CagA, VacA, GGT, KatA and PPT could be major immunogens driving the 
antibody response to infection. Both of the strains express GGT, KatA and PPT, 
therefore their differences in CagA and VacA expression could be responsible 
for the differences in the levels of antibody signals detected.  
This study aimed to determine the contribution of five important H. 
pylori factors, CagA, VacA, GGT, KatA and PPT, to the antibody response of H. 
pylori-positive patients and to investigate whether strong antibodies response 




As shown on the Fgure 4.6 A, B, C, D and E, the H. pylori infected 
individuals had significantly higher level of antibodies for  CagA (P<0.0001), 








Figure 4.6. Serological responses to H. pylori CagA, VacA, KatA, GGT and PPT in H. pylori infected (Hp+) and uninfected (Hp-) patients. CagA 
peptide, and purified recombinant  VacA, KatA, GGT and PPT proteins were spotted on epoxy-silane coated glass slides using BioRobotics 
Micrograd II microarray machine with solid microspot pin. The spots were probed with a total of 188 (94 infected and 94 uninfected) serum 




fluorescence imaging system LI-COR Odyssey SA (LI-COR). The horizontal bars represent median response levels and statistical significance 




4.4.5 Correlations among Tx30a Hp+, 60190 Hp+, PPT Hp+, VacA 
Hp+, KatA Hp+, CagA Hp+, GGT Hp   
To look at the association among and between the response to CagA, VacA, 
KatA, GGT and PPT, Pearson’s statistical correlation was used to analyse the 
data from the H. pylori-positive patients. As shown in Table 4.2 Only KatA/PPT 
and PPT/GGT data provided significant correlations,  with r= 0.606 (p<0.0001) 
and r= 0.454 (p<0.0001) respectively. There were no correlations between 
CagA and any of the other antigens. Anti-VacA responses correlated weakly 












Table 4.2 Pearson correlations in the data between the serological responses of H. pylori-positive patients to Tx30a Hp+, 60190 Hp+, PPT Hp+, 
VacA Hp+, KatA Hp+, CagA Hp+, GGT Hp  
 
           
                       Tx30a Hp+   60190 Hp+  PPT Hp+   VacA Hp+   KatA Hp+   CagA Hp+ 
 
60190 Hp+      0.739 
                        0.000 
 
PPT Hp+        0.364              0.523 
                       0.000              0.000 
 
VacA Hp+       0.143             0.379            0.377 
                        0.170             0.000            0.000 
 
KatA Hp+       0.368              0.412            0.606         0.282 
                       0.000              0.000            0.000         0.006 
 
CagA Hp+       0.076             0.136            -0.021        -0.035         0.066 
                        0.469             0.192             0.842          0.736         0.528 
 
GGT Hp+        0.483             0.406             0.454          0.107         0.375           -0.001 






4.4.6 Association between disease condition Cag and VacA type 
Previously, the group had used both PCR and serology to characterised the 
CagA gene and VacA type in the the positive-H. pylori individuals. As shown in 
Table 4.3, out the 94 H. pylori-positive subjects involved  in the studies, 35 has  
duodenal ulcers (DU), 6 were classified as gastric ulcer (GU), 2 has both 
duodenal ulcer and  gastric ulcer (DU + GU) while 51 showed ulceration. The 
result is represented in the table below shows that CagA+  /VacAs1/i1 contain 50 
(94),  CagA- /VacAs2/i2 was 21(94), CagA+ /VacAs2/i2 15(94) and CagA-/VacAs1/i1 
8(94).  
of the total H. pylori-positive subjects of which   
Table 4.3 The association between duodenal ulcer and gastric ulcer and 
CagA and VacA status.  
CagA and VacA 
type 
CagA+ /VacAs1/i1 CagA- /VacAs2/i2 CagA+ /VacAs2/i2 CagA-/VacAs1/i1 
Total 
No of Patient 50 21 15 8 94 
Duodonal ulcer 20 (57.1%) 7(20%) 4(11.4%) 4(11.4%) 35 





+ gastric ulcer 
0 2(100%) 0 0 
2 
% of total No of 
patient 




















From the results obtained this study, it is clear that immune response 
to H. pylori could easily be observed in distant blood peripheral other than the 
local areas of the gastric. This could be done by observing antibodies against 
one virulence factor as the quest for biomarkers against H. pylori-related 
diseases increases.  The outcome of the investigation is in agreement other 
reports on the serum antibody prevalence of the both suspected H. pylori 
effector immune molecules and regulatory immune molecules (Gao et al., 
2009b, Camargo et al., 2015, Mera et al., 2005, Atanassov et al., 2002). 
Therefore, this result could pave the way to the development of an accurate 
non-invasive diagnostic approach to H. pylori-related disease especially peptic 
ulcer. Besides, although some of the virulence factors are analogous of certain 
molecules in human the result in this chapter shows they are quite 
immunogenic and could serve as a vaccine candidate. 
4.5.1 Influence of amino silane and epoxy silane coated slide glass 
slide surface on the protein array  
Although glass is inert nonetheless it makes a great choice for any 
experiment involving optical sensors, since it is transparent and has little 
inherent fluorescence. Therefore, to make the surface suitable for a number 
biochemical investigation such as protein microarray, the surface is generally 




activities of the protein, the protein natural conformation and the protein 
integrity while preserving the transparency of the glass (Jonkheijm et al., 2008).  
Protein is known to have exceedingly heterogeneous and complex structure 
hence, the need for a suitable surface for almost every investigation involving 
protein array. This surface should be able to fulfil a number of criteria to be 
deemed satisfactory, these criteria includes; maintaining the spotted protein 
activities, guaranteed stability for the spotted protein for a long time, ability to 
bind strongly with proteins, high signal to noise ratios and spotted protein 
retention (Jonkheijm et al., 2008, Robinson et al., 2002, Seurynck-Servoss et al., 
2007a). 
Aminosilane coated surface utilise physical adsorption as its 
immobilisation strategy with no covalent attachment, unlike epoxysilane 
coated surfaces. Physical adsorption involves a situation where the protein 
interacts with slide surface through hydrogen bonding, hydrophobic 
interaction or ionic interactions. This probably leaves the spotted proteins or 
blocking agent vulnerable to exchange with assay reagent (Ball et al., 1994).  
This could lead to poor sensitivity and further background noise. Seurynck-
Servoss et al shows that although aminosilane require shorter immobilisation 
time of 1 hour than epoxysilane, aminosilane generates the lower signal 
intensity which could be due to lower density of the protein use, which is 
antibody (Seurynck-Servoss et al., 2007b), this is in agreement with our finding 
using different proteins, we obtained a far lower signal intensity on the 




The physical adsorption interaction of aminosilane, on the other hand, 
could be advantageous in a situation where the activities of the spotted protein 
are affected by the covalent interaction, for instance in the of an antibody 
(Seurynck-Servoss et al., 2007a). For the case of the protein used in our 
experiment, it is unlikely that covalent bonding would affect the epitopes of the 
protein since unlike antibodies which have limited antigen-region and are easily 
denatured by a change in structure brought about by multiple covalent 
bonding. Therefore, since epoxysilane allows covalent stable binding through 
the primary amine and at the same time due not affect the protein activity it is 
believed to be the most suitable in terms of meeting up with at least two 





Chapter 5  
 
Catalases, evolution from Helicobacter 













5.1 Introduction  
Hydrogen peroxide (H2O2) is produced in living organisms as a by-
product of aerobic metabolism and is the commonest found reactive oxygen 
species in all living species. Disproportionate H2O2 and its products are capable 
of causing damage to proteins, DNA, RNA, lipids and can trigger even apoptosis. 
Hence,  the need for rapid elimination in all levels of living organisms became 
essential for survival (Cabiscol et al., 2000, Kirkman and Gaetani, 2007). On the 
other hand, in immune responses, H2O2 has evolved to play roles in signal 
transduction essential for the inflammatory response, immune cell activation, 
cell division and apoptosis (Veal et al., 2007).  
One of the ways most living organisms use for elimination of this toxic 
molecules and similar molecule such as small organic peroxides is through 
enzymes namely hydroperoxides which act on the peroxides to release oxygen 
in a process known as dismutation (Zamocky et al., 2008).   
2H2O2       2H2O + O2 
Hydroperoxidase has evolved independently of a number of protein 
families that are capable of performing  the function of removing H2O2 and/or 
reducing it to an acceptable concentration useful for cellular signalling. These 
proteins are divided into three groups namely, typical catalases, catalase-




classified as heme-containing while the latter is known as a non-heme 
containing catalase (Passardi et al., 2007).  
Among these three, a typical catalase is one the most studied enzyme 
and it is the largest group which is found in a wide range of organisms from 
prokaryotes to eukaryotes (Zamocky and Koller, 1999). Among enzymes, 
catalase is known is to be one of the enzymes with the highest turnovers shown 
by the ability of 1 molecule of catalase to decompose more than 1 million 
molecules of hydrogen peroxide in a second (Goth and Nagy, 2012). In a 
phylogenetic analyses typical catalases are divided into three clades (Klotz and 
Loewen, 2003). Clade 1 is made up of bacteria, algae and plant catalases with a 
small subunit size of 55-69 kDa and using heme b as a prosthetic group. Clade 
2 is contains bacterial and fungal enzymes with a larger subunit size of 75-84 
kDa with heme d as the prosthetic group and a flavodoxin-like domain. Finally, 
clade 3 contains the most diverse group from archaebacteria, fungi, protists, 
plants and animals. This clade is also a very important group since it contains 
human catalases as well. Contrariwise it contains the small-subunit sizes of 43-
75 kDa with heme b and NADPH as a cofactor. 
Catalase is a highly conserved protein in both bacteria and mammal 
(Alyamani et al., 2007), it is found in the peroxisomes and cytosol of eukaryote 
and prokaryotes respectively. Its existence in peroxisomes is appropriate since 
peroxisomes are considered to be protective compartment with detoxifying 




catalase has been detected in some eukaryotic cytosol, as with fungi, 
Saccharomyces cerevisiae (Taub et al., 1999).  
H. pylori catalase (KatA) has been recognised as one of the most 
important virulence factors that aid the survival of the bacteria. Harris et al 
showed that wildtype SS1 strain of H. pylori consistently colonised the gut of 
C57/BL6 mice at a significantly higher level compared to the mutant deficient 
of KatA and KatA-associated protein (KapA). They showed it is not essential for 
initial colonisation but it was demonstrated to be essential for the maintenance 
of longer colonisation (Harris et al., 2003). Interestingly, recent studies. by 
Richter et al, described the moonlighting of KatA, in which they demonstrated 
KatA protection of H. pylori from complement-mediated killing through a 







The major role of catalase is the removal of hydrogen peroxide from 
living organisms thereby protecting it from the consequences of a high 
concentration of H2O2 (Zamocky and Koller, 1999). Unfortunately, some people 
are without this essential protection due to lack of this enzyme, in a condition 
called acatalasemia. This is a rare congenital abnormality typified by the lack of 
the catalase enzyme. This was first described by Takahara in 1952 which 
showed the development of progressive oral gangrene among people who are 
catalase deficient on infection with bacteria capable of inducing hydrogen 
peroxide (Takahara, 1952).  In the blood, deficiency of the catalase enzyme 
could lead to aggregation of erythrocytes due to high hydrogen peroxide 
generation and subsequent development of disease due to blood flow 
obstruction (Masuoka et al., 2006). Apart from this development of oral 
gangrene, Goth et al in their work demonstrated the link between acatalasemia 
and diabetes mellitus while working with some Hungarian acatalasemia 
patients. They inferred that the inability of catalase to protect the pancreatic 
-cell from the destruction of hydrogen peroxide (Goth and Nagy, 2012, Goth, 
2001). Others reported the generation of reactive oxygen species (ROS) by 
hyperglycaemia which further causes cell damages (Hunt et al., 1988, Jaganjac 




H. pylori KatA is a 505 amino acid tetrameric enzyme with heme prosthetic, 
KatA makes approximately 1% of the total protein expressed by H. pylori 
(Alyamani et al., 2007). Preliminary protein bioinformatics analysis of H. pylori 
KatA shows it shares 78-85% amino acid sequence identity with that from other 
Helicobacter species, about 65% identity with other bacterial catalases and it is 
believed it could share high amino acid sequence. It differs from other bacterial 
catalase proteins by having an additional 17 amino acid sequence at the C-
terminus, containing a poly-lysine motif. The combination of shared homology 
with human catalase and the additional poly-lysine motif, is believed to impart 
different functional characteristics on H. pylori KatA 
We hypothesize that H. pylori catalase (KatA) could offer protection similar to 
that of human catalase. To test this hypothesis, we used the following objective 
Objective 
• To use bioinformatics to evaluate the conservation of catalase among 
different Helicobacter species and between H. pylori and other 
organisms. 
• To evaluate the cross-reactivity of anti-human catalase antibodies with 
catalases from different organisms  
• To evaluate the presence of antibodies against selected catalases in the 





5.3 Materials and Methods 
5.3.1 Conservation of Helicobacter pylori Catalase among other 
Helicobacter species 
The conservation of the catalase (KatA) sequence among 9 Helicobacter 
species was evaluated by a sequence-based method. This includes multiple 
sequence alignment using the Clustal Omega program on the UniProtKB 
through the ExPASy SIB Bioinformatics Resource Portal. Two H. pylori strains: 
Helicobacter pylori (strain ATCC 700392 / 26695) and Helicobacter pylori (strain 
J99 / ATCC 700824) were first aligned to ascertain the degree of similarity. Then 
using Helicobacter pylori (strain ATCC 700392 / 26695) as a reference strain ( 
which is also the source of the catalase I have used throughout my PhD 
experiment);  the catalases of Helicobacter felis (strain ATCC 49179 / NCTC 
12436 / CS1), Helicobacter cinaedi CCUG 18818 = ATCC BAA-847, Helicobacter 
hepaticus (strain ATCC 51449 / 3B1), Helicobacter suis HS5, Helicobacter 
muridarum (ATCC 49282), Helicobacter cholecystus ATCC 700242 and 
Helicobacter canadensis MIT 98-5491 were analysed.  
The percentage of similarities and identical positions were first 





5.3.1.1 Conservation of Helicobacter pylori Catalase among other Helicobacter 
species and other organisms  
Following the protein bioinformatic analysis of Helicobacter spp., I went further 
to look at the analysis of above-named Helicobacter spp. in addition to the 
human catalase, Corynebacterium glutamicum catalase and Aspergillus niger. 
Again, the percentage similarities and identical position were evaluated in 
comparison H. pylori catalase. Furthermore, the catalases’ active sites and 
metal-binding sequence were determined. Then from the aligned sequences 
the domain, helix, Beta strand and chain were assessed.  
5.3.1.2 Structural Bioinformatics 
Likewise, to enhance the understanding of the structure H. pylori KatA, human 
catalase, Corynebacterium glutamicum and Aspergillus niger catalase, and for 
better comparison, 3D structural bioinformatics was carried using the Phyre2 
with the FASTA sequence from the NCBI protein database; H. pylori KatA 
(accession number: TLR88905.1), human catalase (accession number: 
NP_001743.1), Corynebacterium glutamicum (accession number: AIK83984.1) 
and Aspergillus niger (accession number: AAA68206.1)catalase. The 3D 
structures were captured and evaluated for differences, then the secondary 




5.3.1.3 Experimental validation of conservation catalase among organisms  
5.3.1.3.1 Catalase selection criteria 
To assess the conservation we use the cross-reactivity of anti-catalase 
antibodies among different catalases from different organisms, commercially 
available catalase from human erythrocytes (Sigma-Aldrich) (EC 1.11.1.6) 
concentration ≤10 mg/mL, catalase from Aspergillus niger (Sigma-Aldrich) (EC 
1.11.1.6), concentration ≥4,000 units/mg protein, catalase from 
Corynebacterium glutamicum solution, deep brown, concentration ≥500000 
U/mL were purchased and H. pylori catalase produced in our laboratory 
representing human, fungi, gram-positive and gram-negative, respectively. 
5.3.1.3.2 H. pylori-positive and H. pylori-negative Serum sample 
preparation  
From the blood samples collected in section 4.1 H. pylori-positive and 
H. pylori-negative serum samples and were diluted by 1:200 in PBS-Tween 
(0.05% Tween 20, 0.01 M phosphate buffer with pH 7.4 at 25C). 
 
5.3.1.4 Characterisation of the purified protein  
5.3.1.4.1 BCA protein assay, Catalase activity, SDS-PAGE and  
PageBlue Protein Staining  
The concentration of the respective catalases was measured using 




instructions. Then using 3% hydrogen peroxide the catalase activities were 
assessed following the procedure previously used in section 2.3.1.7.3 
Subsequently, SDS-PAGE was to evaluate the purity of the commercially 
available catalases, following the technique previously described section 
2.3.1.7.1 
5.3.1.4.2 Further purification of the Aspergillus niger  
Because all the catalase appeared to be clean on the gel photo except 
the Aspergillus niger catalase. Consequently, the Aspergillus niger suspension 
was further purified by size exclusion chromatography (SEC) as previously 
described in Section 2.3.1.6. The eluted protein was assessed for purity using 
SDS-PAGE as described in section 2.3.1.7.1. The concentration of purified 
proteins was determined using Pierce BCA protein assay kit (Thermo 
Scientific) following the manufacturer’s instructions.  
5.3.1.5 Western blot analysis of catalases Anti-human catalase antibody 
To test whether antibodies against human catalase also react well with 
catalases from H. pylori and other microbes. SDS-PAGE previously described in 
section 2.3.1.7.1 was to resolve to the proteins, Human catalase, Aspergillus 
niger catalase, Corynebacterium glutamicum catalase and H. pylori 
recombinant catalase. The resolved proteins were transferred to the 
nitrocellulose paper following the procedure described in section 2.3.1.7.2. 
According to the western blot procedure described in section 2.3.1.7.2, 




antibody (rabbit polyclonal antibodies )(Sigma-Aldrich). Then secondary 
antibody was anti-rabbit IgG-horseradish peroxide conjugate (Sigma) visualise 
by chemiluminescence readout and the bands were compared with the 
prestained protein marker to ensure it is at the expected molecular weight.  
5.3.1.6 Western blot evaluation of H. pylori-positive and negative patients on 
human, Aspergillus niger, Corynebacterium glutamicum and 
Helicobacter pylori catalase 
The human, Aspergillus niger, Corynebacterium glutamicum and 
Helicobacter pylori catalase were resolved on the SDS-PAGE gel following the 
procedure described in section 2.3.1.7.1 using a double pockets SDS-PAGE 
combs (Figure 5.1.) a uniform lane of the resolved protein. 
 
 
Figure 5.1. Figure 5.1 A double pocket comb used in creating a single well. 
 
 
The proteins on the gel were transferred to a nitrocellulose paper 




upon which the proteins were transferred to was cut into strips of 0.5 
cm each. Two strips selected from each of the respective catalases were 
marked and placed one each on two different containers labelled 
Positive and Negative and was blocked for 1 hour on a shaker at room 
temperature with blocking solution described in section 2.4.2.2. A total 
20 patient samples were used in this study, 10 confirm H. pylori-positive 
and 10 H. pylori-negative sample,  following the blocking 5 ml of the of 
1:200 dilution of the serum sample prepared in section…… was added 
and incubated overnight at 4 C on the shaker. At the end of the 
incubation, the blot was washed in PBS-Tween 3 x with 5 minutes 
shaking incubation in between. The blot was placed in a secondary 
antibody, anti-human IgG-horseradish peroxide conjugate (Sigma) and 
incubated on a shaker for 1 hour. Successively, the strips were washed 
5 x in PBS-Tween with an interval of 5 minutes and 1 x in PBS.  
 The chemiluminescent readout was achieved following the 





5.4 Result  
5.4.1.1 Bioinformatic analysis of conservation among Helicobacter spp  
Nine Helicobacter species were analysed using Clustal-Omega, with 
well-known human pathogens: Helicobacter pylori (strain ATCC 700392 / 
26695). Additionally, Helicobacter felis; a bacterial species commonly isolated 
from mammals such as cat, dog and rabbits, although capable of causing human 
diseases (Lee et al., 1988), Helicobacter cinaedi; another well-known 
Helicobacter isolated from hamsters and monkeys which is also known to cause 
disease in immunocompromised individuals (Kawamura et al., 2014), 
Helicobacter hepaticus; this is a well-known mouse Helicobacter, shown to 
induce lower bowel inflammation(Fox et al., 2011), Helicobacter suis;  H. suis is 
commonly isolated from pig and non-human primate, it is well studied 
Helicobacter sp capable of causing diseases similar to H. pylori, but unlike H. 
pylori, H. suis is notable for infecting parietal cells, causing degeneration of the 
cells (Joo et al., 2007), Helicobacter muridarum, known for its fastidious nature 
and first isolated from the murine mucosa (Lee et al., 1992), Helicobacter 
cholecystus; first described as the filamentous Helicobacter sp isolated from the 
gallbladder of a hamster, it is associated with the occurrence of 
cholangiofibrosis and centrilobular. pancreatitis(Franklin et al., 1996) and 
Helicobacter canadensis; this specie is primarily isolated from poultry and its 




and from rodent faeces have been recorded (Waldenstrom et al., 2003), while 
it is not known to cause disease in humans infection cannot be ruled out (Inglis 
et al., 2006). The percentage identity between H. pylori and other Helicobacter 
spp used in this study ranged from 97% to 50% having an identical position of 
amino acid sequences ranges from 492 amino acid as found in H. pylori J99 to 
255 amino acids found in Helicobacter cholecystus as shown in Table 5.1  
The analysis of the showed that all the catalases share the same active 
site and metal-binding sequence, but interestingly only H. pylori have a beta-
strand region, helix region and sequence are not consecutive (sequence 
conflict). H. pylori also do not possess domain sequence contrasting to the 
other Helicobacter species in the analysis which have domains throughout most 





Table 5.2 Sequence alignment summary of the 9 Helicobacter species showing the percentage identity and identical position with 
Helicobacter pylori 26695 strain. 
Organism Entry Number Entry name Amino acid Sequence 
Identical position WITH 
H. pylori (strain ATCC 700392 / 
26695) 
 
% Identity WITH 
H. pylori (strain ATCC 700392 
/ 26695) 
 
Helicobacter pylori (strain ATCC 





505 - - 






505 492 97.426 
Helicobacter felis (strain ATCC 
49179 / NCTC 12436 / CS1), 
E7AAY6 E7AAY6_HELFC 485 331 65.415 
Helicobacter cinaedi (CCUG 18818 
= ATCC BAA-847) 
I7H4C3 I7H4C3_9HELI 481 311 61.584 
Helicobacter hepaticus (strain 
ATCC 51449 / 3B1), 
Q7VK49 Q7VK49_HELHP 478 298 59.01 
Helicobacter suis (HS5), E7G3S7 E7G3S7_9HELI 494 323 63.708 
Helicobacter muridarum (ATCC 
49282), 
A0A099TYR4 A0A099TYR4_9HELI 482 312 61.782 
Helicobacter cholecystus ATCC 
700242 
A0A3D8IWC8 A0A3D8IWC8_9HELI 468 255 50.296 
Helicobacter canadensis MIT 98-
5491 




5.4.1.2 Bioinformatic analysis of conservation among Helicobacter spp 
catalase, other microbes and human catalase 
Next, the catalases of from other organisms were added to the analysis; 
a Gram-positive bacterium catalase from Corynebacterium glutamicum (C. 
glutamicum), a fungi catalase Aspergillus niger (A. niger) and human catalase. 
Briefly,  C. glutamicum is a non-pathogenic non-spore-forming Gram-negative 
bacterium which is widely used in the industries for the production of industrial 
amino acids (Vertes et al., 2012) and it was named glutamicum because of its 
discovery as a producer of glutamate in the 1950s and was previously named 
Micrococcus glutamicus (Yang and Yang, 2017). Aspergillus niger is also another 
industrial important microbe, it is a filamentous fungus efficient in utilising low-
cost substrates in the production of a large quantity of proteins, metabolite and 
organic acid (Meyer et al., 2015) and was popularly known for citric acid 
production(Ciriminna et al., 2017), although its infection is not common to 
compare to others species of Aspergillus such A. fumigatus and  A. flavus there 
have been reported infections in humans (Person et al., 2010). 
Again, the sequence alignment analysis of the 3 catalases from human, 
C. glutamicum and A. niger with other H. pylori and other Helicobacter spp 
showed that the active site and metal-binding sequence are well conserved 
across all the species (Appendix).  Interestingly, there are so many similarities 
shared only between H. pylori catalase human catalase that is not shared with 




of a beta-strand, helix, turn and sequence conflict in its sequence and absence 
of a domain which is found in every other catalase 
Interestingly, to support the similarity between H. pylori KatA and 
Human catalase, as shown in Table 5.3 there is about 48% amino acid sequence 
identity this is higher than fellow bacteria Corynebacterium glutamicum (42%) 
and the fungi Aspergillus niger (26%). This similarity could be as a result of 






        Table 5.3 Sequence alignment summary of the 9 Helicobacter species showing the percentage identity and identical position with    









Identical position WITH 
H. pylori (strain ATCC 
700392 / 26695) 
 
% Identity WITH 
H. pylori (strain ATCC 
700392 / 26695) 
 
Helicobacter pylori 






505 - - 













































5.4.1.3 3D structure of the H. pylori KatA, human catalase, 
Corynebacterium glutamicum and Aspergillus niger 
The 3D structure of the H. pylori KatA, human catalase, C. glutamicum 
and A. niger were obtained from the Phyre2 using the individual FASTA 
sequence from the  NCBI database. The result as shown below (Figure 5.2). The 
four structures showed similarities in the basic structure but it is worthy to note 
when the secondary structures were analysed. The secondary structure and 
disorder prediction analysis of each of catalases revealed an interestingly close 
similarity between human catalase and H. pylori catalase having an equal 
percentage of both alpha-helix and beta-strand (31% and 16% respectively) 







Table 5.4 The secondary structure and disorder prediction analysis catalase 
from different organisms. 
Organism  Disordered Alpha helix  Beta strand 
H. pylori  25% 31% 16% 
Human  24% 31% 16% 
C. glutamicum 22% 34% 14% 
A. niger 28% 35% 14% 
 
Figure 5.2. Phyre2 3D structural analysis of catalases (A)H. pylori KatA,  (B)human catalase, 
(C) Corynebacterium glutamicum and (D)Aspergillus niger on the Phyre2. Image were 





5.4.1.4 Quantitative and qualitative evaluation of the commercially 
available catalases  
The concentration of the commercially available catalases; Human 
catalase, Aspergillus niger catalase, Corynebacterium glutamicum catalase and 
recombinant H. pylori KatA prepared in section 2.4.1 were measured using 
Pierce BCA protein assay. Then the catalase activity was assessed by 3 % 
hydrogen peroxide presumptive test, the result showed positive activities for 
all the catalases and was confirmed using commercially available Amplex Red 
Catalase. Then the proteins were resolved on the SDS-PAGE to evaluate the 
purity (figure 5.3). Only Aspergillus niger catalase was not up to 95% pure as 






Figure 5.3. A typical SDS-PAGE showing the resolved catalases from H. pylori, 
Human, Corynebacterium glutamicum and Aspergillus niger. Commercially 
available catalases from human erythrocyte, Aspergillus niger, 
Corynebacterium glutamicum and H. pylori were resolved on the SDS-PAGE and 
proteins were visualised using PageBlue Protein Staining Solution. Lane1, 
prestained protein standard; lane 2, H. pylori catalase (KatA); lane 3, Human 






Following the SDS-PAGE revelation of the impurities in the Aspergillus 
niger a decision was made for further purification of the protein. Size exclusion 
chromatography (SEC) was for its further purified since it works on the simple 
principle of differences in the sizes of the molecules involve or sometimes the 
molecular weight. Then protein was purified using SEC, following the procedure 
in section 2.4.1.6 The concentration was measured using Pierce BCA protein 
assay kit. The elution product was resolved on the SDS-PAGE gel together with 
other catalases and stained using PageBlue Protein Staining Solution as 










Figure 5.4. A typical SDS-PAGE showing the resolved catalases from H. pylori, 
Human, Corynebacterium glutamicum and Aspergillus niger. 
Commercially available catalases from human erythrocyte, Aspergillus niger, 
Corynebacterium glutamicum and H. pylori were resolved on the SDS-PAGE and 
proteins were visualised using PageBlue Protein Staining SolutionLane 1, 
prestained protein standard; lane 2, H. pylori catalase (KatA); lane 3, Human 







5.4.1.5 The Western Blot analysis of the catalases from H. 
pylori, human erythrocyte, A. niger and C. glutamicum  
In order to evaluate The Western Blot analysis of the cross-reactivity 
among the antibodies for of  catalases from H. pylori, human erythrocyte, A. 
niger and C. glutamicum  
5.4.1.5.1 Reaction with anti-human catalase antibody with other 
microbe catalase 
In order to evaluate whether antibodies against human catalase (rabbit 
polyclonal antibodies) also react well with catalases from H. pylori and other 
microbes, Aspergillus niger, Corynebacterium glutamicum and H. pylori. 
Therefore, western blot analysis for the four catalases was carried out using 
anti-human catalase IgG as the primary antibody. The bands were compared 
with the prestained protein marker to ensure it is at the expected molecular 
weight. The result showed there was no cross-reactivity between antibodies 
against human catalase and catalase from Aspergillus niger, Corynebacterium 





Figure 5.5. A typical western blot chemiluminescence film showing the 
catalases from H. pylori, Human, Corynebacterium glutamicum and 
Aspergillus niger probed with anti-human catalase IgG to evaluate cross-
reactivity among the catalases. Commercially available catalases from human 
erythrocyte, Aspergillus niger, Corynebacterium glutamicum and H. pylori were 
resolved on SDS-PAGE, then transferred to a nitrocellulose paper and probed 
with anti-human catalase IgG. Lane 1, prestained protein standard; lane 2, H. 
pylori catalase (KatA); lane 3, Human catalase; lane 4, C. glutamicum catalase; 







5.4.1.5.2 Reaction with serum antibodies from H. pylori-positive and 
H. pylori-negative patients  
Following the confirmation that polyclonal anti-human catalase antibody does 
not cross-react with catalase from Aspergillus niger, Corynebacterium 
glutamicum and H. pylori. Especially with the higher-level sequence similarity 
between KatA and human catalase amino acids, it is expected they could share 
a few epitopes which could result to cross-reactivity between anti-KatA 
catalase present in the serum of H. pylori-positive patient.  
Western blot was used to analysis the cross-reactivity of the anti-catalase 
antibody from H. pylori-positive and H. pylori-negative patients. The results 
shown in Fig 5.6 indicated strong bands on the H. pylori-catalase (KatA) with 
the H. pylori-positive serum compare to the H. pylori-negative serum. 
Surprisingly, there are bands on the H. pylori-negative serum.  
Interestingly, there were either weak bands or no band on the human catalase 
with H. pylori-positive serum and no band on the negative serum. Similarly, C. 
glutamicum weakly bands or no band on both positive and negative serum. A. 










Figure 5.6. A typical western blot chemiluminescence film showing the 
catalases from H. pylori, Human, Corynebacterium glutamicum and Aspergillus 
niger probed with H. pylori-positive (+) and H. pylori-negative (-)  patients’ 
serum to evaluate cross-reactivity among the catalases. The catalases are 
commercially available catalases from human erythrocyte, A. niger, C. 
glutamicum and recombinant H. pylori catalase. The catalases were resolved 
on SDS-PAGE, then transferred to a nitrocellulose paper and probed with 1:100 






The major aim of the studies was to investigate the similarity between 
catalase from H. pylori (KatA) and other organisms especially that of human to 
ascertain their relatedness. More importantly to investigate whether the 
antibody against H. pylori-KatA anti-body present in the serum of H. pylori-
positive patient could cross-react with human catalase. The result of these 
studies presented evidence for further understanding H. pylori coevolution 
with human and this could be a benefit in the understanding of the effect of H. 
pylori KatA in immune regulation.   
 
5.5.1 Bioinformatic analysis 
The bioinformatic analysis of the catalases of Helicobacter species from 
different mammalian hosts showed a percentage similarity in the amino acid 
sequence of about 50 to 65%. This can actually be said to be relatively low when 
compared to the other proteins shared among the species such as urease 
subunit beta (UreB) and gamma-glutamyltranspeptidase (GGT), whose 
similarities range between 75-88% and 65-71% respectively.  but the major 
difference is the absence of the beta-strand, helix and sequence conflict in 
other Helicobacter species catalases. Likewise, it is only `H. pylori catalase that 




could be due to common origin of the Helicobacter species which is also shown 
by their tendency to caused similar inflammatory response which resembles 
the type caused by H. pylori (Solnick and Schauer, 2001). On the other hand, 
the difference marked differences seen between H. pylori catalase and other 
species could be explained by the host specificity and several years of 
coevolution with its human host (Kodaman et al., 2014). 
Interestingly, H. pylori catalase s high percentage identity between its 
amino acid sequence and that of human catalase (48%), which is surprisingly 
high when compared to the percentage identity with other microorganisms. 
Actually, the result in this study showed that percentage identity between H. 
pylori catalase and catalases of C. glutamicum and A. niger is 42% and 26% 
respectively, which are both lower than that of human. This is further 
supported by the observation that among all the catalase sequences used in 
the analysis, it was only H. pylori and Human catalase that posses a beta-strand, 
helix, turn and sequence conflict in its sequence interestingly both lack the 
regions of the domain which are found in every other catalase. This observation 
could be appreciated in the light of long term adaptation of H. pylori to its 
human host (Atherton and Blaser, 2009); several factors of the bacteria have 
been modified to enable it to survive and coexist with its host. A typical 
illustration was in the recent report by Richter et al, which showed that H. pylori 
KatA is a receptor to an extracellular matrix and plasma protein, the vitronectin, 
which the bacteria uses to mask itself against the complement-mediated killing 




function of catalase which is the antioxidant activity in every living organism. 
Similarly, it could be the close similarity between human and H. pylori catalase 
means that antibody against one could react to the other. 
The tertiary and secondary structure of protein especially the alpha-
helix and beta-strand have a huge influence on the epitope. This could be due 
to high chemical bond energy found in alpha helices and beta strands of a 
protein in addition to factors such as hydrophobicity, polarity, turns and surface 
accessibility (Poland et al., 2001). Consequently, the tertiary 3D  and secondary 
structure of each of the catalase from the 4 organisms were analysed using 
Phyre2, this showed  A. niger is made up of 28% disorder, 35% alpha-helix and 
14% beta-strand,  C. glutamicum 22% disordered, 34% alpha-helix and 14% 
beta-strand, H. pylori KatA 25% disordered, 31% alpha-helix and 16% beta-
strand while human catalase is made up of 24% disordered, 31% alpha-helix 
and 16% beta-strand.   
Earlier analysis considering only amino acid sequence, primary 
structure, showed 48% similarity between human and H. pylori catalase.  
Primary structure of proteins does not put into consideration of molecular 
interaction which gives rise to the secondary structures, hence cannot 
efficiently establish epitopes on the protein. Consequently, the similarity in the 
percentage of alpha helices, beta-strand and disordered sequence could be a 
good prediction on the resemblance between the two proteins. This also could 
explain the interaction between the pathogen (H.pylori)and host (Homo 




effective. Again coevolution between the two organisms (Kodaman et al., 2014) 
is likely to account immunomodulation and likelihood of H. pylori to persist in 
the incidence of infection.    
 
5.5.2 Investigation cross-reactivities of the anti-KatA antibody 
with catalase from different organisms   
Previously in chapter 4, microarray was used to investigate the anti-
KatA antibody present in the serum of H. pylori-positive and H. pylori-negative 
patients. The result from this study showed that H. pylori-positive patients have 
4-fold higher anti-KatA antibody in their serum compare to that of the H. pylori-
negative patients. Therefore, since KatA elicits such a high level of antibody and 
with the scepticism among several researchers on the protective capability of 
the KatA-specific antibodies to protect against Helicobacter pylori infection 
(Kotiw et al., 2012). The hypothesis that H. pylori KatA specific antibodies could 
behave functions that are normal antibody functions. With a high level of 
similarity between the human and H. pylori catalase, one possible function of 
anti-KatA antibodies could cross-reaction with human catalase to block its 
functions.  
The result from the western blot investigation of the cross-reactivity of 
the anti-KatA specific antibody using serum from both H. pylori-positive and H. 
pylori-negative patient presented an inconclusive result. There is obvious 




glutamicum showed the band at both positive serum and negative serum, the  
A. niger results showed no band with some of the positive serum and weak 
band in some of the negative serum. The positive western blot bands on the 
catalases of C. glutamicum and A. niger catalase is unexpected since both could 
be described as non-pathogenic (Person et al., 2010, Burkovski, 2013).  Further 
experimental evidence through additional studies could provide some answer 

















6.1 Important and Novel  
The fundamental objective of this study was to ascertain the other factors H. 
pylori utilises in inducing immune suppression. `To do this, a hypothesis which 
states that H. pylori molecules have both direct and indirect immune regulatory 
effect on the cells of the immune was developed. The results obtained from the 
study in chapter 2 shows that KatA significantly suppresses IL-2 a 
proinflammatory cytokine, first recognised for its function in the T-cell 
expansion (Smith, 1988). At the same time, the study also supports the already 
existing finding of the immune-suppressive ability of GGT while showing that 
PPT is ineffective in immune suppression. Although the mechanism behind 
KatA immune suppression was not investigated due to time constraints, this 
study is the first to demonstrate another function for this ubiquitous protein. 
Furthermore, data from chapter 4 showed that five H. pylori factors CagA, VacA, 
KatA, GGT and PPT were the potential biomarker for the screen peptic ulcer 
and potentially Gastric cancer, using serum antibodies against these factors. In 
Chapter 5, the bioinformatic analysis of catalase proteins of H. pylori, other 
Helicobacter species, C. glutamicum, fungi-A. niger and human reveal a 
consistent shift in similarities of H. pylori KatA and away from microorganisms 
and unanticipated shift in similarity towards human catalase. These similarities 
between H. pylori KatA and Human catalase might be in important in conferring 
additional functional characteristics during an infection such as 




immune cells activation (Richter et al., 2016), direct suppression of immune and 
probable compensation in the case of acatalasemia (Goth and Nagy, 2012).  
6.1.1 Effect of H. pylori VacA types on the immunoregulation  
H. pylori infection stimulates robust immune response although this response 
is known to often fail in the eradication of the bacteria leading to persistent 
colonialization of the gastric mucosa and/or gastric damage (Perez-Perez et al., 
1988, Tinnert et al., 1997, Blanchard et al., 1999, Jakob et al., 2001, Suerbaum 
and Michetti, 2002). One of the most studied methods utilised by H. pylori in 
surviving the immune assault is the immune suppression (Algood and Cover 
2006). Müller et al in their review described series of processes H. pylori utilised 
in the manipulation of both innate and adaptive immune cell signalling pathway 
to establish persistent infection (Müller et al., 2011a). 
The study in Chapter 2 provided evidence which suggested that KatA could 
directly inhibit proinflammation cytokines. That is  KatA may have 
immunoregulatory properties capable of manipulating of immune cells during 
H. pylori infection.  Most of the early studies have focused on VacA and GGT 
are the main factor providing the immunoregulatory properties in H. pylori 
infection (Salama et al., 2001a, Zheng and Jones, 2003, Gebert et al., 2003, 
Sundrud et al., 2004, Gerhard et al., 2005, Torres et al., 2007, Oertli et al., 
2013a, Wustner et al., 2017). The best of my knowledge this was the first report 
on immunoregulatory properties of H. pylori KatA outside it activities of 




the significant reduction of IL-2 production at concentration 50 g/ml, it is 
worthy of note that KatA is secreted in high level making up to 1% of the total 
bacterial secreted protein (Hazell et al., 1991). Gebert et al reported that in 
addition to inhibition of T cell proliferation, VacA abrogated the nuclear 
translocation of nuclear factor of activated T cells (NFAT) leading to down-
regulation of IL-2 transcription (Gebert et al., 2003). Other reports on GGT only 
agreed on its ability to inhibit cell proliferation without impairing the IL-2 
production (Schmees et al., 2007, Sundrud et al., 2004), this is not in agreement 
with the result of the experiment in Chapter 2 which showed that high 
concentration 50 g/ml, GGT significantly inhibit IL-2 secretion in Jurkat cells.  
Although the biological mechanism through which these two protein factors of 
H. pylori were not investigated, there is a need for further studies for additional 
understanding the pathways of immunosuppression of the molecule this could 
help in the development of new therapeutic alternatives for the treatment of 
associated diseases.    
6.1.2 The anti-inflammatory property of H. pylori proteins  
A number of human diseases such as pathogens infection, allergy, cancer etc 
have been associated with changes in the Treg number and function (Banham, 
2006). Treg has been shown to be vital in the immune regulation during H. 
pylori and subsequent pathogenesis (Kandulski et al., 2010, Overacre and 
Vignali, 2016, Vignali et al., 2008). An earlier study by Liu et al in C57BL/6 mice 




and the spleen of the infected cohort compared to the placebo receiving group. 
Similarly, their work also showed a higher Treg number when stimulated with 
H. pylori antigen in vitro (Liu et al., 2015). Their study focused largely on the 
difference in the Treg and does not put into consideration the difference and 
effect of VacA type being expressed by the infecting H. pylori, the experiment 
in Chapter 3 which utilised similar model but measured the difference in VacA 
type.  
The investigation by Lui et al reported an increase in  Treg number in the spleen 
by just 2.98 16 % which was not a significant change between the infected 
group and the placebo receiving group, this is consistent with the result of the 
investigation in Chapter 3, which showed no significant difference in Treg in H. 
pylori exposed mice compares to the non-exposed group after 9 weeks but 
consistently show an increase in the number of CD4+ Foxp3+. Furthermore, 
there was also no difference in Treg number from the spleen of mice infected 
with H. pylori expressing distinctive types of VacA. 
Unlike the nTreg which differentiate in the thymus before it migrates to the 
peripheral, iTreg are mostly induced at the peripheral from the pool of 
peripheral CD4+ CD-Focp3- precursor (Mayne and Williams, 2013, Schmitt and 
Williams, 2013). The principal function of Treg cells are its immunosuppressive 
activities through IL-10 and other associated cytokines such as TGF- (Ray et 
al., 2010).(Ray et al., 2010) To ensure that the effect of the VacA types was not 
the case of number rather the functionality, the level of immunosuppressive IL-




showed no difference in the level of IL-10 secretion from the Treg derived from 
the mice groups when stimulated with PMA-ionomycin/LPS mitogen. This 
result was in contrast to results from other investigations which indicated that 
on stimulation of Treg derived from mice exposed with H. pylori there would 
increase the IL-10 production. (Rad et al., 2006, Wang et al., 2013a, Liu et al., 
2015).  
Compare to the mitogen, PMA-ionomycin/LPS used the experiment, other 
studies have shown that a more potent activator of H. pylori-experienced Treg 
to the secrete of IL-10 is the H. pylori antigen rather than the PMA-ionomycin. 
Liu et al showed that spleen lymphocytes isolated from H. pylori-infected mice 
stimulated for 15 hours with H. pylori antigen secreted a statistically significant 
amount of IL-10 and TGF- compare to the PMA-ionomycin stimulated spleen 
lymphocyte from H. pylori-infected and unstimulated uninfected mice (Liu et 
al., 2015, Raghavan et al., 2003). The results point to the fact that the IL-10 
production in stimulated Treg is a function of the presence of memory Treg 
rather than other possible sources such as induced Treg. 
 Conclusively, functional analysis of the CD4+ CD25+ Treg isolated from H. pylori 
exposed and non-exposed mice showed an obvious suppression of T cell 
proliferation but does not show any difference immunosuppressive activities in 






6.2 Critique of the experimental design 
Recombinant proteins production has been one of the mainstays in biomedical 
and other scientific research in general. One of the ways of purification of 
recombinant protein has been the addition of extra amino acid residues to the 
N- or C-terminus of the protein by modification of the DNA sequence. The extra 
sequence of amino, known as tags, confer particular properties to the protein. 
One of such properties seen with the tags is exemplified by polyhistidine (His-
tag) addition to the N-terminal which bestow which enable purification of 
recombinant protein from crude cell lysate using immobilized metal affinity 
chromatography (Munro and Pelham, 1984). Booth et al showed that there are 
differences in the stability and functions of N-terminal His-tag protein and 
native protein (protein with its histags cleaved with TEV protease) (Booth et al., 
2018). Consequently, the experimental design of Chapter 2,  may be affected 
since the assays carried out in the investigation are functional assays intended 
to mimic the role of the protein in its native form in vivo.  
Furthermore, the one the hypothesis in this work put into consideration that 
the possible reason for the unique behaviour of H. pylori KatA could be because 
it differs from other bacterial catalase proteins by having an additional 17 
amino acid sequence at the C-terminus, containing a poly-lysine motif and this 
may impart different functional characteristics. Therefore, if it is believed that 
this poly-lysine sequence could affect the functionality and behaviour of the 




  The immune suppression assays have been essential in the evaluation of 
activities Treg. The in vitro studies involving suppression assays have been 
deemed technically difficult due to whole line problems ranging from induction 
to cell purification (McMurchy and Levings, 2012). The use of 
PMA/ionomycin/LPS in Chapter 2 is a  polyclonal mix of mitogens which could 
easily mimic in vivo natural environment. Ionomycin is a Calcium (Ca2+) 
ionophore produced by Streptomyces conglobatus fermentation, with high 
affinity for calcium (Liu et al., 1978). In rest T cells ionomycin induces the 
activation of protein kinase C(PKC) via phosphorylation of CD4 and CD8 
proteins. The function of PMA is to advance the activation by induction of T cell 
proliferation through NFAT nuclear translocation (Chatila et al., 1989, Wang et 
al., 2013a). The LPS is the most common component present in all Gram-
negative bacterial wall, it is a PAMP that is well known for it the ability to bind 
to TLR4 leading to the activation of major immune responses (Ngkelo et al., 
2012). Although this polyclonal mix has been shown to efficient in induction of 
immune response, its aptness to experiment in Chapter 3 could be deemed 
slightly inapt since the experiment is designed to evaluate specific activities of 
H. pylori factors. Thus as stated earlier, H. pylori antigen could have been 
better. 
Finally, the western blot experiments in Chapter 5 appear to be the only 
qualitative rather than quantitative. Consequently, the results of this 
investigation do not permit an adequate conclusion. To overcome this, the use 




could enable analysable digital images. Such an image could then allow 
normalization of the bands and further analyses to acquire quantitative data.  
6.3 Future work  
On the direct immunosuppressive ability of H. pylori KatA, GGT and PPT 
the future work would be mostly on the framework for the understanding of 
how KatA mediate immunosuppression of the T-cell.  Focus on KatA is 
important since immunosuppression ability of GGT has already been 
established (Schmees et al., 2007) and PPT has no T-cell suppression from our 
experiments or any literature report.  To investigate further with KatA, two 
areas are important. 
Firstly, Understand the key KatA binding receptor or cellular structure in human 
T cell and other immune cells. This would entail the investigation of the location 
of the receptor, that is whether extracellular and intracellular. Additionally, 
establishing the means through which KatA could reach its receptor. This is 
important in the light of T-cells being nonphagocytic cell and would require a 
special mechanism to accumulate KatA intracellularly to the level needed to 
exert immunosuppression.  
Another import area to look at is the mechanism through which KatA 
establishes immune suppression. Although VacA and GGT are known to 
suppress T-cell via cycle arrest (Gebert et al., 2003, Gerhard et al., 2005, 




but still, it could novel if another different means id discovered for T-cell 
suppression. 
Largely, the structure and function of mice and the human immune system are 
relatively comparable, in that both species remarkably a prototypical of each in 
immunology experiment (Haley, 2003). However, there are still some obvious 
differences in the activation and development of their immune system which 
could hinder the extrapolating of experimental results from mouse studies to 
human. A prominent example is the variation in the lymphocyte and 
neutrophile balance in adult human and mice which has 30-50% lymphocyte, 
50-70% neutrophils and 75-90% lymphocyte, 10-25 neutrophils, respectively 
(Doeing et al., 2003). Due to some these variations, it is worth investigating the 
correlation between VacA types and Treg numbers in PBMCs of infected human 
patients. This could bring to light the answer to the important question of which 
type of VacA is driving the skewing of the immune toward regulatory immune 
system. 
Furthermore, with VacA already been known to promote the Treg 
differentiation in cases of H. pylori infection (Oertli et al., 2013a), and in vitro 
investigation of the effect of recombinant VacA variants on human dendritic 
cell maturation and the differentiation of naïve T cells, would elucidate possible 
outcome in vivo. 
Equally, the suppressive activity of human Tregs generated via DCs exposed to 
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Table 6.1: katA, ggt and ppt  primer sequence used in the study 
 








5’ - TGAAAGGAAAACCCATGGGACGGAG -3’ 
 


















5’ - TAAGGATCCGCTAGCATGAAAAAAAATATCTTAAAT -3’ 
 







































Figure E Secondary structure and disorder prediction of Human (Homo 
















Figure H Secondary structure and disorder prediction of A. niger 
